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ABSTRACT 
 
Bone Loss During Energy Restriction: Mechanistic Role of Leptin. 
(December 2007) 
Kyung hwa Baek, B.S., Seoul National University; 
Co-Chairs of Advisory Committee: Dr. Susan A. Bloomfield  
                                                    Dr. Joanne R. Lupton 
 
Mechanical unloading and food restriction (FR) are leading causes of bone loss, which 
increase the risk of fracture later in life. Leptin, a 16kDa cytokine like hormone 
principally produced by white adipocytes, may be involved in bone metabolism with 
physiological or mechanical changes causing bone loss. The hypotheses of the first study 
were aimed at determining if serum leptin is reduced by unloading or FR. The serum 
leptin level reduced by unloading or by global FR, is associated with the decline in bone 
formation rate. It was conjectured that decreased serum leptin may be due to reduced 
adipocyte number/size and/or sympathetic nervous system (SNS) activation of beta-
adrenoreceptors with unloading or FR, inhibiting the release of leptin from adipocytes. 
In the second experiment, we tested whether leptin or beta-adrenoreceptor blockade 
attenuates bone loss during unloading and whether such an effect due to beta blockade is 
associated with changes in serum leptin level. Beta-blockade mitigated unloading 
induced reduction in serum leptin and also beta blockade was as effective as leptin 
administration in mitigating a reduction in cancellous bone mineral density with 
unloading through both stimulation of bone formation and suppression of resorption. It 
was previously demonstrated that energy restriction (ER) is a major contributor to the 
iv 
 
 
 
bone loss during global FR. In the third study, we tested whether beta- blockade 
attenuates bone loss during ER and whether such an effect is associated with changes in 
serum leptin level and leptin localization in bone tissues. Beta blockade attenuated the 
ER induced reduction in serum leptin level, cancellous bone mineral density and bone 
formation rate, and also abolished the ER induced increase in bone resorption. Reduction 
in leptin expression in bone marrow adipocytes observed with ER was attenuated by 
beta-blockade. Reduction in the number of cells (bone lining cells, osteocytes and 
chondrocytes in cartilage) which are stained positive for leptin was also attenuated by 
beta-blockade. Collectively, these data identify circulating leptin effects on preventing 
bone loss during mechanical unloading or energy restriction. Also beta blockade is 
associated with mitigating reduction in serum leptin and subsequently with mitigating 
reduction in bone mass with unloading or ER. 
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CHAPTER I 
 
INTRODUCTION 
 
 
Mechanical unloading and restricted dietary intake are leading causes of bone loss, 
which increase the risk of fracture in later in life. Mechanical unloading due to 
spaceflight or bed rest induce decrements in bone health. About 1% of bone mineral 
density (BMD) is lost per month while in microgravity (1, 2) although the magnitude of 
loss is highly variable among subjects and among anatomical sites. A significant 
percentage of pre-menopausal women in modern society utilizes food restriction in their 
attempts to lose weight (3). Dieting and weight cycling are known to result in clinical 
concerns, leading to menstrual cycle disturbances and decreased bone mass (4-7). An 
association between a history of weight loss in pre-menopausal years and increased risk 
of hip fracture later in life has been reported (8). On average, a 1% decrease in bone 
mass (9) and an increase in bone resorption (10, 11) is associated with each 10% 
decrement in body weight.  
 
Leptin, a 16 kDa cytokine-like hormone principally produced by white adipocytes, may 
also be involved in the bone response to microgravity and/or restricted food intake.   Its 
principal function is the regulation of energy balance and body composition through  
negative feedback mechanisms at the hypothalamic nuclei. Leptin is now known to have 
 
___________________ 
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numerous biological effects on the immune system (12), reproduction (13), development 
(14), hemopoiesis (15), angiogenesis (16) and, most recently, on bone metabolism. 
However, there is controversy about the nature of leptin’s effects on bone. Early studies 
demonstrated anti-osteogenic effects of leptin via the sympathetic nervous system when 
delivered directly to the brain’s hypothalamus (17,18), but several more recent studies 
have demonstrated a bone-protective effect of leptin during hindlimb unloading or 
caloric restriction when administered to the peripheral circulation (19,20).   
 
Activation of the sympathethic nervous system (SNS) is increased with stressful 
conditions, such as food restriction (21, 22) and simulated microgravity (23-25), which 
conditions also result in increased bone resorption and/or decreased bone formation. 
Beta-adrenergic receptor activation is also known to inhibit leptin release from 
adipocytes (21, 26). Pharmacological blockade of beta-adrenergic SNS signaling 
mitigates loss of cancellous bone with hindlimb unloading rats (27), but the effect of 
beta-adrenergic blockade on serum leptin and on bone during caloric restriction has not 
been demonstrated.   
 
In the first study described in Chapter III, I investigated the individual and combined 
effects of food restriction and simulated microgravity in adult male rats and the 
contribution of altered serum leptin to changes in bone strength, density, and turnover 
status. With the result from the first study, we conjectured that changes in serum leptin 
during hindlimb unloading (simulating microgravity) in rats may result from the 
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inhibition of leptin synthesis or secretion due to SNS activation of adipocyte β-
adrenoreceptors. In the second study (Chapter IV), we pharmacologically blocked β-
adrenoreceptors to examine the impact of the sympathetic nervous system on changes in 
important bone parameters during unloading. In addition, we replaced leptin during 
hindlimb unloading to determine if leptin deficiency is an important factor in the loss of 
bone mass with unloading.  
 
In a preliminary study quantifying the effect of restricting individual nutrients (calcium, 
protein, energy) to bone loss in a side-by-side comparison (28), we demonstrated that 
reduced energy intake is the major contributor to the impact of restricting all food intake 
(global food restriction) on reductions in bone mineral density.  This dissertation’s first 
and second studies demonstrate that hindlimb unloading and food restriction each 
independently produce a decrease in serum leptin. Further, blockade of beta-adrenergic 
SNS signaling alleviated reductions in serum leptin, bone mineral density, and bone 
formation rate in hindlimb unloading rats. In the third study (chapter V), we tested the 
mechanistic role of leptin in bone loss during another stressful condition, dietary energy 
restriction. We characterized the effect of β-blockade on serum leptin levels and on bone 
parameters during energy restriction. However, yet unproven in the second study was 
whether elevating circulating leptin levels actually resulted in more leptin reaching the 
critical bone cells responsible for bone formation or resorption.  Therefore, in the third 
study, we also confirmed whether increased serum leptin levels actually results in more 
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leptin reaching the critical bone cells responsible for bone formation/resorption by 
staining histological sections of bone with antibodies specific to leptin protein.  
Taken together, the results of these studies illustrate important role of “peripheral” leptin 
mechanisms in regulation of bone mass during mechanical unloading or energy 
restriction. Also, these data illustrate an association between beta-adrenergic signaling 
and leptin pathways in regulating bone cell activity in the context of mechanical 
unloading or energy restriction.   
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CHAPTER II 
 
REVIEW OF LITERATURE 
 
 
Bone remodeling 
 
Mammalian bone has the ability to constantly rejuvenate itself through the process of 
remodeling, which continues until death. The major functions of bone remodeling are, 
first, the maintenance of mechanical strength by constantly replacing old bone by new, 
mechanically healthy bone, and second, assisting in mineral homeostasis as a store of 
calcium and phosphorus. Remodeling is performed by a group of cells, which are termed 
bone remodeling unit (BRU),  that act on bone surfaces in a close and sequential 
collaboration.  
 
 There are four phase in the remodeling cycle: activation, resorption, reversal, and 
formation.  During activation, osteoclast precursor cells, which initiate remodeling on 
quiescent bone, are recruited.  The pre-osteoclasts stick to the bone matrix via binding 
between integrin receptors on the osteoclast surface and RGD- containing peptides in the 
organic matrix, creating a unique sealed microenvironment between itself and bone 
matrix.   During the resorption phase, protons transferred by a specific pump on the 
multinucleated osteoclast surface acidify the resorbing area.  A number of lysosomal 
enzymes that are active at low pH are also secreted (29).  The acidic solution, 
accompanied by lysosomal enzymes, dissolves and digests the bone matrix and mineral.   
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With osteoclast apoptosis, the resorption phase ends and is followed by a reversal phase. 
In the reversal phase, coupling between osteoclasts and osteoblasts takes place; that is, 
signals activating osteoblasts to replace resorbed matrix couple or link activity of these 
two cell types to a specific bone surface site.  The origin of coupling signals or the exact 
mechanism of the coupling process is not fully understood. One major hypothesis is that 
during the resorption process, osteoclasts release growth factors such as TGF-β, IGF-I, 
and bone morphogenetic proteins (BMP’s), which act as chemotatic factors attracting 
osteoblasts and stimulating osteoblast differentiation and proliferation (30-32). During 
the formation phase, osteoblasts initiate the synthesis of organic bone matrix, which is 
termed osteoid, and regulate its mineralization.  
 
There are three stages in the formation phase.  First, collagen synthesized and secreted 
by osteoblasts is deposited and an osteoid seam, the area of unmineralized matrix 
between the osteoblasts and pre-existing mineralized bone, is produced. Then, 
osteoblasts trigger mineralization, which is the process of hydroxylapatite crystal growth 
within osteoid, by releasing matrix vesicles. Matirix vesicles set up suitable conditions 
for initial mineral deposition by concentrating calcium and phosphate ions and 
enzymatically degrading pyrophosphate and proteoglycans which are inhibitors of 
mineralization.  Finally, the rate of collagen synthesis decreases and the mineralization 
continues until the osteoid seam disappears.  After completion of their bone formation 
function, osteoblasts die by apoptosis or are incorporated into the mineralizing matrix as 
osteocytes or remain on the surface as bone lining cells. Osteocytes located deep inside 
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of the bone matrix are in a close connection with each other and osteoblasts on the bone 
surface through the numerous cellular extensions that lie within canaliculi.    
 
Healthy , young adults, there is virtually no bone loss in most regions of the skeleton, 
because the coupling of bone formation to previous bone resorption effectively replaces 
all bone resorbed. Various physiological changes or stressors, such as menopausal 
estrogen deficiency, reduced energy intake, or chronic disuse can induce “uncoupling” 
of this balance between formation and resorption. The activation frequency of bone 
remodeling sites increases and the resorption phase becomes prolonged, leading to  net 
bone loss (33). Cancellous bone loss due to these physiological and/or environmental 
changes is more dramatic than cortical bone loss for several reasons.   Cancellous bone 
has a greater bone surface per unit volume of bone upon which bone cells can act and 
also has a better developed contact with blood vessels. 
 
 
 
Bone and disuse/tail suspension 
 
 
Mechanical loading is an essential factor for maintaining skeletal integrity. Decrements 
in bone health result from spaceflight and other periods of prolonged skeletal disuse. 
Major skeletal losses during spaceflight have been well documented in both humans and 
animals. Although this is highly variable among subjects and among bone sites, about 
1% of bone mineral density is lost per month while in microgravity. This is a rate is 
about 12 times faster than the average 1% loss that normal postmenopausal women 
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experience per year (2,34). Astronauts tend to lose bone only in weight-bearing sites, 
such as the distal tibia and femoral neck, although vertebral bone is also affected. Losses 
are much greater in cancellous bone than in cortical bone, at least over 6 months (2). 
Whether this loss eventually plateaus is not known, because very few astronauts or 
experimental subjects have been exposed to microgravity or strict bed rest for more than 
6 months. Microgravity-induced changes in bone turnover, bone mineral density (BMC), 
bone mineral density (BMD), and mechanical strength have been measured via 
biochemical markers, quantitative computed tomography (QCT), dual energy X-ray 
absorptiometry (DEXA) and mechanical testing.  
 
As a whole body measure, biochemical markers of bone turnover can be used to quantify 
changes in bone formation (e.g., osteocalcin, OC) and bone resorption (e.g., 
deoxypyridonoline, DPD) to imposed changes in the mechanical environment.  
Decreases in OC concentration have been measured in growing rats subjected to 
simulated microgravity by hindlimb unloading (HU) (35).  Serum OC transiently 
decreases by 25% in 6-week old rats after one week of HU, then returns to almost 
normal levels after 28 days of HU (36). Consistent and dramatic increases in DPD have 
been demonstrated in humans exposed to space missions lasting 4 -6 months. DPD 
measured at post-flight increased 55% above preflight levels (37), suggesting that bone 
remodeling becomes uncoupled during disuse, resulting in net bone loss. 
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In Mir crew members, significant reductions in cancellous volumetric bone mineral 
density (vBMD) (by peripheral QCT) in 1 month and significant reductions in cortical 
vBMD in distal tibia after 2 months has been reported, along with substantial inter-
individual variations in this response. . In this study, tibial bone loss persisted during 6 
months of recovery, suggesting that the time needed to recover is longer than the mission 
duration (2). In a recent study in 2006 with crew members of the International Space 
Station (ISS) a comparison of pre- and post flight image measurement by using clinical 
QCT demonstrated that the crew members lost roughly 11% of the total bone mineral 
content from their proximal femora. The cancellous bone mineral content and density 
declined by 14.4-16.5% over the 4.5 to 6 months of the mission.  Consistent with 
previous reports, measures of vBMD and estimated bone strength of proximal femoral 
indicate only partial recovery, although bone mineral content was recovered in the year 
after spaceflight.   An increase of bone volume and cross sectional area at the femoral 
neck during the recovery period has been also reported (34). Small declines in 
cancellous vBMD of cosmonaut’s distal tibia have been reported starting at 1month of 
spaceflight and even greater decreases in cancellous and cortical vBMD are observed by 
6 months of flight (38).  
 
More data exist from microgravity studies using DEXA.   Bone mineral content, 
measured pre- and post-flight using DEXA, declines by 1 to 1.6% per month at the spine, 
femoral neck, trochanter, pelvis, and calcaneus (39). Femoral neck BMD declines 
roughly 22.5% on average in astronauts after 14.4 months of flight (40). The most 
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abundant spaceflight animal data is derived from rodents, particularly rats.  A number of 
studies have demonstrated lower cancellous bone volume in the proximal tibia (41-43), 
vertebrae (43), and pelvic bone (44) of space flown rats as compared to ground controls. 
But the most rats utilized in spaceflight and ground-based simulation studies were 
relatively young, rapidly growing rats, making interpretation relevant to the mature 
skeleton difficult, because a major effect of microgravity on growing bone is growth 
retardation. The skeleton of all the human astronauts who are exposed to microgravity is 
mature, hence the major effect of disuse in this case is altered remodeling.    
 
The precise mechanism of microgravity-induced bone loss isn’t yet fully understood. To 
investigate the alteration in skeletal cell signaling, hormonal effect, bone blood flow, 
fluid shifts, or any other mechanism which induce bone loss in microgravity, invasive 
methods must be utilized. Researchers cannot easily perform such methods on humans, 
so rat models have been developed to provide more mechanistic information about the 
skeleton’s adaptations to unloading.  With several exceptions, the rat skeleton has 
numerous structural and physiological similarities to human skeleton, making it an 
effective model of human bone responses.   A ground-based model to study the effects 
of microgravity on the rats was developed by Emily Morey-Holton in the early 1980’s. 
This model, called hindlimb unloading (HU) has been widely used and accepted among 
microgravity researchers. In HU model, the rat’s hindlimb is elevated around 30° from 
the ground by a tail harness, creating a head down tilt position. The rat can move its rear 
legs without being able to push against the ground.  Rat’s forearms experience normal 
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weightbearing on the ground, thus can act as an internal control. Rats subjected to HU 
demonstrate similar physiological adaptations similar to those observed in rats and 
humans flown in space, including a cephalic fluid shift, a decline in weight bearing bone 
and muscle mass, and negative calcium and nitrogen balance (45).   
 
Decreases in osteoblast number, bone formation rate and cancellous bone volume also 
occur in HU rats, and all of these changes are specific to the unweighted hindlimbs. 
Adult rats suspended for 14 days demonstrate decreased bone formation. Alkaline 
phosphatase activity in the femoral and tibial diaphysis of HU rats is reduced as much as 
two times below the level in control rats (46). Six-mo-old rats suspended for 14 days 
demonstrate a significantly decreased tibial ash weight, calcium content, BMC, and 
BMD versus controls (47). HU results in gender-independent decreases in cancellous 
bone volume (BV/TV) compared with baseline values, accompanied by architectural 
changes, such as decreased trabecular number and corresponding increases in trabecular 
separation.   Histomorphometric measurement reveal decreases in BV/TV in both 
genders  that are associated with decreased bone formation and increased bone resorption 
(48).Twenty-eight days of HU results in ~ 20% decline in cancellous BMD at the 
proximal tibia and femoral neck compared to controls.   Bone formation rate at tibial 
midshaft is lower (by 90%) vs. baseline controls after 21 days of HU (49). Consistent 
with human studies, bone loss in HU rats is site-specific. Bone mineral is lost primarily 
from the cancellous bone compartments in unweighted bones of tail-suspended rats. 
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With some exception (50), bone loss during HU likely occurs predominantly in 
cancellous bone because that is the site where remodeling is most active. 
 
Exposing humans or animals to slightly stressful conditions can increase heart rate and 
blood pressure through activation of the autonomic nervous system and elicit the release 
of catecholamines. Several studies have demonstrated that sympathetic nervous activity 
during microgravity is increased compared with ground-based values.   Plasma 
norepinephrine values are elevated in space flight above values observed in the seated 
position in ground-based experiments (51). Platelet norepinephrine and epinephrine 
increased in four of the five cosmonauts during two weeks of microgravity (Platelet 
norepinephrine and epinephrine are a more reliable measurement for detection of 
changes in epinephrine release than comparable measurements of epinephrine in venous 
blood, because the platelet epinephrine concentration does not depend on the extraction 
ratio in tissues) (52). Platelet norepinephrine concentrations were 153 ± 28% (mean ± 
SE) of pre-flight values. Baseline sympathetic neural outflow is increased moderately in 
spaceflight, as is norepinephrine spillover rate (53). Plasma corticosterone is higher after 
short (5-7 days) and long (> 14 days) term flights, and catecholamine levels in plasma 
increase after 14 days or more in microgravity (54). In simulated microgravity 
experiments with tail suspended rats, plasma norepinephrine and epinephrine increase by 
53 and 42% after 7 days, but only epinephrine returns to baseline after 14 days (24).  
This generalized activation of the sympathetic nervous system and increased circulating 
catecholamines may be involved in the bone loss during spaceflight. Potential 
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relationships between elevated level of catecholamines, especially norepinephrine, and 
bone during exposure to microgravity or to other conditions causing bone loss will be 
discussed in a later section of this chapter. 
 
Food restriction and bone health 
 
 
Individuals with a history of weight loss, weight cycling or low body weight have an 
increased risk of osteoporosis since bone mineral density may be compromised in these 
scenarios (55,56).  Crash dieting, weight cycling and disordered eating are known to 
result in clinical concerns, including a negative impact on reproductive hormone profiles, 
resulting in menstrual cycle disturbances and decreased bone mass (4-7).  
 
The prevalence of dieting and weight loss efforts at any given time amongst U.S. women 
exceeds 50% (3). The 1990 National Health Interview Survey reported that nearly 44 
million persons age 25 years and older were attempting to lose weight, which was a 
significant increase from the 1985 version of the survey (57).   Weight loss attempts are 
not restricted to adults (58). It was reported that 46% of college undergraduates were 
trying to lose weight in 1995 National College Health Risk Behavior Survey (59); 44% 
of female and 15% of male high school students admitted that they were trying to lose 
weight in 1990 Youth Risk Behavior Survey (60).  The gap between the proportion of 
female and male students attempting to lose weight has increased (58)  and women are 
also outnumber men in the quantity of their weight-loss attempts (61).  
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Body mass is positively correlated with BMD (62,63).  On average a 1% decrease in bone 
mass (9) and increased bone resorption (10, 11) is associated with each 10% decrement 
in body weight. A negative correlation between the number of times that dieters cycle 
their weight and their BMC values has also been reported (64). Hip fracture risk is 
significantly increased with weight variability in middle-aged women over a twelve-year 
period, which was further exacerbated by the association between weight loss and hip 
fractures (8). Energy restriction diet induced weight loss results in rapid loss in women’s 
total body BMD (65); even general reductions in body mass can decrease bone density 
as demonstrated a 17% reduction in body mass over 10 weeks  yielding an average 2.5% 
total body BMD decrement.  
 
Global food restriction in the attempt to lose weight results in reduced dietary intake of 
many individual nutrients such as energy, protein, calcium and vitamin D that are 
important to maintain bone health.   There exists a rich literature examining the effect of 
individual nutrient restriction such as calcium, vitamin D, protein, or energy on bone, 
with most of these studies indicating negative effects on bone turnover and bone mass.  
 
Calcium 
Calcium is the most studied nutrient important for optimal bone health. Almost 99% of 
the total body calcium is stored in the bones in the form of hydroxyapatite crystal; 
therefore, bone serves as the primary source of calcium when dietary intake is 
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insufficient and blood calcium level is low. Almost 80-90% of hydroxyapatite in bone is 
composed of calcium and phosphorus (66).  
 
Dietary calcium restriction results in reduced BMD and CSMI in femoral and vertebral 
bone in female rats (67). Dietary calcium deficiency also impairs normal bone 
remodeling as it uncouples bone formation from bone resorption. In a study testing 90% 
reductions in calcium intake over one month, turnover markers osteocalcin (+24%) and 
pyridinoline (+48%) were elevated in mature female rats. In the same study, reductions 
in cancellous bone mass (-26%) and trabecular connectivity (-54%) were observed (68). 
 
In general, the effect of dietary calcium on bone is more dramatic if superimposed on 
estrogen deficiency, as observed after menopause. BMD is maintained or increased in 
postmenopausal women when additional dietary calcium or calcium supplement was 
given (69-74). If estrogen is treated combined with dietary calcium, the preventive effect 
was more pronounced  than either treatment alone in late postmenopausal women (75), 
particularly if Ca intake is low (76). Bone loss is exacerbated in late postmenopausal 
women whose calcium intake is low (76). 
 
 Vitamin D 
Vitamin D is one of the essential nutrients to maintaining bone health because its active 
form, 1,25-dihydroxyvitamin D [1,25-(OH)2D, or calcitriol) influences calcium and 
phosphorus metabolism by affecting the target organs:  intestine, bone and kidney. The 
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homeostasis of extracellular ionized calcium is tightly regulated by a number of 
hormones, among which parathyroid hormone and vitmin D play a major role. Vitamin 
D derived from dietary sources or synthesized from skin by ultraviolet radiation of 7-
dehydrocholestrerol is hydroxylated to 25(OH)D in the liver and further hydroxylated to 
1,25(OH)2D in the kidney.  The 1,25-(OH)2D facilitates active calcium absorption in the 
intestine by stimulating the synthesis of calcium binding protein (calbindin), the 
reabsorption of calcium in kidney and the release of calcium from bone. Parathyroid 
hormone is the major regulator of 1,25-(OH)2D and also maintains extracellular calcium 
homeostasis through its effect on kidney and bone. It is well known that vitamin D 
deficiency may cause rickets in children and osteomalacia in adults. It’s been reported of 
vitamin D inadequacy is prevalent amongst women with osteoporosis (77), and a 
substantial proportion of patients with hip fractures also have osteomalacia, caused by 
vitamin D deficiency (78).  
 
Protein 
Generally, increases in dietary protein result in increased urinary calcium excretion even 
though the long term implications of high protein diet for skeletal health are uncertain 
(79). Higher protein intake could bring about net calcium loss, resulting in negative 
calcium balance. Calcium mobilization via bone resorption may be stimulated to 
counterbalance the net calcium loss, and the prevalence of osteopenia or osteoporosis 
might be increased. 
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On the other hand, adequate intake of dietary protein stimulates the release of IGF-1, 
which promotes bone formation and mineralization by accelerating osteoblastic cell 
differentiation  (80). Research data addressing the effects of high or low protein diets on 
bone are controversial. An uncoupling of bone resorption and formation was observed in 
8-month-old male rats with isocaloric low-protein diet (2.5% casein vs 15% casein in 
control diet)(81).  It has also been demonstrated dietary protein restriction lowers plasma 
insulin-like growth factor-1, impairs cortical bone formation, and induces osteoblastic 
resistance to insulin-like growth factor-1 in adult female rats (82). In epidemiological 
studies, most data demonstrate a positive association between protein intake and BMD 
(83-85), but not all. Many (86-88), but not all (89), report higher fracture rates in groups 
consuming a high protein diet. Clinical intervention studies generally support the 
negative effect of high protein on bone hypothesis. Many studies report increases in 
bone resorption when animals or humans are fed a high protein diet (90-92),  but some 
do not (93-96).    Bourrin et al. (81) reported that an isocaloric low protein (2.5% casein) 
diet in male rats significantly decreased proximal tibial BMD and mechanical strength. 
Moderate (40%) protein restriction, when combined with aerobic exercise, appears to 
strengthen the femoral neck more than those in the exercising control (97). Kerstetter et 
al (98) reported that the status of PTH is affected by various protein intake, and 
secondary hyperparathyroidism induced by low protein diet is attributed to a reduction in 
intestinal calcium absorption. 
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Energy 
As previously described, restricting calories is known to have negative consequences on 
bone integrity. Bone loss is associated with energy restriction in both animals (99-101) 
and humans (102,103). When mature (aged 20 weeks) female rats were fed an 40% 
energy-restricted diet for nine weeks, significant reductions were found in their femoral 
BMD and cortical area, tibial BMD, and uterine weights (99).  In human studies, the 
effects of graded energy availability decreased from 40 kcal/kg/lean body mass to 10 
kcal/kg/lean body mass in young exercising women were assessed with bone 
resorption/formation markers. The bone resorption marker NTX increased as dietary 
intake was reduced from 20-  to 10/kcal/LBM/day.  The bone formation marker serum 
PICP decreased as the degree of energy restriction increased from 40- to 
30/kcal/LBM/day and continued as restriction was increased.   Estradiol levels increased 
at 30/kcal/LBM/day initially, but its level steadily declined as energy restriction 
increased (102).   
 
In the study to find out relationship between calcium and energy intake on bone (100), 
bone mineral density is compromised by calcium restriction in both older and younger 
female rats, whereas only older rats are negatively influenced by energy restriction, 
suggesting an adverse effect not only of low calcium but also low energy on skeletal 
health in mature animals. In this study, adverse effect of calcium restriction on bone 
mineral density in older rats was slightly greater than that of energy restriction, but not 
significant. A few data are available on a secondary deficiency of another bone-relevant 
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nutrient that is a consequence of restricted caloric intake.   Restricting energy by 40% for 
10 weeks reduces fractional calcium absorption in mature obese and lean rats, from 30% 
to 24%, compared with 25% to 29% in 100% fed control rats (99). In a study trying to 
quantify the magnitude of each individual nutrients restriction’s contributions to bone 
loss in a side-by-side comparison in adult female exercising rats, 40 % energy restriction  
resulted in the greatest negative effects on bone health versus 40% calcium or 40% 
protein restriction (28). 
 
There are several potential mechanisms by which restricted energy intake may contribute 
to lower bone mass, including the decreased mechanical loading on the skeleton with 
reduced body mass, the reduction in number and size of adipocytes that secrete bone-
active hormones, and alterations in secretion of bone- related hormones from the gut or 
pancreas.   With energy restriction, there is a decrease in circulating adipocyte-derived 
leptin that normally promotes bone mass increase. But the effect of leptin on bone is still 
controversial and it likely varies depending on the bone site. [The review for leptin and 
its effect on bone will be described in more detail in the last section of this chapter.] 
Consequent to restricted energy intake (and subsequent weight reduction) serum levels 
of circulating estrogen and other sex hormones that may play a role in 
osteoblast/osteoclast activity decrease.  Estrogen receptors are present on both 
osteoblasts and osteoclasts.   Estrogen promotes the differentiation of bone marrow 
stromal cells (BMSC) to osteoblasts rather than to adipocytes (104), increases osteoblast 
proliferation (105), and increases production by osteoblasts of proteins such as IGF-1, 
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transforming growth factor-beta (TGF-β), and bone morphogenetic protein-6 (BMP-6) 
(106-108). Estrogen normally suppresses bone resorption by increasing osteoclast 
apoptosis and by contributing to increased osteoprotegerin (OPG) relative to another 
regulator of osteoclast activity, receptor activator of nuclear factor-kappaB ligand 
(RANKL), thereby increasing the OPG/RANKL ratio (109). Exposure of BMSC’s to 
estrogen also reduces their production of cytokines such as interleukin-1 (IL-1), IL-6, 
and tumor necrosis factor-α (TNF-α), which are potent stimulators of osteoclast 
recruitment and activity (110).  
 
IGF-I stimulates proliferation of osteoblast precursor cells and independently promotes 
matrix production by mature osteoblasts; during energy restriction, serum IGF-I is 
suppressed (31). In addition, energy restriction induces a rise in the calcium-PTH axis; 
serum PTH rise, in women consuming low/normal calcium (0.6-1.0g/d), resulting in 
reduced fractional calcium absorption (99).  
 
Noradrenaline and/or epinephrine release is increased with fasting or weight reduction 
(111,112) that also results in loss of bone mass. Mammalian bones are widely innervated 
by sympathetic and sensory nerves, which are particularly abundant in regions of high 
osteogenic activity (113,114). Chemical denervation of sympathetic and/or sensory 
nerves has been demonstrated to impair bone resorption in rats by decreasing the number 
of osteoclasts (115,116). Relatively recent studies confirmed that osteoblasts express β-
adrenergic receptors (117). Sympathetic activation or increased sympathetic tonic output 
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reduces osteoblast proliferation and stimulates bone resorption (117). It is well known 
that beta-adrenergic agonists can stimulate bone resorption in the intact mouse calvaria 
(118). This may be mediated by the activation of osteoclastic cells and/or the production 
of osteotrophic factors by osteoblastic cells. Activation of beta adrenoreceptors by 
epinephrine increases the expression of osteotrophic factors such as receptor activator of 
NF- kappa B ligand (RANKL), interleukin (IL)-6, IL-11 and prostaglandin E2 (PGE2), 
as well as the formation of osteoclast-like cells from mouse bone marrow cells (119). 
Beta-adrenergic blockade, on the other hand, blunts the inhibition of alkaline 
phosphatase activity by isoproterenol (a beta agonist) in an osteoblast-like cell line, 
which suggests that beta blockers may enhance bone formation by preserving 
osteoblastic activity in the face of beta adrenergic receptor stimulation (120).  
 
Supporting these in vitro studies, in vivo studies also have demonstrated that adrenergic 
stimulation modulates osteoblastic activity and osteoblast-mediated osteoclastogenesis. 
Administration of lipopolysaccharide (LPS) increases the norepinephrine (NE) turnover 
rate in various brain areas and peripheral tissues (121,122).  Intracerebroventricular 
injection of LPS induces an increase in IL-6 serum levels and in IL-6 mRNA expression 
in the brain and peripheral organs (123,124). Treatment of mouse calvaria with NE 
increases IL-6 synthesis in an organ culture system. (125). Pretreatment with a beta-
blocker inhibits both stress- and LPS-induced increases in the level of IL-6 mRNA, but 
pretreatment with an alpha-blocker did not inhibit them in mouse calvaria . Recently, it 
was reported that an increase in bone norepinephrine levels triggered by depression is 
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associated with bone loss, suggesting the sympathetic nervous system mediates even 
psychological stress-induced effect on skeleton (126). 
 
Energy restriction in human clinical studies 
Studies have demonstrated beneficial effects of chronic energy restriction on slowing the 
aging process and increasing the maximal lifespan in nonhuman primates (127,128). 
Little is known regarding the effects of long term energy restriction in humans. 
Feasibility studies for human ER, referred to as CALERIE (Comprehensive Assessment 
of Long-term Effect of Reducing Intake of Energy), were completed recently.  At 
CALERIE phase 1, effects of 20% ER with those of a 20% increase in energy 
expenditure induced by exercise with caloric intake kept constant (EX) were compared. 
Reductions in body weight and abdominal fat, induced by ER or by EX, improve insulin 
action and glucose tolerance (129).  
 
But the fact is, many dieters lose and regain weight many times in their lifetime. Weight 
cycling dieters, especially in female athletes, are at risk of compromising long-term bone 
health due to nutritional deficits with weight loss and related menstrual irregularities 
(130). One-time diet-induced weight loss is accompanied by a significant decrease in 
bone mineral density (BMD); for every kg fat loss,  16.5 g of bone mineral loss was 
observed in eight energy -restricting women volunteers before and 10 weeks after a 
very-low-calorie diet [405 kcal/day] (131). In another more liberal diet regime, which 
prescribed energy intake up to 4.2 MJ (1000kcal) and moderate weight losses, 
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significant losses in total body bone mineral and lumbar bone mineral density were 
documented.  
Generally, low-calorie diets (1000-1200 kcal/d for women, 1200-1400 kcal/d for men) 
are considered as a safe strategy for weight loss (132,133) and have been selected for 
several diet education programs (134,135) and some commercial programs (132). This 
low-calorie diets represents 40% or more energy restriction compared to the 2006 DRI 
energy requirements for moderately active young men and women. Sometimes very-
low-calorie diets (~800kcal/day) are recommended to people with a body mass index 
over 30 kg/m2, who face major health risks (136). Very-low-calorie diets result in an 
average weekly weight loss of 1.5–2.5 kg, compared with 0.4–0.5 kg with low-calorie 
diets (137). Even though conclusions from human epidemiological studies are limited by 
the inability to measure the common degree of voluntary dieters and by the lack of data 
regarding plausible biological mechanisms underlying the effects of voluntary weight 
loss, bone loss in weight losers is an unwanted effect of very low calorie diets, and it can 
be avoided by using regimes with a higher energy content (138). 
 
 
Bone and leptin 
 
 
Leptin  
 
Fourteen years ago, a study identifying the “obese” (Ob) was reported (139), launching a 
new era in obesity research.   Leptin (Ob), a 16 -kDa cytokine-like hormone principally 
produced by adipocytes, has emerged as a candidate signaling molecule to link energy 
metabolism and regulation of bone mass. White adipose tissue is the primary site of 
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leptin synthesis and secretory regulation, but recent studies demonstrate that leptin is 
produced in placenta, skeletal muscle, fetal bone/cartilage and primary cultures of 
human osteoblasts (140-143). Leptin interacts with the central nervous system by 
binding to its own receptor in the hypothalamus, with its main functions being the 
regulation of appetite and energy metabolism. Leptin also exerts effects on cells in 
peripheral tissues via high-affinity leptin receptors (140-145). In terms of its structure, 
leptin is a member of the growth hormone four-helical cytokine subfamily. 
 
Even though serum leptin level in humans and rodents are primarily regulated by the 
relative size of body fat stores (146), there are several other factors that affect circulating 
leptin levels independently of alterations in adipocity. Studies in human and rodent 
models demonstrate that stimulation of sympathetic nervous system output and 
activation of β-adrenergic receptors decrease serum leptin levels over a short time frame 
(147-149). β-adrenergic agonist administration decreases serum leptin and subcutaneous 
adipose tissue interstitial leptin concentration in humans within 3 hrs (150). Activation 
of the β-adrenergic receptors, combined with a decrease in serum insulin , is thought to 
be responsible for the decrease in leptin levels with fasting.  In addition to short-term 
fasting, long-term food restriction (85%, 70% and 50% of ad libitum energy intake for 
one month) in rats produces a substantial fall in serum leptin and leptin mRNA levels in 
epididymal white adipose tissue (151). 
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Leptin receptor 
Leptin receptor (db) is classified as a member of the class I cytokine receptor 
superfamily due to strong homology in signal transducing subunits and a shared 
signaling pathway with IL-6, G-CSG, and LIF. Five isoforms (OBRa, OBRb, OBRc, 
OBRd and OBRe) are known to exist. The OBRa, OBRb, OBRc and OBRd have a 
membrane-spanning domain that anchors the cell membrane, but OBRe does not (152). 
Leptin circulates in plasma in a free form and a protein-bound form, and OBRe functions 
as a major binding component for plasma leptin (153).  Overexpression of OBRe in 
ob/ob mice produces phenotypic changes suggesting that OBRe serves to delay leptin 
clearance, increasing the available leptin in circulation (154). OBRb, the longest form of 
receptor, is thought to be the only isoform that is capable of full signal transduction 
because it contains cytoplasmic domain with specific sequence that binds to intracellular 
signaling molecules. The db/db (leptin receptor-deficient) mouse, whose phenotype is 
obese with high bone mass at select bone sites, has a db locus mutation that eliminates 
OBRb (152). OBRb is primarily expressed in the hypothalamus. Expression of OBRb in 
peripheral tissue such as bone, skeletal muscle, adrenals, pancreatic β-cells adipocytes, 
immune cells, kidneys, and liver also has been reported (12,155-158) . The cellular 
effects of leptin are dependent on the receptor subtypes that cell expresses and the fate of 
endocytosed leptin inside the cells. Endocytosed leptin can remain intact for at least 1 h. 
This stability is further enhanced by inhibition of lysosomal activity. Thus, the 
intracellular pool of intact leptin may allow for prolonged biological functions for this 
adipokine (159). 
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Leptin transport/Leptin resistance 
Blood brain barrier 
Nutrients and drugs diffuse freely between the blood stream and tissues in the body, but 
this is not so between the blood and the brain.  Between blood and brain, precise 
control over the substances that leave or enter the brain is required, because the brain’s 
neuronal tissue must be protected from potential toxic compounds in the bloodstream 
and from the chemical or hormonal fluctuations that occur after a meal or exercise that 
might disrupt optimal function. Simultaneously, glucose, oxygen, and other nutrients 
should be in constant supply to meet the high metabolic needs of central nervous system 
(CNS) tissue. To meet tboth requirements; the need for constant supply of nutrients and 
protection  from potentially harmful compounds or sudden chemical fluctuation, blood 
vessels in the brain are coated with a tight-knit layer of endothelial cells, which are 
largely responsible for the blood-brain barrier (BBB) (160,161). These cells coat the 400 
miles of capillaries and blood vessels in the brain, creating a barricade. An elaborate 
network of complex tight junctions between the endothelial cells forms the structural 
basis of the BBB and restricts the paracellular diffusion of hydrophilic molecules (161). 
Also, transcellular passage of molecules across the barrier is also blocked due to the very 
low pinocytotic activity and the scarcity of fenestrae in BBB endothelial cells (162). The 
structures located in the midline of the ventricular system (160) and that lack an 
endothelial BBB are collectively referred to as circumventricular organs (CVO’s). 
CVO’s are responsible for monitoring hormonal stimuli and other substances within the 
bloodstream or secrete neuroendocrine factors into the peripheral circulation (163). 
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Molecules have to enter BBB endothelial cells via membrane-embedded protein 
tranporters or by slipping directly through its outer membrane. Hypothalamus is one of 
the CVO’s and it’s been suggested the existence of leptin specific transporter for 16 kDa 
size of leptin to pass the BBB (164). Expression of leptin transporter may be regualated 
with serum leptin level (164).  Once passing the outer membrane of the BBB, foreign 
compounds must avert various protein pumps trying to evict any foreign molecules and 
also lots of metabolic enzymes that may able to digest the compound. Having avoided 
these obstacles, foreign molecules must then pass through the inner membrane of a BBB 
cell to finally reach the brain. In terms of drug delivery to heal brain-related disease, 
BBB is considered more of an obstacle than safeguard. Molecules that can slip across the 
BBB membrane cells are typically small (under 500 daltons), are lipid-soluble, and have 
a low polar surface area (160). 
 
Leptin resistance 
Leptin needs to cross the blood brain barrier to reach to its receptor in the  hypothalamus, 
especially arcuate nucleus and ventromedial nucleus to regulate food intake. The ratio of 
leptin in cerebrospinal fluid to plasma in obese human is low comparing to nonobese 
subjects, suggesting that obesity may arise from an impaired capacity for leptin transport 
into the brain (165).  Rats made obese rats due to overfeeding successfully lose body 
weight with leptin infused directly into the brain’s ventricle, but do not respond to 
peripheral (outside the CNS) leptin administration, serving to support this transport 
hypothesis (166). In human clinical studies, peripheral leptin injections have a limited 
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ability to reduce food intake and body weight (167). Leptin resistance, which is caused 
by impaired leptin transport to brain even with high serum leptin, appears to the major 
cause of human obesity. 
 
A suppressor of cytokine signaling, (SOCS-3),  has been identified as a negative 
feedback regulator of leptin signaling which diminishes leptin sensitivity, throwing an 
additional hypothesis in leptin resistance. SOCS-3 knockout mice exhibit enhanced 
tyrosine residue phosphorylation in JAK/STAT3 leptin signaling pathway, associated 
with a decrease in food intake and weight loss (168,169). Whether a specific leptin 
transporter molecule exists, and the details of its specific function, needs to be 
investigated further. 
  
Leptin signal transduction 
After leptin binds to and activates its receptor, signal transduction takes place to the 
hypothalamic genes activating signals regulating food intake, lipid metabolism and bone 
metabolism. Activated leptin receptor activates JAK2 kinase, resulting in tyrosine 
phosphorylation of Tyr1138 residue. Signal transducer and activator of transcription 3 
(STAT3) binds to phosphorylated Tyr1138 residue, resulting in its own phosphorylation 
and dimerization.   The STAT3 dimer eventually translocates to the nucleus, where 
transcriptional activity of several target genes are modulated (170). Genes whose 
expression is modulated by Janus kinase (JAK)/STAT3 pathway are thought to be pro-
opiomelanocortin (POMC) and Agouti related peptide (AgRP) (170,171), which are 
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important for food intake and body weight regulation and Thyrotropin-releasing 
hormone (TRH), which plays a role in thermogenesis (172). AMP-activated protein 
kinase (AMPK) is an enzyme that works as a fuel gauge which becomes activated in 
situations of energy consumption.  Leptin in skeletal muscle stimulates the 
phosphorylation of AMPK, reducing acetyl CoA carboxylase (ACC) activity.  Inhibition 
of ACC lowers intracellular malonyl CoA, eventually increasing fatty acid oxidation 
(173). The leptin-induced signal transduction pathway in bone cells is not yet fully 
understood. Leptin may increase bone mass by stimulating osteoblast proliferation 
through activation of PI3K and MAPK signaling pathway in human osteosarcoma cells 
(174). 
 
Leptin as an endocrine factor (central vs peripheral actions on bone) 
 
Leptin’s principal function is the regulation of energy stores and body composition 
through negative feedback at the hypothalamic arcuate nuclei. Leptin is now known to 
have numerous biological effects in the immune system (12), reproduction (13), 
development (14), hemopoiesis (15), angiogenesis (16) and, most recently, in bone 
metabolism. The nature of leptin’s effects on bone has not been fully determined.   Early 
studies claimed to demonstrate an anti-osteogenic effect of leptin signaled via the 
sympathetic nervous system when leptin was administered intracerebroventricularly 
(17,18), but several studies later demonstrated an osteoprotective effect of leptin during 
hindlimb unloading or caloric restriction when administered into the systemic circulation 
(19,20). Peripheral administration of leptin has a stimulatory effect on bone growth and 
bone formation via regulation of osteoblastic function (175) or, possibly, via preferential 
  
 
30
differentiation of bone marrow stromal cells into osteoblasts rather than to adipocytes 
(176). Inhibition of osteoclast generation (177) and positive effects on angiogenesis with 
peripheral leptin administration also has been demonstrated (178-180). By contrast, 
intracerebroventricular leptin administration, in other words, leptin signaling that is 
mediated by the central nervous system (CNS), results in a negative effect on bone mass. 
It has been proposed that centrally infused leptin suppresses bone formation via a 
hypothalamic relay. Neuropeptides upregulated by leptin in the hypothalamus activate 
SNS pathways, resulting in stimulation of β-adrenergic receptors on osteoblasts and 
inhibition of bone formation.   However, leptin deficiency produces contrasting 
phenotypes in bones of the limb and spine (181). Also, injections of leptin into rat 
ventromedial hypothalamus increase apoptosis of bone marrow adipocytes; loss of these 
adipocyte populations may be a factor contributing to age-related bone loss (182).  
Together, these studies elucidate that the effect of leptin on bone is dependent on bone 
site (perhaps varying with the degree of sympathetic innervation), leptin transport into 
the hypothalamus, and the heterogeneity in bone-marrow composition. Studies utilizing 
pharmacological blockade of sympathetic nervous signaling can reveal important clues 
about the relative importance of SNS signaling to a particular cell population. 
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Beta-adrenergic signaling blockade 
 
β-blocker pharmacological agents 
β blockers are a class of drugs used for various indications. Originally developed as a 
medication to treat hypertension, β blockers have also become essential therapies for 
patients with cardiovascular disease, acute myocardial infarction and those with 
tachyarrythmias (183-190). β blockers inhibit the action of endogenous catecholamines 
(epinephrine and norepinephrine in particular), on β-adrenergic receptors, key elements  
of the sympathetic nervous system. Three types of β receptors are known to exist:  β1, β2 
and β3.  β1-adrenergic receptors are located mainly in the heart and in the kidneys.  β2-
adrenergic receptors are located mainly in the lungs, gastrointestinal tract, liver, uterus, 
bone, vascular smooth muscle, and skeletal muscle, whereas β3 receptors are located on 
adipocytes (191).  
 
β-adrenergic receptor activation 
An activated β-adrenergic receptor couples to heterodimeric guanine-nucleotide-biding 
protein (Gs protein), which stimulates adenyl cyclase to increase intracellular cAMP 
level. cAMP activates cAMP-dependent kinase (PKA), which phosphorylates cellular 
and nuclear targets.  Stimulation of β receptors by catecholamines induces various 
results depending on the cell type affected.   β1 receptor stimulation of myocardial cells 
in the heart causes increases cardiac conduction velocity and automaticity.   Activated β1 
receptors in the kidney induce renin release. Reduction in renin release in kidney due to 
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β blockade results in reduced serum aldosterone via the renin-angiotensin-aldosterone 
system, with a resultant decrease in blood pressure due to decreased sodium and water 
retention (191).  In smooth muscle, stimulation of β2 receptors induces smooth muscle 
relaxation, resulting in vasodilation and bronchodilation.  Glycogenolysis in the liver and 
skeletal muscle is increased also with β2 receptor stimulation, while stimulation of β3 
receptors induces lipolysis in the fat cells (191). 
 
Activation of β2-adrenergic activity in osteoblastic and osteoclastic cells are associated 
with increased bone resorption and decreased bone formation. The mechanistic signaling 
pathway in osteoblast has been demonstrated.   Following binding to β2-adrenergic 
receptor, norepinephrine increases RANKL expression and bone resorption via a 
signaling pathway involving Gs protein, adenylyl cyclase, the phosphorylation of 
activating transcription factor 4 (ATF4) by activated PKA, and the binding of ATF4 to a 
cAMP response element (CRE)-like site in the RANKL promoter (192).  
Adrenergic signaling requires b2AR and ATF4, which are both mainly expressed in 
immature osteoblasts, while PTH signaling requires PTHR1 and CREB, which are 
expressed in mature, fully differentiated osteoblasts (193). The distinct signaling 
pathways, and the fact that b2AR and PTHR are expressed at different stages of 
osteoblast differentiation, suggest that PTH and adrenergic signaling act on different 
stages of osteoblast to regulate the RANKL expression and bone resorption.  Increased 
expression of interlenkin (IL)-6 and IL11, two cytokines stimulating osteoclast 
differentiation, in epinephrine-treated osteoblasts has been reported.  This effect of 
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epinephrine appeared to involve PKA and P38 MAPK (194,195).  The signaling 
pathway leading to reduced bone formation has not yet been fully characterized.  Such 
findings indicate that β-blockers may be effective against osteoporosis, in which case 
there is increased sympathetic activity stimulating the bone loss.    
Reduction in dilation of blood vessels, that is, vasoconstriction induced by β blockers 
seems to somewhat contradictory to its antihypertensive effect. It is likely that 
antihypertenstive effect of β blockers is related to reduction in cardiac output, reduction 
in renin release in kidney, and a central nervous system effect to reduce sympathetic 
activity.  
 
Propranolol 
Propranolol is a non-selective β blocker mainly used for antihypertensive purpose. It was 
the first successful β blocker developed in the late 1950s. It blocks the action of 
epinephrine on all β1-, β2- and β3 adrenergic receptors. Absorption of propranolol is rapid 
and complete;  the peak level in plasma is achieved in 1-3 hours after ingestion. 
Propranolol is a highly lipophilic drug, which is able to cross the blood brain barrier into 
the CNS, achieving high concentrations in the brain. The duration of action of a single 
oral dose may be up to 12 hours. Effective plasma concentrations are between 10–100 
ng/mL.  Toxic effects are associated with plasma concentrations above 2000 ng/ml. 
Propranolol is clinically used for the management of hypertension ,tachyarrhythmias, 
myocardial infarction, control of tachycardia/tremor associated with anxiety and 
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hyperthyroidism, essential tremor, and migraine prophylaxis.  Propranolol is currently 
being investigated as a potential treatment for post-traumatic stress disorder (191,196). 
In fact, there are some data indicating a statistical link between the use of propranolol 
and a reduced risk of fractures (179), although this potential beneficial effect on bone 
health remains controversial. 
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CHAPTER III 
 
FOOD RESTRICTION AND SIMULATED MICROGRAVITY: 
EFFECTS ON BONE AND SERUM LEPTIN 
 
 
Introduction 
 
The effects of microgravity or disuse on weight bearing bones have well been 
documented. About 1% of bone mineral density (BMD) is lost per month while in 
microgravity, although the magnitude of loss is highly variable among subjects and 
among anatomical sites (1, 2). Whether this loss eventually plateaus is unknown, 
because very few humans have been exposed to microgravity or strict bedrest for more 
than 6 months. The rodent model of hindlimb unloading by tail suspension effectively 
mimics the microgravity environment and produces significant bone loss, allowing for 
ground-based, invasive studies to be performed (49,197). 
 
Crew members frequently undereat during space flight missions (198-200). Food intake 
has been observed to be as low as 50% of a flight member's estimated required amount, 
and even as low as 25% in one instance (the latter assuming the adult male needs 2500 
calories) (200,201). Reduced food intake results in decreased availability of nutrients 
important for maintaining bone health, but may also independently affect bone status. 
When these effects are combined with the reduced mechanical loading of the 
microgravity environment, the deleterious effect on the skeleton could be augmented. 
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This change of bone status due to space flight and/or negative energy balance involves 
numerous endocrine factors. Hormones such as estrogen, growth hormone, insulin-like 
growth factor-1, insulin, T4, thyroid-stimulating hormone, calcitonin, active D3, and 
parathyroid hormone have been shown to play a role in the deleterious skeletal 
adaptation to actual or simulated microgravity and/or to negative energy balance (202-
210). Leptin, a 16 kDa cytokine-like hormone principally produced by white adipocytes, 
may also be involved in the bone response to microgravity and/or restricted food intake.   
Its principal function is the regulation of energy stores and body composition through 
negative feedback at the hypothalamic nuclei. Leptin is now known to have numerous 
biological effects on the immune system (12), reproduction (13), development (14), 
hemopoiesis (15), angiogenesis (16) and, most recently, on bone metabolism. 
However, there is controversy about the nature of leptin’s effects on bone. Early studies 
demonstrated antiosteogenic effects of leptin via the sympathetic nervous system when 
administered centrally (17,18), but several more recent studies have demonstrated a 
bone-protective effect of leptin during hindlimb unloading or caloric restriction when 
administered peripherally (19,20).   
 
No published data, to our knowledge, test a side-by-side comparison of the effect of 
microgravity and/or food restriction on serum leptin level and on bone outcomes.   
Our purpose, then, was to investigate the individual and combined effects of food 
restriction and simulated microgravity in adult male rats and to investigate the 
contribution of altered serum leptin to changes in bone strength, density, and turnover 
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status. Our primary hypotheses were that food restriction and hindlimb unloading 
independently impair skeletal integrity via decreased bone formation and/or increased 
bone resorption and, if rats are subjected to both treatments, even greater decrements and 
changes in the above variables would result. 
 
 
Materials and methods 
 
 
Animals and experimental design 
 
Forty-eight 6-month-old adult male Sprague Dawley rats (Harlan; Indianapolis, IN) were 
used in this experiment lasting six weeks. The chow utilized by our animal facility (8604 
Harlan Teklad) provides excess densities of vitamins and minerals; providing 70% of 
usual intake of this chow would not result in deficiencies in any key vitamins/ minerals. 
Therefore, we chose to use for this experiment, purified diet AIN93-M, a casein- based 
purified diet that provides 100% of NRC- determined requirement levels of vitamins and 
minerals for rats.  Table 1.1 illustrates details on nutrient content in the 8604 Harlan 
Teklad chow and the AIN93-M diet. 
 
During the first two weeks, all rats were fed ad libitium and food intake was measured 
daily to establish each rat’s usual food requirement (average grams chow eaten per day). 
Then rats were randomly assigned to four groups. One group (CC100) was allowed 
regular cage activity with each rat receiving 100% of its usual food intake. The second  
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Table 1.1 Comparison of feed relative to rat requirements 
 
 
Nntrient* Rat requirement1 AIN-93M2 8604 Harlan Teklad3 
Protein (g) 50 125 244 
Calcium (g) 5 5 13.6 
Magnesium (g) 0.5 0.5 2.8 
Phosphorus (g) 3 3 10.1 
Vitamin D (IU) 1000 1000 2400 
Vitamin K (mg) 0.9 0.86 4.11 
Energy 
(Kcal/g)  3.50 3.40 
 
* Amounts of nutrients are given as unit of nutrient/kg of feed 
1. (211); 2.(212); 
3. 8604 Harlan Teklad Rodent diet (W) fed by vendor to rats first 5 months of life. 
 
 
group (CC70) was also allowed regular cage activity, but each rat was provided 70% of 
its usual food intake. The remaining rats were subjected to hindlimb unloading by tail 
suspension, using a tail harness as previously described (213), and received 100% 
(HU100) or 70% (HU70) of usual food intake. The treatment period lasted for 28 days. 
During the entire experiment, the rats were housed in a light – controlled room (12:12 
light: dark cycle) maintained at 70-72º F in a AAALAC- accredited animal care facility. 
All procedures in this study were approved by Texas A&M University Lab Animal Care 
Committee. 
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On day 1 of treatment and on sacrifice day, peripheral computed tomography (pQCT) 
scans were performed and urine and serum samples were collected while the rats were 
anesthetized.  For the hindlimb unloading experiment, bone mineral density and cross-
sectional geometry were measured both in vivo (tibia) on experiment days 0 and 28 and 
after sacrifice ex vivo (humerus and femur). Blood and urine collections were performed 
on both day 1 and 28 of the treatment at the same time of the day and before 10 AM to 
minimize contribution of diurnal variation to leptin and bone turnover markers. On days 
9 and 2 before sacrifice, animals were given subcutaneous injections of calcein 
(25 mg/kg) to label mineralizing bone for histo-morphometric analysis. HU animals were 
anesthetized before removal from tail suspension to prevent any weight bearing by the 
hindlimbs.  Right tibia and humeri were removed, cleaned of soft tissue and stored at 
80°C in PBS-soaked gauze for ex-vivo pQCT scan and/or mechanical testing, whereas 
left femora were stored in 70% ethanol at 4°C for histology.  
 
 
Peripheral computed tomography (pQCT) 
The XCT Research M (Stratec; Norland Corp., Fort Atkinson, WI) scanner has a 
minimum voxel size of 0.07 mm, a scanning beam thickness of 0.50 mm, and is 
calibrated daily using a standard hydroxyapatite phantom.  In vivo scans were taken of 
the proximal metaphysis of the right tibia on days 0 and 28 with the animal anesthetized. 
Transverse images were scanned at 5.0, 5.5, and 6.0 mm from the proximal tibia plateau. 
Ex vivo scans were taken at the proximal humerus metaphysis (5.0, 5.5, 6.0 mm from 
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proximal end) and at the distal femur (6.0, 6.5, 7.0 mm from the distal condylar edge). 
Bones for ex vivo scans were thawed and placed in a vial filled with 1× phosphate-
buffered saline for scanning to ensure standard hydration. A standardized analysis for 
either metaphyseal bone (contour mode 3, peel mode 2, outer threshold of 0.214 g/cm3, 
inner threshold of 0.605 g/cm3) or diaphyseal bone (separation 1, threshold of 
0.605 g/cm3) was applied to each section. The same contour and peel modes and 
thresholds were used by our laboratory to successfully differentiate cortical and 
cancellous bone in skeletally mature unloaded animals (49) and are explained in detail 
elsewhere (214). Values of total, cortical shell, and cancellous volumetric bone mineral 
density (vBMD), cross-sectional area, cortical area, and marrow area (A) were averaged 
across 3 slices at each bone tissue to yield a mean value for each site. In addition, 
middiaphyseal cross-sectional moment of inertia (CSMI) was obtained with respect to 
the neutral bending axis during three-point bending for later calculation of material 
properties. Machine precision (based on manufacturer's data) is ± 3 mg/cm3 for 
cancellous BMD and ± 9 mg/cm3 for cortical BMD. Reproducibility in our laboratory 
for both in vivo and ex vivo measures was determined from five repeat scans with 
repositioning of the animal or bone between scans. Coefficients of variation for these 
measurements were 1.24, 2.13, and 1.95% for in vivo proximal tibia total BMD, 
cancellous BMD, and total area, respectively. Ex vivo distal metaphysis coefficients of 
variation for the same variables were 0.37, 1.43, and 0.28%, respectively. 
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Biochemical analyses 
 
A rat osteocalcin ELISA immunoassay kit was used (Biomedical Technologies, INC.; 
Stoughton, MA) to measure the concentration of osteocalcin in the animals’ serum. 
Osteocalcin is reported as ng/ml serum. Precision C.V. within-run was ± 7% and C.V. 
between run was ± 10.5%. The concentration of urinary deoxypyridinoline (DPD) 
crosslinks, one of the pyridinium crosslinks, was assessed to estimate changes in bone 
resorption, using a competitive enzyme immunoassay (Pyrilinks-D; Quidel, Mountain 
View, CA). Results were normalized to urine creatinine, determined by a colorimetric 
assay (Quidel).  DPD is reported as nmol DPD/mmol creatinine. Precision C.V. within-
run was ± 3.5% and C.V. between run was ± 7.0%.  A rat leptin ELISA immunoassay kit 
(Crystal Chem, Chicago, IL) was used to measure the concentration of leptin in serum 
and reported as ng/ml serum. Precision C.V. intra-assay was ± 3.1% and C.V. inter-assay 
run was ± 6.4%. 
 
Cancellous histomorphometry 
Undemineralized distal left femora were subjected to serial dehydration and embedded in 
methylmethacrylate (Aldrich M5, 590-9). Serial frontal sections were cut 8µm thick and 
left unstained for fluorochrome label measurements, and cut at 4µm sections for Von 
Kossa staining for measurement of cancellous bone volume normalized to tissue 
volume, % BV/TV and quantification of osteoid and osteoclast surfaces as a % of total 
cancellous surface. 
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At 20X, a defined region of interest was established ~0.8 mm from the growth plate and 
within the endocortical edges encompassing 8-9 mm2. Total bone surface, single-labeled 
surface, and double-labeled surface were measured at 100x and  interlabel distances, 
bone volume and osteoid/osteoclast surface were measured at 200x magnification. 
Mineral apposition rate (MAR, µm/day) was calculated by dividing the average 
interlabel width by the time between labels ( 7 days), and mineralizing surface (MS/BS) 
for cancellous bone surfaces was calculated by using the formula MS/BS = {[(single 
labeled surface/2) + double label surface]/surface perimeter} x 100. BFR was calculated 
as MAR × MS/BS. Histomorphometric analyses were performed with BioQuant True 
Color Windows image-analysis software (BQTCW98, Version 3.05.6, R&M 
Biometrics) interfaced with Optronics 3-chip color camera and an Olympus BX60 
Microscope with epifluorescent light (Leeds Instruments, Inc. Irving, TX). All 
nomenclature for cancellous histomorphometry follows standard usage (215). 
 
 
Mechanical testing of bone 
 
An Instron 1125 machine in the TEES material testing laboratory was used to perform 3-
point bending to failure on tibiae and humeri. Excised bones were allowed to thaw to 
room temperature prior to mechanical testing. Anterior-posterior (AP) and medial-lateral 
(ML) surface diameters at the mid –shaft were measured at the same midshaft location 
as scanned on by pQCT. The tibia was then set medial side down on two metal supports 
18 mm apart. The humerus was loaded posterior side down, on supports 12mm apart. 
Bone was loaded at mid-shaft in 3-point bending with a 50-lb load cell using quasi-static 
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loading rate of 2.5 mm/min until the bone fractured. Force and displacement data were 
obtained with a sampling rate of 10Hz using a linear variable differential transformer 
(LVDT) interfaced with Gardener Systems software. Values obtained from this data 
were ultimate load, defined as the maximum load prior to breaking, and stiffness, which 
is the change in load/change in displacement during the pre-yield portion of the load-
deformation curve. Elastic modulus and ultimate stress are material properties calculated 
from stiffness and ultimate load, respectively, by normalizing for cross-sectional 
moment of inertia at the midshaft derived from the automated analysis of the pQCT data. 
The equations used were same as used in a previous study (50).   
 
Statistical analysis 
 
To analyze pre- and post- treatment values of tibia pQCT and blood/urine variables, a 3-
way ANOVA with repeated measures was used.  In addition, a simple main effects 
analysis was performed on any 2-way or 3-way interactions and, when appropriate, 
Duncan post-hoc tests were used within the simple main effects analyses. For end point 
measures (e.g. mechanical testing variables, soleus weight, and histomorphometry data), 
2-way ANOVA was performed, with appropriate post-hoc tests.    Linear associations 
between change of serum leptin level to the bone formation rate were described with 
Pearson correlation coefficients. All values reported are means ± standard errors. 
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Results 
 
 
Food intake/body weight  
 
Actual food intake over the 28 days’ experiment was low for all groups during week1, 
but during the remainder of the experiment rats ate close to 100% of their assigned food, 
achieving intended food intake (Table 1.2). By week 4, mean body weights for CC70, 
HU100, and HU70 groups were significantly lower than that observed in CC100 (Figure 
1.1). The HU 100 and CC70 rats exhibited a significant drop of body weight during first 
7 days, but maintained body weight thereafter till the end of the experiment. The CC100 
group had the highest mean body weight at sacrifice (519 ±14 g), followed with 
progressively lower body weights by the HU100 group (448 ± 12 g), the CC70 group 
(439 ±12 g) , and then the HU70 group (388 ± 17 g), who weighed the least. 
 
     Average soleus weight in weight bearing CC rats was 199.5 ± 6g and in HU rats, 84.5 
± 4 g (on average, 60% lower than pooled CC value, p<0.0001), confirming that tail 
suspension effectively unloaded rats’ hindlimbs.  
 
 
  
 
 pQCT data 
 
Proximal tibial metaphysis    
Hindlimb unloading and food restriction caused a reduction in total vBMD (cortical 
shell with cancellous core) (Figure 1.2). Progressively greater reductions of total vBMD 
over time were observed in CC70 rats (4.7%) and HU100 rats (8.1%), with this 
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reduction exacerbated in combined treatment (HU70) rats (9.3%)  Cancellous vBMD at 
this site decreased an average of 20% in all groups over time (Table 1.3); there were no 
significant independent effects of loading condition or food restriction on this bone 
compartment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1  Body weights over 28 days of hindlimb unloading (HU) or cage activity (CC) in rats 
consuming 100% (100) or 70% (70) of usual intake. All groups are n=11 except for HU100 in 
which n=12. p< 0.05 vs *CC100, #HU100, +CC70; &  p<0.05 vs initial body weight within 
group. 
 
 
Midshaft tibia   
Tibial midshaft vBMD and geometry variables were not affected by HU or FR (Table 
1.3). However, almost all measured parameters increased over time (total area, cortical 
area, marrow area, cross-sectional moment of inertia) in all groups. Cortical density did 
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not change in any group. These data suggest a uniform continued growth of midshaft 
cortical bone in all animals, unaffected by loading condition or food intake. 
 
Midshaf humerus 
 No significant differences in vBMD or bone geometry were noted at the humerus 
midshaft with food restriction or hindlimb unloading (data not shown). 
 
 
Table 1.2 Food intake 
  
 
Actual Food Intake During Experiment 
Group 
Baseline 
Intake 
Average(g) 
70% of 
Baseline 
Intake Week1* Week2 Week3 Week4 
CC100 23±0.6 -- 17±1.0 23±0.6 23±0.6 22±0.7 
CC70 21±0.6 15 13±1.5 14±0.7 15±0.4 15±0.4 
HU100 23±0.8 -- 17±0.9 21±0.6 22±0.7 22±0.6 
HU70 23±0.9 16 13±0.8 16±0.6 16±0.7 16±0.7 
 
 
 
 
 
 
 
CC: age matched cage controls, HU: hindlimb unloading. Baseline intake assessed  
for 5 days prior to actual experiment. Values presented as mean ± SE. 
* Within all groups, week1 intake is less than that of all other weeks, p<0.05 
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Figure 1.2 Changes in Proximal tibia total volumetric bone mineral density (vBMD) 
over 28 days of hindlimb unloading (HU) or cage activity (CC) in rats consuming 100% 
(100) or 70% (70) of usual intake (∆ mg/cm3). Bars with different letters are 
significantly different, p<0.01. 
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Table 1.3 In vivo PQCT measures of FR and/or HU effects on tibia density and geometry 
 
 
 
 CC100 CC70 HU100 HU70 
 Day 0 Day 28 Day 0 Day 28 Day 0 Day 28 Day 0 Day 28 
 
Proximal Tibia         
Cancellous vBMD 
‡ (mg/cm3) 
203 ±7 166 ±6 204 ±7 167± 5 214 ±7 161± 5 221 ±8 180 ±5 
Marrow Area 
(cm2) † 
10.3 ±0.5 10.8 ±0.7  10.0 ±0.4 10.5 ±0.5  11.3 ±0.5 11.8 ±0.5  10.5 ±0.5 11.2 ±0.6  
Total Area (cm2) 19.0 ±0.5 19.5 ±0.8 18.5 ±0.6 18.9 ±0.6 20.1 ±0.7 20.1 ±0.6 19.1 ±0.8 19.1 ±0.8 
         
 
Tibia Diaphysis         
Cortical 
vBMD(mg/cm3) 
1324 ±4 1326 ±7 1324 ±4 1317 ±15 1312 ±6 1328 ±6 1315 ±4 1329 ±2 
Cortical Area 
(cm2) § 
6.2 ±0.2 6.2 ±0.2  6.2± 0.1 6.2 ±0.2  6.2 ±0.1 6.3 ±0.1  6.0 ±0.1 6.1 ±0.1  
Total Area (cm2) § 8.4 ±0.3 8.6 ±0.3  8.5 ±0.2 8.7 ±0.3  8.9 ±0.2 9.0 ±0.2  8.4 ±0.2 8.5 ±0.2  
Marrow Area 
(cm2) § 
2.3 ±0.1 2.3 ±0.2  2.3 ±0.1 2.4 ±0.1  2.6 ± 0.1 2.7 ±0.1  2.3 ±0.1 2.4 ±0.1  
CSMI (mm4) § 11.2 ±0.7 12.3 ±0.8  11.3 ±0.5 12.1 ±0.7  12.1 ±0.4 12.8 ±0.4  11.0 ±0.6 11.5 ±0.6  
 
CC: age-matched cage controls, HU: hindlimb unloading. 100 and 70 = 100% and 70% of usual intake, respectively. For all 
experimental groups, n=11, except for HU 100, in which n=12.  †All groups’ means  increased over 28 days vs day 0, p< 0.01; 
‡All groups’ means decreased over 28 days vs day 0, p< 0.0001. § All group’s values increased over time, p≤ 0.005. 
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Table 1.4 Mechanical properties of tibial mid-shaft 
 
 
 
 
 
 
 
 
CC: age-matched cage controls, HU: hindlimb unloading.100 and 70 = 100% and 70% of usual intake, respectively. For all 
experimental groups, n=11, except for HU 100, in which n=12.  * p ≤ 0.01 for pooled HU groups vs pooled CC groups 
 
 
 
 
 
 
 
 
 
 
 Ultimate Load (N) Ultimate Stress (MPa) Stiffness (N/mm) Elastic Modulus(GPa)     
CC100 164 ±8 235 ±13 299 ±14 6.1 ±0.4 
CC70 159 ±6 225 ±7 308 ±13 6.3 ± 0.3 
HU100 157 ±7 217 ±12 315 ±16 6.8 ±0.3 * 
HU70 155 ±6 229 ±4 319 ±18             7.6 ±0.4 * 
50 
 
 
 
Mechanical testing 
 
When collapsed over food intake, elastic modulus of tibial midshaft was higher in HU vs 
CC rats (Table 1.4).   No independent effect of food restriction on material or structural  
properties at mid-shaft tibia was detected.   No changes of mechanical properties were 
observed with food restriction and/or hindlimb unloading in humeri of any group (data 
not shown).  
 
 
Distal femur cancellous bone histomorphometry 
 
Due to technical error, 4-5 rats in each treatment group did not receive fluorochrome 
labels previous to sacrifice; hence, histological analyses for % MS/BS, MAR and BFR 
were performed on femurs from 20 animals spread across all groups.  Decreases in 
mineral apposition rate due to FR (CC70) and to unloading (HU100) were similar (-25%), 
as were the decreases in % mineralizing surface (%MS/BS) for both groups (-59%) 
(Figure1.3). Reduction in MAR and %MS observed in the combined treatment group 
(HU70) were similar to that of CC70 and HU100, which implies no additive effect of FR 
and HU on MAR and %MS.  These reductions in MAR and %MS/BS contributed to the 
70% reduction in bone formation rate observed in all three treatment groups.   Osteoid 
surface was 33% lower in the CC70 and the HU100 groups as compared to the control 
group (CC100).   In this case, an additive effect of food restriction and hindlimb 
unloading was observed; a much larger decrement of % osteoid surface was observed in 
HU70 rats (60%). The % BV/TV in HU rats was lower than that of CC rats by 28.5%, but 
not statistically significant. Cancellous % osteoclast surface did not vary among the 4 
groups (Fig 1.3E, 1.3F).   
51 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Effect of hindlimb unloading (HU) or cage activity (CC) in rats consuming 
100% (100) or 70% (70) of usual intake on histomorphometric indicator.  
Due to technical error, 4-5 rats in each treatment group did not receive fluorochrome 
labels previous to sacrifice; hence, histological analyses for % MS/BS, MAR and BFR 
were performed on femurs from 20 animals spread across all groups.  
(A) mineral apposition rate (MAR), *p<0.03 compared with values in CC100.  
(B) % mineralizing surface (% MS/BS), *p<0.0001 compared with values in CC100.  
(C) bone formation rate (BFR), *p<0.0001 compared with values in CC100.   
(D) % osteoid surface, * p<0.02 compared with values in CC100; ** p<0.0001 compared 
with values in CC100;  # p<0.06 compared with values in CC70 ; $ p<0.05 compared 
with values in HU100. Values are means ± SE. 
(E) % Bone volume/ Tissue Voulme (BV/TV), No significant difference among groups. 
(F) % Osteoclast surface, No significant difference among groups. 
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Figure 1.3 Continued 
 
 
 
 
Leptin and turnover markers 
 
As compared to day 0 values, decreases in serum leptin levels (Figure 1.4A) were 
observed by 28 days in all groups except CC100, with 27% and 60% reductions 
observed in CC70 and HU100 groups, respectively. Serum leptin was not detectable 
after 28 days in HU70 rats. Assays for this group were repeated with increasing serum 
volumes (5μl, 10μl and 20μl), but serum leptin remained undetectable. The change in 
serum leptin level over the experimental period correlated well with bone formation rate.  
Those rats exhibiting the greatest decline in serum leptin had the lowest bone formation 
rates in distal femur cancellous bone (Fig 1.4B). 
The mean serum osteocalcin for the all food-restricted rats (pooled 70% intake groups) 
was 32% lower at the end of the experimental period than that of the pooled 100% 
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groups (Fig 1.5). When collapsed over food intake levels, HU animals exhibited a 
greater decline in serum osteocalcin (-23 %) versus that observed in the CC animals (-
10%) (p< 0.01) . At the end of the experimental period, the mean serum osteocalcin for 
pooled HU groups was 14% lower than that of the CC groups. The average value of 
DPD, the resorption marker urinary, at day 0 was 21.23nmol/mmol creatinine and 
increased in all groups over the experimental period.   Urinary DPD rose by 17% 
(CC100), 24% (CC70) 29% (HU100) and 46% (HU70) over 28days (data not shown).   
However, these magnitudes of increases were not statistically different among groups. 
 
Discussion 
 
This experiment is the first to demonstrate the independent and combined effects of food 
restriction and hindlimb unloading on skeletal integrity. Our data confirm our hypothesis 
that food restriction and hindlimb unloading independently impair skeletal integrity via 
decreased bone formation and/or increased bone resorption and, if rats are subjected to 
both treatments, even greater decrements and changes in the above variables would 
result. Food restriction and hindlimb unloading independently reduced total vBMD in 
the proximal tibia after 28 days. The impact of hindlimb unloading was significantly 
greater than that of food restriction and some additive effects of the combined treatment 
were also observed.    
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Figure 1.4 (A) Serum leptin levels after 28 days of food restriction (FR) or hindlimb 
unloading (HU) in rats consuming 100% (100) or 70% (70) of usual food intake. All 
groups are n=11 except for HU100 in which n=12.* p<0.0001 vs pre-value, # p<0.05 vs 
post-value in CC70. (B) Correlation between change in serum leptin value and bone 
formation rate (BFR) measured at 28 days for 20 animals 
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Figure 1.5 Effect of hindlimb unloading (HU) or cage activity (CC) in rats consuming 
100% (100) or 70% (70) of usual intake on serum osteocalcin over 28 days. Values are 
means ± SE. All groups are n=11 except for HU100 in which n=12. The decline in the 
pooled HU groups is greater than the decline in the CC groups, p≤ 0.05. The decline in 
the pooled 70% group is greater than the decline in the pooled100% group, p≤ 0.05. * 
p<0.0001 vs pre-value 
 
 
 
 
 
 
These declines in vBMD are due to consistent decreases in mineral apposition rate and 
especially mineralized surface/bone surface, leading to significant reductions in bone 
formation rate in cancellous bone observed in both food restriction and hindlimb-
unloaded rats.  Osteoid surface was the only histomorphometric variable exhibiting an 
additive effect when both treatments were applied.   Osteoid deposition is an early step 
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in formation of new bone, which must precede mineralization. This additive effect of 
restricted food intake and hindlimb unloading was not observed in the mineralization-
dependent variables after 28 days. It is reasonable to surmise that a longer duration of 
unloading combined with food restriction would eventually yield greater decrement in 
mineralization and bone formation rates. 
 
We could not confirm an additive effect of unloading and food restriction on proximal 
tibial cancellous vBMD in this study.   Proximal tibial cancellous vBMD after 28 days 
was not significantly different among the 4 groups; a significant 18% reduction in 
cancellous vBMD was observed even in weight bearing control (CC100) rats.   It is 
important to note that rats were switched from 8604 Harlan Teklad Rodent diet (fed by 
vendor till rats were supplied at 5 months of age) to AIN-93M 5 days before the 
experiment started.   The 8604 chow has a high content of minerals and vitamins, 
providing about three times the nutrient requirement for laboratory rats established by 
the NRC (212).   In this study, the use of a purified diet containing the minimum amount 
of nutrients for good rodent health was required in order to effectively restrict nutrient 
intake below those NRC- recommended intakes. Even though purified diet AIN93-M 
meets 100% rats’ nutrient and energy requirement, a switch to AIN93-M from 8604 
chow results in reduced vitamin and mineral intake, which may explain the reduction in 
cancellous vBMD even in CC100. Recent studies have demonstrated that 40% food 
restriction causes significant increase in disuse-like bone turnover of endocortical bone 
in the tibial diaphysis of 13 month-old female rats (216) and that 20% food restriction 
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augments decrements in bone mineral content and vBMD in total tibia of 7 month-old 
ovariectomized rats (217), supporting our findings. Ideally, a more prolonged 
acclimatization period for rats to new chow should be utilized to allow changes in 
vBMD and other key variables to plateau.  
 
In the bone microenvironment, there is a dynamic balance between resorption and 
formation that maintains skeletal homeostasis. In the present study, we demonstrated 
reduced % osteoid surface with food restriction and/or hindlimb unloading, and no 
differences in % osteoclast surface among the groups, as measured at the proximal tibia. 
As a whole body measure, biochemical markers of bone turnover showed more 
responsive changes in a marker of bone formation (osteocalcin) to imposed change of 
nutritional and/or mechanical environment than in a bone resorption marker (DPD).  
Decreases in osteocalcin concentration and bone formation activity in young rapidly 
growing rats have been measured (35). Serum OC transiently decreases by 25% in 6-
week-old rats after one week of HU, then returns to almost normal levels after 28days of 
HU (36). However, there are few published data on the osteocalcin responses to HU in 
adult rats.  The skeletally mature (6-month-old) male rats used in the present study 
subjected to HU experienced an average decline of 23% OC decline as measured after 
28 days.  To our knowledge, only one published study reports urinary DPD 
measurements on tail suspended rats, which has exhibited the same result as our study 
(218). By contract, consistent and dramatic increases in DPD have been demonstrated in 
humans exposed to space missions lasting 4 -6 months. With crew members on space 
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missions for 4-6 months, study showed deoxypyridinoline was increased 55% above 
preflight levels. (37) 
 
It has been proposed that leptin is responsible for linking energy metabolism to bone 
mass and also may play a role in bone loss during HU. To our knowledge, our study’s 
results provide the first documentation of the independent effect of microgravity and 
food restriction on serum leptin and skeletal integrity.  There still exists some 
controversy about the putative effect of leptin on bone. Obesity and hypogonadison 
result in an increased bone mass in ob/ob (leptin deficient)- and db/db (leptin receptor 
deficient)-mice deficient mice (17).   Evidence for a central (CNS) action for leptin has 
been provided by Takeda et al.  demonstrating that leptin's anorexigenic and anti-
osteogenic effects act via two distinct neuronal pathways involving the sympathetic 
nervous system (18). By contrast, peripherally administered leptin has an anabolic effect 
on bone metabolism in adult HU rat (27) and in ob/ob mice (219).   In ob/ob mice altered 
leptin signaling affects bone differently in axial and appendicular regions of the skeleton 
(181).  Mice in missing ob/ob gene have significantly shorter femora, lower femoral 
bone mineral content (BMC), BMD, cortical thickness, and trabecular bone volume 
compared to wildtype littermates.  In contrast to the pattern observed in the femur, ob/ob 
mice have significantly increased vertebral length, lumbar BMC, lumbar BMD, and 
trabecular bone volume compared to lean controls. Interestingly, ob/ob (leptin deficient) 
mice demonstrate increased adipocyte numbers in femoral bone marrow but fewer 
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adipocytes in vertebral bone marrow, suggesting that leptin’s impact on bone marrow 
stromal cell’s differentiation varies by bone site.       
 
In the present study, we found a significant decrease of serum leptin after 28 days in 
response to hindlimb unloading and to food restriction, with undetectable levels of serum 
leptin in rats exposed to both treatments, which suggests a striking effect of the 
combined treatments on serum leptin level. The decrement in serum leptin was strongly 
associated with the decline in bone formation rate.   This finding is consistent with 
previous research demonstrating a positive effect of circulating leptin on bone (19).    
Interestingly, after 28 days hindlimb unloading had a greater suppressive effect on serum 
leptin that did restricting food intake. Given that rats exposed only to unloading had 
lower serum leptin but higher body weights than rats exposed to only food restriction by 
the end of the experiment, it may be that some other factor than body weight and food 
intake is associated with regulation of serum leptin. It is interesting to speculate that 
increased stress or increased sympathetic neural output may be another potential 
regulator of serum leptin levels, which then may impact on bone outcomes (21, 23-
25,220). 
 
In summary, moderate caloric restriction caused nearly as much bone loss at the 
proximal tibia as did the unloading effect of simulated microgravity; osteoblast activity 
was more responsive than that of osteoclasts to changes in the nutritional and mechanical 
environment.   Deleterious effect of food restriction and/or hindlimb unloading on bone 
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was observed only in metaphyseal bone but not in diaphyseal bone.  Serum leptin level 
was reduced more by hindlimb unloading than with food restriction, and was associated 
with the decline in bone formation rate. Many outcomes in the present study provide 
evidence for an additional negative effect of poor nutrition in the context of disuse bone 
loss. We conclude that bone loss during spaceflight could be aggravated by consistent 
reductions in food intake as is frequently observed during short-term shuttle missions 
(200).  These results may also have serious implications for bed-rest patients who restrict 
food intake or for those individuals who utilize food restriction in attempts to lose 
weight.   Serum leptin may be an important endocrine regulator contributing to this 
change in bone metabolism. 
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CHAPTER IV 
β-BLOCKADE MITIGATES BONE LOSS  
DURING HINDLIMB UNLOADING  
 
Introduction 
 
 Decrements in bone health result from spaceflight and other periods of skeletal disuse. 
About 1% of bone mineral density is lost per month while in microgravity, although this 
is highly variable among subjects (2, 34). Astronauts tend to lose bone only in weight-
bearing sites, such as the distal tibia and femoral neck, although vertebral bone is also 
affected. Losses are much greater in cancellous bone than in cortical bone- up to 24% 
and 5%, respectively, over 6 months (2). Whether this loss eventually plateaus isn’t 
known, because very few humans have been exposed to microgravity or strict bedrest for 
more than 6 months.  
 
This change of bone status due to microgravity may involve the sympathetic nervous 
system (SNS) and numerous endocrine factors. Hormones such as growth hormone, 
insulin-like growth factor-1, insulin, luteinizing hormone, T4, thyroid stimulating 
hormone, calcitonin, active D3 and parathyroid hormone have been shown to play a role 
in the deleterious skeletal adaptation to actual or simulated microgravity in rodents and 
humans (209, 221-224). Leptin, a 16kDa cytokine like hormone principally produced by 
white adipoytes, may also be involved in the bone response to microgravity. Leptin’s 
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principal function is the regulation of energy stores and body composition through 
negative feedback at the hypothalamic nuclei. Leptin is now known to have numerous 
biological effects in the immune system (12), reproduction (13), development (14), 
hemopoiesis (15), angiogenesis (16) and, most recently, in bone metabolism. Early 
studies claimed to demonstrate an antiosteogenic effect of leptin via the sympathetic 
nervous system when leptin was administered intracerebroventricularly (17,18), but 
several studies later demonstrated an osteoprotective effect of leptin during hindlimb 
unloading or caloric restriction when administered peripherally (19,20). Peripheral 
administration of leptin has a stimulatory effect on bone growth and bone formation via 
regulation of osteoblastic function (175) or, possibly, via preferential differentiation of 
bone marrow stromal cells into osteoblasts rather than to adipocytes (176). Inhibition of 
osteoclast generation (177) and positive effects on angiogenesis by peripheral leptin 
administration also has been demonstrated (178-180).  
 
Using the rodent hindlimb unloading model to mimic spaceflight effects on the hindlimb 
bones, we observed a decrease in serum leptin after 28 days of  hindlimb unloading 
(225). Serum leptin also declined in cage-activity rats subjected to food restriction (70% 
of usual intake) for a similar time period. The magnitude of the decrease in serum leptin 
was greater with unloading than with food restriction (60% vs 27%, respectively), even 
though body weight decreased similarly in both conditions. If rats were subjected to both 
treatments (food restriction during hindlimb unloading), serum leptin decreased to non-
detectable levels.  
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Evidence indicates that activation of β-adrenoreceptors inhibits leptin release from 
adipose tissue (21, 220). Exposing animals to slightly stressful conditions such as tail 
suspension could increase heart rate and blood pressure through activation of the 
autonomic nervous system (23, 24) and elicit the release of the catecholamine 
norepinephrine (25). We conjectured that the lower serum leptin in HU rats may be 
caused by the inhibition of leptin synthesis or secretion resulting from activation of 
adipocyte β-adrenoreceptor by circulating catecholamines. We pharmacologically 
blocked β-adrenoreceptors to examine the impact of the sympathetic nervous system on 
changes in serum important bone parameters during unloading. In addition, we replaced 
leptin during hindlimb unloading to determine if leptin deficiency is an important factor 
in the loss of bone mass with unloading.  
 
 
                                                Materials and methods 
 
Animals and experimental design 
After one week acclimatization, sixty-six adult male Sprague-Dawley rats 
(Harlan;Indianapolis,IN)  were randomized into six groups of ten animals each: cage 
activity controls (n=10 each) treated with vehicle, leptin, or β- blocker, and 3 groups of 
hindlimb unloaded rats (HU) (n=12 each) treated with the same 3 agents. All animals 
were 6- mo-old at the beginning of the experimental period. Time-release osmotic pump 
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(Alzet osmotic pumps, Cupertino, CA) were implanted subcutaneously in all rats on day 
0 to deliver either placebo vehicle (saline), propranolol (DL-propanolol, Sigma ; 
250μg/kg·hr), or leptin (leptin analog, Lilly; 0.35mg/kg·day). Leptin was generously 
donated by Eli Lilly. Rats were singly housed and maintained under condition of 
12h:12h light and dark cycle . On the day osmotic pumps were implanted, half the rats 
began a 28 day period of HU using tail suspension as previously described (49).  Cage 
controls were allowed normal cage activity and were pair-fed with normal rat chow 
(2018 Harlan Teklad) to the HU animals in order to control for reduced food intake 
usually observed over the first 7 days of HU. On day 0 of treatment and on sacrifice day, 
peripheral computed tomography (pQCT) scans were performed by using a XCT 
Research M scanner (Stratec; Norland Corp., Fort Atkinson, WI). Urine was expressed 
and serum samples were collected from a leg vein while the rats were anesthetized.  
Volumetric bone mineral density (vBMD) and cross-sectional geometry of the proximal 
and mid-shaft tibia were measured in vivo on experiment days 0 and 28. On days 9 and 
2 before sacrifice, animals were given subcutaneous injections of calcein (25 mg/kg) to 
label mineralizing bone for histomorphometric analyses. Right tibiae were removed, 
cleaned of soft tissue and stored in 70% ethanol at 4°C for histology. All procedures in 
this study were approved by Texas A&M University Lab Animal Care Committee. 
 
Peripheral computed tomography 
The XCT Research M (Stratec; Norland Corp., Fort Atkinson, WI) has a minimum voxel 
size of 0.07 mm, a scanning beam thickness of 0.50 mm, and is calibrated daily using a 
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standard hydroxyapatite phantom. In vivo measures were made of the proximal 
metaphysis of the right tibia by collecting transverse images at 5.0, 5.5, and 6.0 mm 
from the proximal tibia plateau and at the midshaft (50% of total bone length). A 
standardized analysis for either metaphyseal bone (contour mode 3, peel mode 2, outer 
threshold of 0.214 g/cm3, inner threshold of 0.605 g/cm3) or diaphyseal bone (separation 
1, threshold of 0.605 g/cm3) was applied to each section and is explained in detail 
elsewhere (214). Values of total (cortical shell + cancellous core) and cancellous 
volumetric bone mineral density (vBMD), total cross-sectional area, and marrow area 
(A) were averaged across 3 slices at each bone tissue to yield a mean value for each site. 
Machine precision (based on manufacturer's data) is ±3 mg/cm3 for cancellous BMD and 
±9 mg/cm3 for cortical BMD.   Reproducibility in our laboratory for both in vivo and ex 
vivo measures was determined from five repeat scans with repositioning of the animal or 
bone between scans. Coefficients of variation for these measurements were 
1.24, 2.13, and 1.95% for in vivo proximal tibia total BMD, cancellous BMD, and total 
area, respectively.  
 
Serum leptin analyses 
A rat leptin ELISA immunoassay kit (Crystal Chem, Chicago,IL) was used to measure 
the concentration of leptin in animal’s serum and reported as ng/ml serum. All tests were 
performed in duplicate and control serum tested with each assay. Precision C.V. within-
run was ± 3.2% and C.V. between run was ± 6.4%. 
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Cancellous histomorphometry 
Undemineralized proximal tibia were subjected to serial dehydration and embedded in 
methylmethacrylate (Aldrich M5, 590-9). Serial frontal sections were cut 8µm thick and 
left unstained for fluorochrome label measurements; 4µm sections with Von Kossa 
staining were used for measurement of trabecular bone volume and quantification of 
osteoid and osteoclast surfaces. 
At 20X, a defined region of interest was established ~0.8 mm proximal from the growth 
plate and within the endocortical edges encompassing 8-9 mm2. Total cancellous bone, 
single-labeled, and double-labeled surfaces were measured at 100X and interlabel 
distances, bone volume and osteoid/osteoclast surface were measured at 200X 
magnification. Mineral apposition rate (MAR, µm/day) was calculated by dividing the 
average interlabel width by the time between labels (7 days), and mineralizing surface 
(MS/BS) for cancellous bone surfaces was calculated by using the formula 
MS/BS = {[(single labeled surface/2) + double label surface]/surface perimeter} x 
100.  BFR was calculated as MAR × MS/BS. Histomorphometric analyses were 
performed with BioQuant True Color Windows image-analysis software (BQTCW98, 
Version 3.05.6, R&M Biometrics) interfaced with Optronics 3-chip color camera and an 
Olympus BX60 Microscope with epifluorescent light (Leeds Instruments, Inc. Irving, 
TX). All nomenclature for cancellous histomorphometry follows standard usage (215). 
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Statistical analysis 
 
To analyze pre- and post- treatment values of tibia pQCT variables, and serum leptin 
variables, a 3-way ANOVA with repeated measures was used.  To analyze the delta 
values (pre-post) of tibia pQCT variables, and serum leptin variables, 2-way ANOVA 
was used.  For end point measures (e.g. body and tissue weights, and histomorphometry 
data), 2-way ANOVA was performed. In those cases where a significant interaction 
(p<0.05) was detected, appropriate post-hoc Duncan and LSD test was performed. 
Linear associations between change of serum leptin and bone formation rate were 
described with Pearson correlation coefficients. All values reported are means ± standard 
errors. 
 
Results 
 
 
Body weight and tissue weights  
 
 Mean body weight tended to decrease for all groups except BBCC over the first 7 days 
(Figure 2.1). However, by day 28, all groups’ mean body weight except that of BBHU 
rats increased significantly compared to initial body weight. Mean body weight of 
BBHU rats gradually increased after day 14 and at day 28 was not significantly different 
from initial body weight. Daily food intake during week 1 was low (~17.5g) for all 
groups compared to that of remainder of the experiment (22.0~ 25.9g) (Table 2.1). 
Within each time point, there was no food intake difference among groups implying that 
beta blocker and leptin treatment didn’t impact on food intake. 
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Figure 2.1 Body weights over 28days of hindlimb unloading (HU) or cage activity (CC) 
in rats administered vehicle (VEH), beta blocker (BB) or leptin (LEP).   For all 
experiment groups, n=10.  * p< 0.05 vs day 0. 
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Table 2.1 Food intake for 28 days 
 
Food Intake During Experiment 
Group 
Week1 Week2 Week3 Week4 
  
VEHCC 17.3±0.3* 20.9±0.7
# 25.3±1.0 25.7±0.5 
VEHHU 18.7±0.9* 22.9±0.8 26.2±1.2 26.1±0.6 
BBCC 18.0±0.6* 22.3±0.8 25.3±0.8 25.7±0.6 
  BBHU 16.8±1.2* 21.5±1.2# 24.7±1.2 25.1±1.1 
LEPCC 17.0±0.7* 21.4±0.9$ 24.3±1.3 25.9±0.8 
LEPHU 18.2±0.7* 23.2±1.4# 26.5±1.4 27.2±1.1 
 
CC: age matched cage controls, HU: hindlimb unloading.  
VEH: vehicle (saline) administration, BB: beta blocker administration, LEP: leptin 
administration.Values presented as mean ± SE. 
* Within group, week 1 intake is less than that of all other weeks, p<0.05 
#  Within group, week 2 intake is less than that of week3 and week 4, p<0.05 
$ Within group, week 2 intake is less than that of week 4, p<0.05 
Within each time point, there is no difference in food intake among groups. 
 
 
 
Mean epididymal fat weights in BBCC rats were significantly greater than in VEHHU 
rats at days 28, but there were no significant difference among other groups (Table 2.2). 
Although not statistically significant, the decrease in epdidymal fat weight observed 
after HU in VEH and BB rats (21% and 15%, respectively), not seen in leptin treated 
rats.   Soleus muscle weights of all HU groups (pooled average: 0.123 ± 0.017) were 
43% lower than that observed in weight bearing CC groups (pooled average: 0.209 ±  
0.025)( p<0.0001), confirming that tail suspension provided effective unloading of rats’ 
hindlimbs (Table 2.2). 
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Table 2.2 Soleus muscle and epididymal fat weights 
 
 
 
CC: age matched cage controls, HU: hindlimb unloading.  
VEH: vehicle (saline) administration, BB: beta blocker administration, LEP: leptin administration.Values presented as mean ± SE. 
a, b : Means sharing same letter are not different,  p<0.05 
c, d : Means sharing same letter are not different,  p<0.0001 
 
 
 
 
 
 
 
 
 
 
 VEHCC VEHHU BBCC BBHU LEPCC LEPHU 
Epididymal fat 
weight (mg) 351 ± 20 
a,b 276 ± 10 b 375 ± 30 a 322 ± 20 a,b 321 ± 10 a,b 
 
332 ± 20 a,b 
 
Soleus muscle 
weight (mg) 209 ± 9 
c 121 ±  4 d 217 ± 10 c 121 ± 10  d 211 ± 8 c 127 ± 5 d 
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pQCT data 
 
Proximal tibial metaphysis vBMD  
Hindlimb unloading (HU) caused a reduction in total vBMD (cortical shell with 
cancellous core) and cancellous vBMD; these losses were attenuated by beta-blocker 
and leptin treatments (Fig 2.2A). The 11% decline in total vBMD observed in VEHHU 
rats was attenuated in βBHU rats (7%) and LEPHU rats (5%). Similarly, the 20% 
decline in cancellous vBMD observed in VEHHU rats was attenuated by half in βBHU 
(11%)  and LEPHU rats (10%) (Fig 2.2B). Marrow area (area inside endocortical 
perimeter) tend to increase in both VEHHU (+9.3%) and in βBHU rats (+9.1%), but not 
in HU rats treated with leptin analog (+3%) (p<0.1) (Table 2.3). 
 
Midshaft site, tibia    
Tibial midshaft vBMD and geometry variables did not exhibit significant changes with 
unloading or with treatment (data not shown).  
 
Proximal tibia cancellous bone histomorphometry 
 
Mineral apposition rate in VEHHU rats was significantly lower than in VEHCC rats; 
however, beta-blockade and leptin treatments appear to prevent this decrease in MAR, 
since this value in BBHU and LEPHU rats is  not significantly different from that in 
their respective control groups (Fig 2.3A). Percent osteoid surface in LEPHU and βBHU 
rats tended to be greater than in VEHHU (7.90 & 6.54 vs 4.39, respectively; p< 0.09) 
(Table 2.4). Percent resorbing surface (the surface covered by osteoclasts) in  VEHHU 
rats were 3.5-fold higher than in VEHCC rats, but beta-blockade and leptin treatments 
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abolished this increase in % resorbing surface (Fig 2.3B). Significantly lower cancellous 
bone volume (%BV/TV) observed in VEHHU rats vs VEHCC rats was not observed in 
βBHU and LEPHU rats  (Table 2.4). No significant differences in any 
histomorphometric values were observed among LEPCC, βBCC and VEHCC.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 2.2 (A) Changes of proximal tibia total volumetric bone mineral density 
(vBMD) over 28 days of hindlimb unloading (HU) or cage activity (CC) in rats 
administered vehicle (VEH), beta blocker (BB) or leptin (LEP) (post value- pre value in 
∆ mg/cm3).  For all experiment groups, n=10.Bars with different letters are significantly 
different; * p<0.01 vs CC within treatment group. (B) Changes of proximal tibia 
cancellous volumetric bone mineral density (vBMD) over 28 days of hindlimb unloading 
(HU) or cage activity (CC) in rats administered vehicle (VEH), beta blocker (BB) or 
leptin (LEP) (post value- pre value in ∆ mg/cm3).  For all experiment groups, n=10.   
Bars with different letters are significantly different; # p<0.05 vs CC within treatment 
groups. 
 
a * 
b * 
c * 
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          Figure 2.2 continued 
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Table 2.3 In vivo PQCT measures of proximal tibia cross-sectional geometry 
 
 
 
 
Table 2.4 Proximal Tibia cancellous bone histomorphometric data 
 
 
*p< 0.05 vs CC within treatment groups 
#p<0.01vs CC within treatment groups 
$p<0.001 vs CC within treatment groups 
£ p<0.05 vs BBHU
 VEHCC VEHHU BBCC BBHU LEPCC LEPHU 
 Day 0 Day 28 Day 0 Day 28 Day 0 Day 28 Day 0 Day 28 Day 0 Day 28 Day 0 Day 28 
Marrow 
Area 
(cm2)  
55.1 ± 1.0 54.1 ± 2.2 55.9 ± 0.6 61.0 ± 1.5 53.8 ± 1.0 54.4 ± 1.2 53.3 ± 1.0 58.9 ± 0.9 54.7 ± 1.1 54.9 ± 1.0 53.9 ± 1.2 56.0±1.1 
Total 
Area 
(cm2) 
20.6 ± 1.0 20.7 ± 1.7 19.3 ± 0.6 18.9 ± 1.0 17.7 ± 0.6 17.9 ± 0.5 18.1 ± 0.4 17.7± 0.4 19.2 ±1.2 18.6 ± 0.8 18.0 ± 0.6 17.3 ± 0.6 
 VEHCC VEHHU BBCC BBHU LEPCC LEPHU 
% osteoid surface 7.7 ± 1.2 4.3 ± 0.8 7.3 ± 1.7 6.0 ± 1.3 8.7 ± 1.2 7.9 ± 1.3  
 
Static measures       %BV/TV  22.2±1.6 13.4±1.3$ 18.1 ±1.4 16.6±2.9 19.3±1.6 16.7±1.7 
 
% Mineralizing surface 
 
25.2 ± 2.8 17.3 ± 2.2 21.0 ± 2.6 20.1 ± 2.2 26.6 ± 3.6 16.5 ± 1.5 Dynamic 
measures 
 
 
 
Bone formation rate 
(mm3/mm2/day) 
 
51.4 ±9.5 21.4 ± 5.6*, £ 44.5 ± 7.1 50.4 ± 7.3 64.3 ± 10.9 34.5 ± 4.6# 
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Figure 2.3 (A) Effect of vehicle (VEH), beta blocker (BB) or leptin (LEP) during 
hindlimb unloaded (HU) or cage activity (CC) rats on proximal tibia mineral apposition 
rate (MAR).Values are means ± SE.  For all experiment groups, n=10.  *p<0.0001 vs 
VEH HU,  #p<0.004 vs VEH HU, $p< 0.05 vs CC within treatment group. 
(B) Effect of vehicle (VEH), beta blocker (BB) or leptin (LEP) during hindlimb 
unloaded (HU) or cage activity (CC) rats on % resorbing surface. Values are means ± SE. 
For all experiment groups, n=10.  * p<0.0001 vs VEH HU,  # p<0.0003 vs VEH HU, $ 
p<0.0001 vs CC within treatment group.
V E H B B L E P   
  M
in
er
al
 A
pp
os
iti
on
 R
at
e 
(u
m
/d
ay
)
0
1
2
3 C C
H U*
#
$
V E H B B L E P
%
 R
es
or
bi
ng
 s
ur
fa
ce
0
2
4
6
8
1 0
1 2
1 4
1 6
C C
H U
* # 
$
 
 
 
76
Serum leptin  
 
The reduction in serum leptin level was significantly less in βBHU(-25%) and in 
LEPHU (-31%) than in VEHHU (-62%) (Fig 2.4A) and did not correlate with changes in 
body weight. Changes in serum leptin among all CC groups were not significantly 
different. The change in serum leptin level over the experimental period correlated with 
BFR (r2= 0.57, p< 0.0001). Those rats exhibiting the greatest decline in serum leptin had 
the lowest BFR in proximal tibial cancellous bone (Fig 2.4B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 (A) Changes of serum leptin level over 28 days of hindlimb unloading (HU) 
or cage activity (CC) in rats administered vehicle (VEH), beta blocker (BB) or leptin 
(LEP) (post value- pre value in ng/ml). Bar sharing same letters are not significantly 
different.* p<0.0001 vs CC within treatment groups. (B) Correlation between change in 
serum leptin value (post value- pre value in ng/ml) and bone formation rate (BFR) 
measured at 28 days for all animals.  
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Fig 2.4 continued 
 
 
Discussion 
 
 This experiment is the first to demonstrate the relationship between beta blocker 
treatment and serum leptin level in the context of simulated microgravity , modeled with 
hindlimb unloading of adult rats. Our primary hypotheses were that beta-blockade would 
attenuate the decrease of serum leptin and volumetric bone mineral density during 
hindlimb unloading and that replacing leptin during HU would also mitigate the 
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reduction in vBMD during HU, confirming that leptin is an important factor protecting 
against loss of bone mass during HU. 
 
In this study, beta-adrenergic blockade resulted in significant mitigation of serum leptin 
reduction during HU. Reductions in total vBMD and cancellous vBMD in proximal tibia 
during HU were also significantly mitigated by beta-blocker treatment. These effect of  
beta-adrenergic  blockade were as effective as replacing leptin. There exist numerous 
studies examining the individual effects of peripheral beta blocker treatment or 
peripheral leptin treatment on vBMD during HU or physiological changes resulting in  
bone loss. Martin et al. recently demonstrated that leptin modulates both resorption and 
formation while preventing disuse-induced bone loss in tail-suspended female rats (19). 
Ovariectomized adult female rats exhibit less loss of cancellous and cortical BMD when 
treated with propranolol (226). However, no investigation to our knowledge has 
simultaneously demonstrated the effect of beta-adrenergic blockade on serum leptin and 
its subsequent effect on vBMD.  
 
Assuming that mitigated loss of vBMD by beta-adrenergic blockade or leptin may result 
from suppressed resorption or attenuated decrease of formation, we examined 
histomorphometric measures of formation and resorption. Consistent with vBMD data, 
the decrease of mineral apposition rate (MAR) during HU was abolished by beta blocker 
treatment and leptin replacement. Another indicator of osteoblast activity, percent 
osteoid surface, may also positively affected by beta-adrenergic blockade or by leptin 
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treatment, but did not reach statistical significance (p<0.09). As previously demonstrated 
in vitro (175,176), and in vivo (19,227), changes in circulating leptin were directly 
correlated with bone formation rate.  The dramatic increase of bone resorbing surface 
during HU was successfully suppressed by beta blocker treatment and leptin replacement, 
which is also consistent with our cancellous vBMD data. We conjecture that the 
normalized serum leptin levels with beta-adrenergic blockade or peripheral leptin 
administration prevented the transient increase in osteoclast number with tail suspension. 
Regulation of osteoclast number by leptin or beta blocker could be mediated by the 
receptor activator of nuclear factor kappa B-ligand (RANKL)/osteoprotegerin (OPG) 
pathway. Martin et al. determined with RT-PCR analyses that the suspension-induced 
increase in RANKL gene expression was counterbalanced during exogenous leptin 
administration with a 3-fold increase in OPG expression, resulting in a RANKL to OPG 
ratio similar that observed in weight bearing rats (19). It would be desirable to verify this 
in our study model in the future. 
 
Because adrenergic receptors also exist on osteoblasts, we cannot overlook the potential 
direct effect of beta-adrenergic blockade on osteoblast function.  Takeda et al. confirmed 
that osteoblasts express β-adrenergic receptors (18). To determine if bone formation is 
regulated by the SNS, wildtype and overiectomized mice were administered a β-
adrenergic blocker, which resulted in increase in bone mass.  An earlier in vitro study 
demonstrated that beta-adrenergic blockade blunts the inhibition of alkaline phosphatase 
activity by isoproterenol in an osteoblast-like cell line, which suggests that propranolol 
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may enhance bone formation by preserving osteoblastic activity in the face of beta 
adrenergic receptor stimulation (120).  
 
We speculate that the positive effects of beta-adrenergic blockade on mitigating bone 
loss with HU may derive from the synergistic effects of these two mechanistic pathways.  
That is, one pathway involves the direct effect of beta-adrenergic blockade on osteoblast 
function and the other the indirect effect of beta--adrenergic  blockade on adipocyte 
function, resulting in rescue of suppressed leptin synthesis or leptin release. Therefore, 
further studies are needed to determine whether removal of beta-adrenergic signaling 
effectively restores normal leptin release from adipocytes and to confirm if this leptin 
actually reaches mature osteoblasts in bone tissue to impact on their bone formation 
activity during disuse or other stressors  causing bone loss.  
 
Leptin is also expressed in and secreted from primary cultures of human osteoblasts as 
well as from adipoctyes (143).  Investigations testing the effect of beta-adrenergic 
blockade on expression, secretion and putative autocrine signaling of leptin in 
osteoblasts would be needed. 
 
Our result showed mitigated reduction of vBMD during HU with leptin rescue by beta-
adrenergic blockade or with leptin replacement, confirming that circulating leptin is an 
important factor protecting against loss of bone mass during HU.  However, there is 
controversy about the nature of leptin’s effects on bone. Intracerebroventricular leptin 
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administration, which is employed to demonstrate effects mediated by the central 
nervous system (CNS) results in a negative effect on bone mass (18). It has been 
proposed that centrally infused leptin suppresses bone formation via a hypothalamic 
relay.  Neuropeptides upregulated by leptin in the hypothalamus stimulate SNS 
pathways, resulting in stimulation of beta-adrenergic receptors on osteoblasts and 
inhibition of bone formation.  However, leptin deficiency (ob/ob) produces contrasting 
phenotypes in bones of the limb and spine, which is high bone mass in spine and low 
bone mass in limb (181).  Injections of leptin into rat ventromedial hypothalamus 
increase the apoptosis of bone marrow adipocytes, which may be a factor contributing to 
age-related bone loss (182).  All these studies taken together indicate that the effect of 
leptin on bone is dependent on condition and dose, and also may vary between 
axial/appendicular and bone shell/marrow regions. 
 
In the present study, no significant differences in histomorphometric values were 
observed among CCVEH, CCBB and CCLEP, suggesting that leptin and beta-adrenergic 
blockade exert effects on bone in the context of reduced mechanical loading and/or 
serum leptin deficiency, but not during normal weight-bearing activity. Also, alterations 
in  body weight were not the critical determinant regulating serum leptin and vBMD in 
this study, given that beta blocked HU rats experienced similar weight loss as VEHHU 
rats  but exhibited little change of bone mass or  serum leptin. 
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Interestingly, a slight decrement in cancellous vBMD was observed even in cage activity 
control groups over 28days. These cage activity rats were switched from double housing 
to single housing and from ad-lib feeding to pair-feeding to HU rats’ food intake when 
the experiment started.   In several previous studies, we have observed similar effect of 
pair-feeding and single housing on reduction in cancellous vBMD of cage activity 
control rats (23, and unpublished observations). Even though rats’ food intake was 
reduced for the first several days of hindlimb unloading, it then returned to normal levels 
and was maintained for the rest of the experiment; however, the effect of this mild food 
restriction for the first week on bone may be important, given changes observed in 
normal weight-bearing rats. Also, reductions in spontaneous physical activity due to 
single housing may need to be considered as another factor contributing to cancellous 
bone loss in cage activity control rats.  
 
In summary, beta-adrenergic blockade and leptin replacement mitigated the decrease in 
total vBMD, cancellous vBMD, MAR and cancellous bone volume in the tibia during 
hindlimb unloading and also attenuated the increase in resorption activity during 
hindlimb unloading. Beta-adrenergic blockade also attenuated the decrease in serum 
leptin during HU. We conclude that beta-adrenergic blockade is as effective as leptin 
analog administration in mitigating bone loss with hindlimb unloading through both 
stimulation of osteoblastic activity and suppression of osteoclastic activity, perhaps in 
part by disinhibition of leptin release from adipose. 
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CHAPTER V 
 
BONE LOSS DURING ENERGY RESTRICTION:  
MECHANISTIC ROLE OF LEPTIN  
 
 
Introduction 
 
Significant percentage of premenopausal women, especially athletes and military personnel, 
utilize food restriction in their attempts to lose weight.  The prevalence of dieting and weight 
loss efforts at any given time amongst U.S. women exceeds 50% (3).   
Dieting, weight cycling are known to result in clinical concerns, leading to menstrual 
cycle disturbances and decreased bone mass (4-7). An association between a history of 
weight loss in premenopausal years and increase in hip fracture risk in later in life has 
been reported (8). It’s been known that 1% decrease in bone mass (9) and an increase in 
bone resorption (10, 11) is associated with 10% weight loss. 
 
Importance and underlying mechanisms of dietary calcium and vitamin D as critical 
nutrients for bone has been established through numerous studies. In contrast, our 
understanding of how energy restriction consequentially happens in the context of food 
restriction, affect skeletal metabolism is limited. Researches has been performed that 
suggest bone loss is associated with energy restriction in both animals (11,99) and 
humans (102,103). In our previous study trying to quantify the magnitude of each 
individual nutrient’s (calcium, protein, energy) to bone loss in a side-by-side comparison 
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(28), we demonstrated that reduced energy intake is the major contributor to the impact 
of global food restriction on reductions in bone mineral density and serum estrogen 
levels in exercising rodents. Hence, one mechanism for bone loss subsequent to 
restricted energy intake may be via estrogen –dependent pathways. 
 
Another important endocrine change with energy restriction is a decrease in circulating 
leptin. Leptin, a 16 kDa cytokine-like hormone principally produced by white adipocytes, 
is another endocrine factor that impacts on bone cell function by linking energy 
metabolism and bone metabolism. Its principal function is the regulation of energy stores 
and body composition through negative feedback at the hypothalamic nuclei. The nature 
of leptin’s effects on bone is controversial. Leptin that binds to its receptors on 
hypothalamus demonstrates antiosteogenic effects via the sympathetic nervous system 
(18,117), but when administered peripherally (e.g. via osmotic pump), leptin 
demonstrates a bone protective effect with hindlimb unloading or caloric restriction or 
overiectomy (27, 20, 228). Expression of long and short forms of leptin receptors on the 
cells of osteoblastic lineage has been demonstrated, confirming that osteoblasts are 
targets for leptin action with the ability of signal transduction (17,176,229). In addition 
to a positive effect on osteoblastic differentiation (17), leptin inhibits the expression of 
RANKL, synthesized by oseteoblasts, an important inhibitor of bone resorption (230). 
 
Noradrenaline release is increased with stressful conditions, such as food restriction (21, 
22), simulated microgravity (23-25), which are normally associated with increased bone 
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resorption and/or decreased bone formation. Beta-blocker treatment mitigates loss of 
cancellous bone with hindlimb unloading rats (27), but the effect of beta blockade on 
serum leptin and/or bone during calrorie restriction hasn’t been demonstrated.  Several 
evidence indicate that beta-adrenergic receptor activation is known to one of the 
inhibition mechanism against leptin release from adipocyte (21, 6). We previously 
demonstrated that hindlimb unloading and food restriction each independently produce a 
decrease in serum leptin (225). Our data also indicated that beta blockade alleviated 
serum leptin decrement and also mitigated reduction in bone mineral density and bone 
formation rate in hindlimb unloading rats (27). However, yet unproven is whether 
elevating circulating leptin levels actually results in more leptin reaching the critical 
bone cells responsible for bone formation or resorption.  
 
In the present study, we tested the mechanistic role of leptin in bone loss during another 
stressful condition, dietary energy restriction. First, we characterized the effect of β-
blockade on blood leptin levels and on bone mass during energy restriction. With the 
result of bone loss mitigation by beta blockade, we then confirmed whether increased 
serum leptin levels actually results in more leptin reaching the critical bone cells 
responsible for bone formation by staining histological sections of bone with antibodies 
specific to leptin protein. Our primary hypotheses were, therefore, 1) beta-blockade 
would attenuate the decrease of serum leptin and bone mineral density during energy 
restriction and 2) the rescued serum leptin would result in more leptin localizing on the 
critical bone cells responsible for bone formation. 
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Materials and methods 
 
Animals and experimental design 
Adaptation period to achieve bone stabilization on new diet 
Day 0 was defined as the start of the restrictive dietary and pharmaceutical interventions; 
time points before day 0 are designated as “minus” days.  We used a specially 
formulated rat chow, AIN93-M, which most closely matches National Research Council 
(NRC) recommendations for adult rat dietary requirements (212,231). Because we had 
previously observed a significant loss in volumetric bone mineral density (vBMD) at the 
proximal tibia in rats switched from the vendor’s rat chow (Harlan Teklad 2018) to this 
AIN93-M diet, we tested an extended period of acclimation to this diet.   At least 7 
weeks were required before a “stable” proximal tibia vBMD (defined by two 
consecutive average vBMD values that change by less than 10 mg/cm3) was observed. In 
total, 40 Sprague-Dawley female rats, aged 4 months at purchase, were singly housed 
and allowed to eat AIN93-M chow for 8 weeks to assure complete adaptation to the new 
diet.  
 
Experiment: day 0 to week12 
On day 0, 40 adult female Sprague-Dawely rats (Harlan; Indianapolis, IN) was 
randomized into four groups of ten animals each by trabecular vBMD first and them by 
body weight : ad-lib fed controls (n=10 each) treated with vehicle (CONVEH), or β- 
blocker (CONBB), and 2 groups of energy restricted rats (n=10 each) treated with 
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vehicle (ERVEH), or β- blocker (ERBB). The dose of beta-blocker used was equivalent 
to that which in previous studies effectively mitigated loss of bone during disuse 
(hindlimb unloading). The CONVEH and the CONBB groups were fed ad lib for the 
twelve-week protocol.  Daily food intake for the CONVEH rats was measured each day. 
To achieve the 40% energy restriction, but with all other nutrients at 100% levels, 
ERVEH and ERBB rats were fed 0.61 gm of the specially formulated diet (AIN-93M-E) 
for every 1 gm of AIN-93M of the CONVEH group average consumption (Table 3.1).  
Beta-blocker treated group was administered propranolol (DL-propanolol, Sigma, 
6mg/kg), via drinking water. A graduated tube was installed in each cage 7 days prior to 
day 0 for measuring daily water intake. At day 0, based on daily water intake average 
(19ml /day), 94.7mg of propranolol/ 1L of water was distributed into the water tube in 
order to deliver 1.8mg/d (for a 300g rat) or 6mg/kg BW of propranolol to each rat. Over 
the 12 week experimental period, daily water intake of each rat was measured and 
concentration of propranolol in drinking water was adjusted from 1.8mg/16ml to 
1.8mg/22ml inn order to deliver the goal dose. Over the 12 week experiment, Rats were 
singly housed and maintained under condition of a 12h:12h light and dark cycle. Dual X-
Ray Absorptiometry (DEXA) Scans and peripheral quantitative computed tomography 
(pQCT) scans of the lower leg bone (tibia) were performed while rats were anesthetized 
with Ketamine/medetomidine  (55 mg/kg (ket) + 0.3 mg/kg (med)) on days 0, week4 and 
week 12 to measure early and late changes in outcome variables. A blood sample was 
drawn from a leg vein at Days 0, week 4 and week 12 (maximum volume 1.5 ml) while 
the rat is anesthetized and saved at -80°C. On days 9 and 2 before sacrifice, animals 
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were given subcutaneous injections of calcein (25 mg/kg) to label mineralizing bone for 
histomorphometric analyes. Right femora were removed, cleaned of soft tissue and 
stored at 80°C in PBS-soaked gauze for ex-vivo pQCT scan and/or mechanical testing, 
 
Table 3.1 AIN-93M mature rodent diet and modifications for 40% energy restriction  
               diets  
 
 
 AIN-93M AIN-93M-E (40% energy restriction) 
 gm% kcal% gm% kcal% 
Protein 14 15 23 24 
Carbohydrate 73 76 56 60 
Fat 4 9 6 16 
Total  100  100 
kcal/gm 3.85  3.76  
     
Ingredient gm kcal gm kcal 
Casein, 80 Mesh 140 560 140 560 
L-cystine 1.8 7.2 1.8 7.2 
     
Corn Starch 495.692 1982.8 112.5 450 
Maltodextrin 10 125 500 125 500 
Sucrose 100 400 100 400 
     
Cellulose, BW200 50 0 50 0 
     
Soybean Oil 40 360 40 360 
t-Butylhydroquinone 0.008 0 0.008 0 
     
Mineral Mix 35 0 35 0 
     
Vitamin Mix 10 40 10 40 
Choline Bitartrate 2.5 0 2.5 0 
     
Total  1000 3850 616.808 2317 
     
Phosphorus 3.1  3.1  
Calcium 5.0  5.0  
Potassium 3.6  3.6  
Magnesium 0.5  0.5  
Vitamin K 0.000750  0.000750  
Vitamin D 0.0100  0.0100  
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whereas left femora were fixed in 4% paraform aldehyde for immunihistochemistry 
(IHC) staining. Left tibiae were stored in 70% ethanol at 4°C for histology. Ex Vivo CT 
scans of the femoral neck (near the hip joint) and mechanical testing of mid-shaft femur 
and of the femoral neck was performed. All procedures in this study were approved by 
Texas A&M University Lab Animal Care Committee. 
 
Peripheral computed tomography 
XCT Research M (Stratec; Norland Corp., Fort Atkinson, WI) model has a minimum 
voxel size of 0.1 mm, a scanning beam thickness of 0.50 mm, and was calibrated daily 
using a standard hydroxyapatite phantom. In vivo measures were made of the proximal 
metaphysis of the right tibia on day 0, week4 and week 12 with the animal anesthetized. 
Transverse images were scanned at 5.0, 5.5, and 6.0 mm from the proximal tibia plateau. 
A standardized analysis for either metaphyseal bone (contour mode 3, peel mode 2, outer 
threshold of 0.169 g/cm3, inner threshold of 0.650 g/cm3) or diaphyseal bone (separation 
1, threshold of 0.650 g/cm3) was applied to each section. Values of total, cortical shell, 
and cancellous volumetric bone mineral density (vBMD), cross-sectional area, cortical 
area, and marrow area (A) were averaged across 3 slices at each bone tissue to yield a 
mean value for each site. In addition, middiaphyseal cross-sectional moment of inertia 
(CSMI) was obtained with respect to the neutral bending axis during three-point bending. 
Machine precision (based on manufacturer's data) is ±3 mg/cm3 for cancellous BMD and 
±9 mg/cm3 for cortical BMD. Reproducibility in our laboratory for both in vivo and ex 
vivo measures was determined from five repeat scans with repositioning of the animal or 
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bone between scans. Coefficients of variation for these measurements were 
1.24, 2.13, and 1.95% for in vivo proximal tibia total BMD, cancellous BMD, and total 
area, respectively. Ex vivo distal metaphysis coefficients of variation for the same 
variables were 0.37, 1.43, and 0.28%, respectively. 
 
Dual energy x-ray absorptionmetry (DEXA) 
Total body BMD and BMC, total body fat mass and lean mass were measured by DEXA 
with a Lunar DPX-MD+ bone densitometer (GE Lunar, GE Medical Systems, 
Milwaukee, Wis), with software standardized for small animals. Anesthetized rats were 
laid prone on the platform and measurement was performed. BMD determinations are 
expressed in grams per square centimeter and BMC, fat and lean mass are expressed in 
gram. Percent fat mass was calculated as fat mass (g)*100/body weight (g). Daily 
densitometer standardization with a phantom spine showed variation from one day to the 
next of <0.1%.  
 
Serum leptin analyses 
A rat leptin ELISA immunoassay kit (Crystal Chem, Chicago, IL) was used to measure 
the concentration of leptin in animal’s serum and reported as ng/ml serum. Assays were 
run on duplicate samples. Precision C.V. within-run was ± 3.2% and C.V. between run 
was ± 6.4%. 
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Cancellous histomorphometry 
Undemineralized distal left femora were subjected to serial dehydration and embedded in 
methylmethacrylate (Aldrich M5, 590-9). Serial frontal sections were cut 8µm thick and 
left unstained for fluorochrome label measurements, and cut at 4µm sections for Von 
Kossa staining for measurement of cancellous bone volume and quantification of 
osteoblast, osteoid and osteoclast surfaces. 
At 20x, a defined region of interest was established ~1.0 mm from the growth plate and 
within the endocortical edges encompassing 6-7 mm2. Total bone surface, single-labeled 
surface, and double-labeled surface were measured at 100x and interlabel distances, bone 
volume and osteoid/osteoclast surface were measured at 200x magnification. Mineral 
apposition rate (MAR, µm/day) was calculated by dividing the average interlabel width 
by the time between labels (7 days), and mineralizing surface (MS/BS) for cancellous 
bone surfaces was calculated by using the formula MS/BS = {[(single labeled 
surface/2) + double label surface]/surface perimeter} x 100. BFR was calculated as 
MAR × MS/BS. Total bone surface, osteoid surface, osteoclast surface were obtained by 
manual tracing. The raw data were exported to an excel sheet and derived indices of 
bone volume (BV)/tissue volume referent, osteoid/bone surface (BS), osteoclast 
surface/BS, osteoid thickness were calculated using previously described formulae (27). 
Histomorphometric analyses were performed with OsteoMeasure system (OsteoMetrics, 
Inc., Atlanta, GA) and digitizing pad, interfaced with color video camera (DXC-390P, 
Sony, Japan) and an Olympus BX60 Microscope with epifluorescent light (Leeds 
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Instruments, Inc. Irving, TX). All nomenclature for cancellous histomorphometry 
follows standard usage (215). 
Immunohistochemistry 
Femur specimens from rats were fixed by immersion in 4% paraformaldenyde in 0.1M 
sodium phosphate buffer (PBS), pH 7.4. After 20~24 hours fixation, the samples were 
decalcified with 50% formic acid (by mixture with 20% sodium citrate, 1:1 ratio), 
dehydrated in a graded series of ethanol and embedded in paraffin (Paraplast). Sections 
(5μm thick) were immunostained by avidin-biotin technique (232). Tissue sections were 
deparaffinized, hydrated in PBS and incubated in 0.3% H2O2 in D.I. water for 30 min at 
room temperature to block endogenous peroxidase activity. After being washed in PBS, 
the sections were preincubated with avidin D solution and then biotin solution for 15 
minutes each, then with  normal serum from the same species as the secondary antibody 
for 20 min at room temperature (to minimize background staining). Then, they were 
incubated first overnight at 4°C with primary rabbit polyclonal anti-leptin antibody (Ob 
(A20): sc-842, Santa Cruz Biotech, CA, USA), diluted 1:500 in PBS/2% BSA, then with 
the corresponding biotinylated anti-rabbit IgG secondary antibody, made in goat, diluted 
by manufacturer’s protocol (VECTOR) in PBS/2% BSA/5% NGS and finally with ABS 
complex (Vectastain elite ABC reagent, VECTOR). Peroxidase activity was revealed by 
developing sections with enzyme substrate (NovaRED substrate kit, VECTOR). Sections 
then counterstained with hematoxyline, mounted with Eukitt (Kindler, Germany) and 
observed under microscope. Method specificity was tested by omitting the primary 
antibody in the immunostaining procedures. 
  
 
93
Statistical analysis 
 
To analyze pre- and post- treatment values of tibia pQCT variables, and blood variables, 
a 3-way ANOVA with repeated measures was used. In addition, a simple main effects 
analysis was performed when 3-way interactions were significant and, when appropriate, 
Duncan post-hoc or LSD tests were used within the simple main effects analyses. For 
end point measures (e.g. histomorphometry data), 2-way ANOVA was performed, with 
appropriate post-hoc tests. Linear associations between change of serum leptin level to 
the bone formation rate were described with Pearson correlation coefficients. All values 
reported are means ± standard errors. 
 
 
Results 
 
 
Food intake/ water intake 
 
Over the course of the 12-wk study, CON rats (ad-lib fed) consumed 15.3±2.7g /day of 
the AIN-93M diet in VEH and BB groups. ER rats consumed 9.3g±1.7g /day of the AIN-
93M-E diet in VEH and BB groups. These intake provided 58.6±10.5 and 34.8±6.3 
kcal/d, respectively for CON and ER rats.   Food intake over 12 weeks’ experiment was 
not different between VEH and BB rats (data not shown). Water intake over 12 weeks’ 
experiment was not different among all groups (16-21.5ml/day); average propranolol 
dose delivered via water intake was 1.70mg ± 0.2 /day and 1.77 ±0.2 /day for CONBB 
and ERBB, respectively. 
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Body weight/body composition 
 
ERVEH and ERBB rats had lower body weights than CONVEH and CONBB rats 
starting at week 2 of treatment until the end of the experiment (Fig 3.1). Over the 12-wk 
experiment period, ER reduced body weight body weight to 249 ± 12.63g in VEH 
treated  (- 20.1%) and to 254 ± 3.73g in BB  treated ( -18%) rats (p< 0.0001), while 
CONBB rats increased body weight to   347 ± 6.44 g (+ 10.4% ) (p < 0.01). Significant 
interaction between energy status and time was observed in fat mass and in lean mass 
variables (but no significant interaction with 3 factors: energy status, beta blocker 
treatment, and time), so 2 way ANOVA with repeated measure test in each energy status 
group (CON and ER) was performed seperately. At week 12, fat mass and lean mass in 
ER rats were significantly lower rats subjected to ad lib feeding.  Over 12 weeks, control 
rats gained fat mass in VEH (+ 47 %) and BB (+ 64 %) rats and energy restricted rats 
lost body fat mass in VEH (-63%) and BB (-78%) rats (p < 0.0001).  Lean body mass 
increased by 4 weeks in energy restricted rats, but not in control rats; by week 12, there 
was no difference in lean body mass among groups or versus week 0 value within group 
(Table 3.2). 
 
Serum leptin 
The reduction in serum leptin level was significantly less in ERBB (-1.14 ± 1.0ng/ml) 
than in ERVEH (-5.31± 1.1ng/ml) at week12 (Fig 3.2A). The change in serum leptin 
level over the experimental period correlated with bone formation rate (BFR) (r= 0.62, 
p< 0.0001) (Fig 3.2B). Those rats exhibiting the greatest decline in serum leptin had the 
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Table 3.2 In vivo DEXA measures of ER and/or BB effects on body composition and total body BMD, BMC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                   CONVEH 
 
CONBB ERVEH ERBB 
 wk0 wk4 wk12 wk0 wk4 wk12 wk0 wk4 wk12 wk0 wk4 wk12 
 
Fat mass 
(g)$ 
65.0±4.5 86.1±7.0 
96.1±11.8
* 65.9±2.9 91.4±4.9 
108.9±6.0
* 66.4±4.2 41.1±5.7 24.2±7.8* 61.5±6.7 35.0±3.5 12.8±2.8* 
Lean 
mass 
(g)& 
213±6.3 214±5.8 212±5.9 212±3.7 215±3.3 212±4.8 220±8.4 243±5.7† 216±4.4 213±6.6 236±3.6† 216±2.2 
Total 
body 
BMC$ 
9.6±0.2 10.0±0.2 10.3±0.4* 9.4±0.1 10.2±0.1 10.5±0.1§ 9.6±0.2 9.5±0.2 9.0±0.3* 9.5±0.2 9.4±0.1 8.7±0.1* 
Total 
body 
BMD$ 
0.179± 
0.001 
0.182± 
0.001 
0.180± 
0.003 
0.180± 
0.001 
0.183± 
0.001 
0.183± 
0.001 
0.182± 
0.001 
0.175± 
0.002 
0.174± 
0.001£ 
0.182± 
0.002 
0.174± 
0.001 
0.172± 
0.002£ 
CON: ad-lib fed, ER: energy restriction, VEH: vehicle administration, BB: beta blocker administration, respectively. For all 
experimental groups, n=10, except for CONVEH, in which n=9.  
  & ER groups’ means lower at week 4 vs CON group’s means, p<0.0001 
† p< 0.0001 vs wk 0 within energy status group 
$ ER groups’ means lower at week 12 vs CON group’s means, p<0.0001  
* p<0.05 vs wk 0 within energy status group 
£ p<0.01 vs wk 0 within energy status group 
§ p< 0.0001 vs wk 0 within energy status group 
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lowest BFR in proximal tibial cancellous bone. The serum leptin level at week 12 
correlated with bone formation rate (r= 0.54, p<0.0001) (data now shown). Serum leptin 
level at week 12 normalized by fat mass(g) in ERBB rats tended to be greater than that 
of ERVEH, but not statistically significant (Table 3.3).  
 
 
 
Table 3.3 
 
Serum leptin level normalized by fat mass from DEXA analysis at week 12 
 
Group Serum leptin (ng/ml)/g fat 
CONVEH 0.127±0.04 
CONBB 0.103±0.04 
ERVEH 0.069±0.02 
ERBB 0.167±0.01 
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Figure 3.1 (A) Body weights over 12 weeks of energy restriction (ER) or ad-lib fed 
(CON) in rats administered vehicle (VEH) or beta blocker (BB). 
For all experiment group, n=10 except CONVEH, in which n=9.  
* p<0.01 vs CONVEH, & P<0.0001 VS CONVEH, # p<0.01 vs wk 0 within group 
$ p<0.001 vs wk 0 within group, % p<0.0001 wk 0 within group 
 (B) Total body fat mass and lean mass at week12. Fat mass portion of bars sharing same 
letters are not significantly different. 
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Fig 3.2 (A) Change of serum leptin over 4 weeks and over 12 weeks of energy 
restriction (ER) or ad-lib fed (CON) in rats administered vehicle (VEH) or beta blockade 
(BB) (post value- post value in ng/ml).* p<0.05 vs CONVEH at week 4, & p<0.05 vs 
CONVEH at week 12, $ p<0.05 ERVEH at week 12. 
 (B) Correlation between change in serum leptin value (post value- pre value in ng/ml) 
and bone formation rate (BFR) measured at 84 days for all animals. 
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Bone mass 
Proximal tibial metaphysis and midshaft vBMD (pQCT)  
Longitudinal vBMD measurement at the proximal tibia revealed a significant decrement 
in cancellous vBMD, compared to their initial value, in ERVEH rats starting at week 4  
(-12%), which decrement increased by the end of the experiment (-22%)(Table 3.4). 
Even though the significant reduction in cancellous vBMD  was also observed in ERBB 
rats at week12 (-16%) compared to their initial value, but the magnitude of decrement 
caused by ER over 12 weeks was significantly attenuated by BB treatment (-53.94 
mg/cm3 vs    -85.24 mg/cm3 in ERVEH rats) (Fig 3.3) (p < 0.05). Total vBMD 
(including cortical shell and cancellous core) decreased over the experimental period in 
all groups starting at week 4. ER alone (-91.34 mg/cm3), but not ER rats given BB (-
62.68 mg/cm3), resulted in significantly greater reduction in total vBMD than in 
CONBB and CONVEH rats (-36.00, -33.28 mg/cm3, respectively). Cortical shell vBMD 
in CONBB and ERBB rats (+17, +19 mg/cm3, respectively) tended to increase over 12 
weeks (p < 0.07), but this increment was not observed in VEH treated rats (data not 
shown). Longitudinal vBMD measurement at midshaft tibia revealed a significant and 
similar (~2.0%) increment in cortical vBMD for all groups except ERVEH rats. 
(p<0.001) (Table 3.4).  
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Fig 3.3  
Proximal tibia cancellous volumetric bone mineral density (vBMD) over 12 weeks of 
energy restriction (ER) or ad-lib fed (CON) in rats administered vehicle (VEH) or beta 
blocker (BB). * p<0.05 vs wk 0 within group, $ p<0.01 vs wk 0 within group, # p<0.001 
vs wk 0 within group, & p<0.05 vs ERBB at week 12. 
 
 
 
Total body BMD and BMC (DEXA) 
Significant interaction between energy status and time was observed in Total body 
BMD and BMC (but no significant interaction with 3 factors: energy status, beta 
blocker treatment, and time), so 2 way ANOVA with repeated measure test in each 
energy status group (CON and ER) was performed separately. At week 12, total body 
BMC and BMD in ER rats were significantly lower rats subjected to ad lib feeding.  
Total body BMD and BMC decreased in rats subjected to ER (Table 3.2). No difference 
between ERVEH and ERBB rats was observed in any of the DEXA variables.  
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Table 3.4 In vivo PQCT measures of ER and/or BB effects on tibia density and geometry 
  
 
 CONVEH CONBB ERVEH ERBB 
 wk0 wk4 wk12 wk0 wk4  wk12     wk0 wk4 wk12 wk0 wk4 wk12 
 
Proximal 
Tibia 
            
Total  vBMD 
(mg/cm3) 
 
699.2± 
12 
680.8± 
12* 
666.2± 
14* 
712.2± 
14 
679.6± 
15* 
676.2± 
12* 
712.4± 
13 
657.2± 
16* 
632.4± 
17* 
722.2± 
11 
680.4± 
9* 
663.9± 
7*  
Marrow Area 
(cm2)  
7.9±0.4 8.3±0.6 8.6±0.5 7.8±0.3 8.2±0.2 8.3±0.2 7.8±0.4 8.6±0.6 9.4±0.6 8.0±0.4 8.7±0.3 8.8±0.4 
Total Area 
(cm2) 
15.1±0.5 15.4±0.8 15.6±0.6 15.1±0.4 15.3±0.3 15.3±0.3 15.1±0.6 15.6±0.8 16.3±0.9 15.7±0.5 15.8±0.3 15.8±0.4 
Cortical Area 
(cm2) 
6.3 ±0.2 6.1±0.2 6.1±0.2 6.3±0.2 6.1±0.1 6.1±0.1 6.2±0.2 6.0±0.3 6.2±0.2 6.4±0.3 6.2±0.2 6.1±0.2 
 
Tibia 
Diaphysis 
            
Cortical 
vBMD(mg/c
m3) 
1334±3 1344±3 1360±4# 1333±5 1340±5 1357±4# 1341±3 1342±6 1357±6 1332±5 1342±5 1361±4# 
Cortical Area 
(cm2)  
5.0±0.09 5.0±0.10 5.0±0.10 5.1±0.09 5.1±0.07 5.0±0.06 5.2±0.13 5.2±0.13 5.2±0.13 5.4±0.10 5.4±0.06 5.2±0.09 
Total Area 
(cm2)  
5.8±0.11 5.8±0.11 5.7±0.10 5.8±0.10 5.8±0.10 5.7±0.10 6.0±0.15 6.0±0.17 6.0±0.20 6.1±0.15 6.1±0.10 5.9±0.11 
CON: ad-lib fed, ER: energy restriction, VEH: vehicle administration, BB: beta blocker administration, 
respectively. For all experimental groups, n=10, except for CONVEH, in which n=9.  
*p<0.05 vs wk 0 within group, # p<0.001 vs wk 0 within group 
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Proximal tibia cancellous bone histomorphometry 
 
The decrease in % MS/BS observed in ERVEH rats vs CONVEH rats was abolished in 
ERBB rats (Fig 3.4A). The MAR observed in ERVEH was significantly lower, but the 
MAR observed in ERBB rats was not significantly lower than that of CONVEH rats (Fig 
3.4B). These decreases in MAR and %MS/BS contributed to the 79% reduction in BFR 
(Fig 3.4C) in ERVEH rats; this reduction in BFR with energy restriction was 
significantly attenuated in ERBB rats. The reduction in % osteoid surface vs CONVEH 
was observed both in ERVEH and ERBB rats (Fig 3.4D). The 2-fold increase in % 
resorbing surface (the surface covered by osteoclasts) observed in ERVEH rats was 
abolished in ERBB rats (Fig 3.4E). Percent BV/TV in ERVEH rats tended to be lower 
than in ERBB rats (Fig 3.4F). No significant differences in any histomorphometric 
values were observed with beta blocker treatment in CON rats (vs CONVEH). 
 
 
Immunohistochemistry 
 
Reduction in leptin expression in bone marrow adipocytes observed in ERVEH rats was 
attenuated in ERBB rats (Fig 3.5). Reduction in the number of cells (bone lining cells, 
osteocytes and chondrocytes in cartilage) staining positive for leptin observed in 
ERVEH rats was also attenuated in ERBB rats. No background staining was observed in 
negative control studies when primary antibody was omitted.  
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Fig 3.4 Proximal tibia histomorphometric indicators 
Effect of vehicle (VEH), beta blocker (BB) during energy restriction (ER) or ad-lib fed 
(CON) rats on proximal tibia (A) mineral apposition rate (MAR), (B) % mineralizing 
surface (%MS/BS), (C) bone formation rate (BFR), (D) % Osteoid surface, (E) % 
osteoclast surface and (F) % bone volume/tissue volume (% BV/TV). Values are means 
± SE. For all experiment groups, n=10 except CONVEH, ERVEH, in which n=9. Bar 
sharing same letters are not significantly different. 
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Fig 3.4 Continued 
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(A)                                                                            (B) 
 
(C)                                                                            (D) 
 
 
 
 
 
Fig 3.5  
Adipocytes positive for leptin expression (red staining) in the marrow space of femur in 
CONVEH(A), CONBB(B), ERVEH(C) and ERBB(D) 
Bone lining cells positive for leptin expression in femur CONVEH(E), CONBB(F), 
ERVEH(G) and ERBB(H). Magnification: x 400. 
 
 
 
 
 
 
CONVEH CONBB 
ERVEH ERBB 
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(E)                                                                        (F) 
 
 
(G)                                                                           (H) 
 
 
Fig 3.5 Continued 
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Discussion 
 
 These experiments extend upon previous work demonstrating interesting links between 
the sympathetic nervous system, regulation of serum leptin and/or bone mass. The 
primary hypotheses of our study were that beta-adrenergic blockade would attenuate the 
decrease of serum leptin and bone mineral density during energy restriction and that 
rescued serum leptin would result in more leptin localizing to the critical bone cells 
responsible for bone formation. 
 
Our data demonstrate that beta- adrenergic blockade significantly mitigate the reduction 
in serum leptin during energy restriction in adult rats. Reductions in cancellous vBMD 
and bone formation rate in proximal tibia during restricted calorie intake was also 
significantly mitigated by beta-adrenergic blockade. No investigation to our knowledge 
has demonstrated the effect of beta blockade on bone mass with energy restriction. 
Furthermore, no study has demonstrated the effect of beta blockade on leptin expression 
and serum leptin level and its correlation with bone cell activity or bone formation rate 
with energy restriction.  
 
In the present study, the reduction in cancellous vBMD in proximal tibia with 40% 
energy restriction was significantly attenuated by beta blockade. There exist literatures 
examining the effect of peripheral beta blockade on bone in the rats under the 
circumstances causing bone loss. We recently demonstrated that beta blocker modulates 
both resorption and formation while attenuating disuse-induced bone loss, which is 
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almost as effective as providing a leptin analog in tail-suspended male rats (27). 
Exposing animals to stressful conditions such as tail suspension could increase heart rate 
and blood pressure through activation of the sympathetic nervous system (23,24) and 
elicit the release of the catecholamines norepinephrine (25). It’s been shown that 
noradrenaline release is increased with food restriction (21) which is associated with 
increased bone resorption or decreased bone formation.  
 
Attenuated loss of vBMD by beta blockade may result from suppressed resorption or 
attenuated decrease of formation or both, so we examined histomorphometric measures 
of formation and resorption. The 71% decreases in mineralizing surface (%MS/BS), the 
37% decrease in mineral apposition rate and the 79% decreases in bone formation rate 
during ER were successfully attenuated by beta blockade (-13%,-16% and -27%, 
respectively). Percent MS/BS indicates osteoblasts recruitments and MAR indicates the 
vigor of individual osteoblast teams. Reduction in bone formation rate was more related 
to reduction in % MS/BS rather than to mineralizing surface, suggesting that the change 
in osteoblast recruitment rather than osteoblast cell activity contributed more to the 
reduction in bone formation rate during ER. The dramatic increase of bone resorbing 
surface during ER was abolished by beta blocker treatment. By this result, we conjecture 
that rescued serum leptin level due to beta blockade would prevent the transient increase 
in osteoclast number with energy restriction. Regulation of osteoclast number by letpin 
or beta blocker could be mediated by the receptor activator of nuclear factor kappaB-
ligand (RANKL)/osteoprotegerin (OPG) pathway, and Martin et al. showed in their 
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study by using RT-PCR that a suspension-induced increase in RANKL gene expression 
in proximal tibia, which was counterbalanced by leptin administration with a similar 3-
fold increase in OPG expression and a RANKL to OPG ratio close to nonsuspended 
conditions (19). It would be desirable to verify this study model, which is beta blockade 
with energy restriction, in the future. 
 
Even though serum leptin level in humans and rodents are mainly correlated with fat 
mass, there are several factors affecting circulating leptin levels independently of 
alterations in adipocity. Studies in humans and rodent model demonstrate that 
stimulation of sympathetic nervous system and activation of beta-adrenergic receptors 
decrease serum leptin levels (233). Activation of the beta-adrenergic receptors, 
combined with a decrease in insulin level, is thought to be responsible for the decrease in 
leptin levels with fasting (17). 
 
Besides fasting, long-term food restriction (from 50% to 80% of ad libitum energy 
intake) in rats results in a substantial fall in serum leptin concentration and in white 
adipose leptin mRNA levels (151). In the present study, there was no difference in gram 
body fat at week 12 in ERBB and ERVEH rats. However, serum leptin level normalized 
by body fat tended to be greater in beta-blockade treated ER rats than that in ERVEH 
rats at the end of the study, although this comparison did not reach statistical 
significance. This observation suggests that the level of leptin synthesis or release per 
unit adipocyte was greater when beta-adrenergic signaling is blocked in energy restricted 
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rats. The exact mechanism for beta blockade rescue of leptin synthesis or release has not 
been fully investigated. There is agreement that elevated cyclic AMP inhibits leptin 
release by adipose tissue (21, 234). Stimulated adenylyl cyclase and subsequent PKA 
phosphorylation is thought to be the regulating mechanism of leptin release from adipose 
tissue. Measurement of adipocyte cyclic AMP level and/or adenylyl cyclase activity in 
beta blockade treated animals could help define the mechanism underlying the rescue of 
leptin release by beta blockade during energy restriction. 
 
Although we confirmed that beta blockade attenuated the reduction in serum leptin, and 
bone mass in energy restricted rats, we cannot overlook the possibility that these effects 
may be due to blocking beta-adrenergic input to osteoblasts. Takeda et al. confirmed that 
osteoblasts express β-adrenergic receptors (18). To address bone formation is regulated 
by the SNS, Wildtype and overiectomized mice given a β-adrenergic antagonist 
experienced an increase in bone mass. Sympathetic activation reduces osteoblast 
proliferation (18) and it stimulates bone resorption by increasing RANKL expression 
(235). Beta-adrenergic blockade blunts the inhibition of alkaline phosphatase activity by 
isoproterenol (a beta agonist) in an osteoblast-like cell line, which suggests that 
propranolol may enhance bone formation by preserving osteoblastic activity in the face 
of beta adrenergic receptor stimulation (120). We speculate that the positive effects of 
beta-blockade on mitigating bone loss with ER may derive from the synergistic effects 
of these two mechanistic pathways, that is, one from the direct effect of beta blockade on 
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osteoblast and the other from the indirect effect of beta blockade on leptin release from 
adipocytes, resulting in rescue of suppressed leptin synthesis or leptin release.  
 
White adipose tissue is the primary site of leptin synthesis and secretory regulation, but 
recent studies show that leptin is produced in placenta, skeletal muscle, fetal 
bone/cartilage and primary cultures of human osteoblasts (140-143). Our 
immunostaining results suggest greater leptin expression in bone marrow adipocytes in 
groups showing higher serum leptin level and higher cancellous vBMD. In the same 
groups, more bone lining cells and osteocytes also stained positive for leptin.The 
hypothesis that beta blockade would positively affect the leptin synthesis and/or release 
is supported by the mitigated reduction in serum leptin with energy restriction in the 
present study. But we cannot affirm the leptin-positive staining observed in osteocytes, 
and bone lining cells are the result of localization of leptin derived from the marrow 
adipocytes or derived from the other peripheral adipose tissue or the result of leptin 
synthesized and secreted from the cell itself. Further investigation on the effect of beta 
blockade on expression, secretion and autocrine signaling (if exists) of leptin among 
bone cells is justified. 
 
The beta blocker dose used in this study was 6mg/ kg•d and was achieved by oral 
drinking throughout 24 hours.  It has been previously demonstrated that 0.1 or 5 mg/kg 
of propranolol injection (5 days/week) prevents the deterioration of cancellous bone due 
to the different physiological challenge of estrogen deficiency (ovariectomy) (226) but 
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the high-dose treatments (20-mg) did not.  Interestingly, the lower dose was more 
effective in attenuating the increase of ostoclastic cells after ovariectomy. When beta 
blockade is administered by oral drinking (0.5 g/L) in estrogen deficient (by 
ovariectomy) mice, loss of total body bone mineral density is attenuated and osteoblast 
number and mineralizing surface is increased on cancellous bone.  
The contradictory results reported in the human literature regarding to the relationship 
between the beta blockade and bone (236-238) might be explained by different doses 
utilized. More study is needed to determine the adequate dose of beta-blocker in various 
physiological conditions causing bone loss. 
  
Importantly, in the present study, no significant differences in any outcome measures 
were observed with beta blockade in ad lib fed rats, suggesting that beta blockade and 
leptin exert their bone protective effects in the context of energy restriction and/or serum 
leptin deficiency, but not in the energy-balanced state. We tested the correlation between 
final serum leptin level and bone formation rate, which convinced the rescued serum 
leptin plays a role in mitigating reduction in BFR during energy restriction. Interestingly, 
the bone formation rates vary a great deal in very high serum leptin values (mostly seen 
in CONBB rats) are scattered, whereas low and mid level of serum leptin values 
correlate relatively well with low bone formation rate. This result suggests that there 
may exist a limit of level for circulating leptin exerts beneficial effect on bone. 
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In summary, 40% caloric restriction over 12 weeks caused bone loss at the proximal 
tibia and serum leptin reduction. Beta- adrenergic blockade mitigated the energy 
restriction induced cancellous bone loss via attenuating reduction in osteoblastic cell 
recruitment and activity and increase in osteoblastic cell recruitment. Reduction in serum 
leptin with energy restriction was mitigated by beta- adrenergic blockade, and change of 
serum leptin level was correlated with the bone formation rate. Reduction in leptin 
expression in bone marrow adipocytes observed with energy restriction was attenuated 
by beta-adrenergic blockade. Reduction in the number of bone lining cells and 
osteocytes stained positive for leptin was also attenuated by beta-blockade. We conclude 
that beta blockade effects on preventing the bone loss during energy restriction. Also 
beta blockade is associated with mitigating reduction in serum leptin, subsequently with 
mitigating reduction in bone mass by normalized leptin’s localization to the bone cells. 
These results may have serious implications for those individuals who utilize energy 
restriction in attempts to lose weight with usage of beta blocker in order to treat 
hypertension or other cardiovascular disease. 
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CHAPTER VI 
 
CONCLUSION AND FUTURE RESEARCH 
 
 
 
 
The ultimate goals of these projects was  to identify the relationship between activation 
of the sympathetic nervous system, altered circulating levels of leptin  and decrements in 
markers of bone integrity during stressful condition such as mechanical unloading or 
energy restriction (ER).   Beta adrenergic blockade was used to determine the 
association between mitigated reductions in serum leptin and subsequent alterations in 
the reductions in bone mass observed with mechanical unloading or ER. To do so, serum 
leptin, bone mineral density and geometry, formation and resorption parameters were 
documented after subjecting adult rats to hindlimg unloading and food restriction. Then, 
hindlimb unloaded rats or energy-restricted rats were treated with propanolol to elucidate 
if beta blockade attenuates bone loss during unloading or energy restriction and whether 
such an effect is associated with changes in serum leptin level.   Leptin localization to 
the important cells for bone formation andresorption was also quantified.  
 
These data document that 1) serum leptin level was reduced by unloading and by global 
food restriction, and was associated with the decline in bone formation rate; 2) beta-
blockade mitigated unloading-induced reductions in serum leptin and was as effective as 
leptin administration in mitigating reduction in cancellous bone mineral density with 
unloading through both increased bone formation and suppressed bone resorption; and 3)
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beta blockade attenuated the reduction in serum leptin, cancellous bone mineral density 
and bone formation rate observed with reduced energy intake and also abolished the 
induced increase in bone resorption; 4) the reduction in leptin expression in bone 
marrow adipocytes observed with ER was attenuated by beta-blockade, as was the 
reduction in the number of bone lining cells, osteocytes and chondrocytes which stained 
positive for leptin.  
 
We conclude that bone loss during spaceflight could be aggravated by consistent 
reductions in food intake as is frequently observed during short-term shuttle missions.  
The importance of avoiding voluntary food restriction should be emphasized to 
astronauts or bed rest patients, because the bone loss which already occurs with disuse 
could be exacerbated by reduced serum leptin due to the energy restriction. We also 
conclude that sympathetic nervous system activation contributes to the bone loss 
observed during stressful condition such as spaceflight or energy restriction.   Beta 
blockade is associated with mitigated reductions in serum leptin, bone mass, perhaps by 
restoring leptin’s localization and signaling to important bone cell populations. These 
data illustrate the important role of “peripheral” leptin mechanisms in regulation of bone 
mass during energy restriction, as opposed to “central” pathways operating solely via the 
hypothalamus.   Also, these data are the first to illustrate an association between beta-
adrenergic signaling and leptin pathways in regulating bone cell activity in the context of 
energy restriction.  Many adults in developed countries suffer from both cardiovascular 
disease and osteoporosis.  The potential dual effect of beta blocker treatment on both 
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heart and skeletal system could be an important consideration.  But recent human 
epidemiological studies contain contradictory results. One study showed use of beta 
blockers is associated with a 30% decrease in fracture risk (236), but other study showed 
that the use of beta blockers did not present any link to bone mineral density (238). In- 
depth study regarding the proper prescription of propranolol for bone treatment must be 
preceded. 
 
While these results provide support for a mechanistic role of leptin in preventing bone 
loss during energy restriction or mechanical unloading, many questions remain. We 
observed that the dramatic increase of bone resorption surface during mechanical 
unloading or energy restriction was abolished by beta blocker treatment, but the 
underlying mechanism has not been demonstrated.   Additional techniques could be used 
to investigate if regulation of osteoclast number by leptin or, more indirectly by beta 
blockade is mediated by the receptor activator of nuclear factor kappaB-ligand 
(RANKL)/osteoprotegerin (OPG) pathway.   This could be accomplished by quantifying 
RANKL/OPG gene expression with real time PCR or RANKL/OPG expression with 
immuno-histostaining methods. Also, as previously discussed, the effects of altered 
sympathetic nervous system signaling on bone vary throughout the skeleton according to 
local factors. Besides limb bones that used in this study, the same investigation could be 
performed with the vertebral bones.  These studies could provide data on whether there 
is a different response in axial bone and appendicular bone to the blockade of beta-
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adrenergic signaling or leptin treatment during mechanical unloading or energy 
restriction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
118
LITERATURE CITED 
 
1.   LeBlanc A, Shackelford L, Schneider V. Future human bone research in space. Bone. 
1998; 22:113S-116S. 
2.   Vico L, Collet P, Guignandon A, Lafage-Proust M, Thomas T, Rehailia M, Alexandre C. 
Effects of long-term microgravity exposure on cancellous and cortical weight-bearing 
bones of cosmonauts. Lancet. 2000;355:1607-1611. 
3.   Warber JP, McGraw SM, Kramer M, Lesher L, Johnson W, Cline AD.The Army Food 
and Nutrition Survey.Technical Report No.T98-XX.Natick, Mass. U.S. Army Research 
Institute of Environmental Medicine. 2000. 
4.   Institute of Medicine. Not Eating Enough, Overcoming Underconsumption of Military 
Operational Rations, B.M. Marriott, ed. Committee on Military Nutrition Research, 
Food and Nutrition Board. Washington, D.C.: National Academy Press. 1995a. 
5.   Institute of Medicine. Weighing the Options: Criteria for Evaluating Weight-
Management Programs, P.R. Thomas, ed. Committee to Develop Criteria for Evaluating 
the Outcomes of Approaches to Prevent and Treat Obesity, Food and Nutrition Board. 
Washington, D.C. National Academy Press. 1995b. 
6.   Institute of Medicine. Assessing Readiness in Military Women:  The Relationship of 
Body Composition, Nutrition and Health, B.M. Marriott, ed. Committee on Military 
Nutrition Research, Food and Nutrition Board. Washington, D.C.: National Academy 
Press. 1998a. 
  
 
119
7.   Nichols DL, Sanborn CF, Essery EV. Bone Density and Young Athletic Women : An 
Update. Sports Med. 2007;37(11):1001-1014.  
8.   Meyer HE, Tverdal A, Selmer R. Weight variability, weight change and the incidence of 
hip fracture: a prospective study of 39,000 middle-aged Norwegians. Osteoporos Int. 
1998;8(4):373-8. 
9.   Riedt CS, Cifuentes M, Stahl T, Chowdhury HA, Schlussel Y, Shapses 
       SA. Overweight postmenopausal women lose bone with moderate weight reduction and 
1 g/day calcium intake. J Bone Miner Res. 2005;20:455– 63. 
10.  Ricci TA, Chowdhury HA, Heymsfield SB, Stahl T, Pierson RN Jr, 
       Shapses SA. Calcium supplementation suppresses bone turnover during 
       weight reduction in postmenopausal women. J Bone Miner Res. 1998;13:1045–50. 
11.  Talbott SM, Cifuentes M, Dunn MG, Shapses SA.Energy restriction reduces bone 
density and biomechanical properties in aged female rats. J Nutr. 2001;131:2382-2387. 
12.  Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI. Leptin modulates 
the T-cell immune response and reverses starvation-induced immunosuppression. 
Nature.1998;394(6696):897-901. 
13.  Lage M, Garcia-Mayor RV, Tome MA, Cordido F, Valle-Inclan F, Considine RV, Caro 
JF, Dieguez C, Casanueva FF. Serum leptin levels in women throughout pregnancy and 
the postpartum period and in women suffering spontaneous abortion. Clin Endocrinol 
(Oxf). 1999;50(2):211-6. 
  
 
120
14.  Rayner DV, Dalgliesh GD, Duncan JS, Hardie LJ, Hoggard N, Trayhurn P. Postnatal 
development of the ob gene system: elevated leptin levels in suckling fa/fa rats. Am J 
Physiol. 1997;273(1 Pt 2):R446-50. 
15.  Gainsford T, Willson TA, Metcalf D, Handman E, McFarlane C, Ng A, Nicola NA, 
Alexander WS, Hilton DJ. Leptin can induce proliferation, differentiation, and 
functional activation of hemopoietic cells. Proc. Natl. Acad. Sci. USA. 1996; 
93(25):14564-8. 
16.  Sierra-Honigmann MR, Nath AK, Murakami C, Garcia-Cardena G, Papapetropoulos A, 
Sessa WC, Madge LA, Schechner JS, Schwabb MB, Polverini PJ, Flores-Riveros JR. 
Biological action of leptin as an angiogenic factor. Science. 1998;281(5383):1683-6. 
17.  Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, 
Rueger JM, Karsenty G. Leptin inhibits bone formation through a hypothalamic relay: a 
central control of bone mass. Cell. 2000;100(2):197-20 
18.  Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, Armstrong D, Ducy P, 
Karsenty G. Leptin regulates bone formation via the sympathetic nervous system. Cell. 
2002;111(3):305-17. 
19.  Martin A, de Vittoris R, David V, Moraes R, Begeot M, Lafage-Proust MH, Alexandre 
C, Vico L, Thomas T. Leptin modulates both resorption and formation while preventing 
disuse-induced bone loss in tail-suspended female rats. Endocrinology. 
2005;146(8):3652-9.  
  
 
121
20.  Gat-Yablonski G, Ben-Ari T, Shtaif B, Potievsky O, Moran O, Eshet R, Maor G, Segev 
Y, Phillip M. Leptin reverses the inhibitory effect of caloric restriction on longitudinal 
growth. Endocrinology. 2004;145(1):343-50.  
21.  Trayhurn P, Hoggard N, Mercer  JG, Rayner DV. Leptin:fundamental aspects. Int J Obes. 
1999; 23 (Suppl 1): 22-28. 
22.  Zauner C, Schneeweiss B, Kranz A, Madl C, Ratheiser K, Kramer L, Roth E, Schneider 
B, Lenz K. Resting energy expenditure in short-term starvation is increased as a result of 
an increase in serum norepinephrine. Am J Clin Nutr. 2000;71(6):1511-5. 
23.  Tucker BJ, Mundy CA, Ziegler MG, Baylis C, Balntz RC. Head-down tilt and restraint 
on renal function and glomerular dynamics in the rat. J Appl Physiol. 1987;63:505-513. 
24.  Woodman CR, Stump CS, Stump J, Sebastian LA, Rahman Z, Tipton CM. Influences of 
chemical sympathectomy and simulated weightlessness on male and female rats. J Appl  
Physiol. 1991;71(3):1005-14. 
25.  Funk D, Stewart J. Role of catecholamines in the frontal cortex in the modulation of 
basal and   stress-induced autonomic output in rats. Brain Research 1996;741: 220-229. 
26.  Fain JN, Bahouth SW. Regulation of leptin release by mammalian adipose tissue. 
Biochem Biophys Res Commun. 2000;274(3):571-5.  
27.  Baek K, Bloomfield S. Beta-blockade mitigates bone loss with hindlimb unloading. J 
Bone Miner Res. 2005;20 (Suppl 1):F176. 
28.  Baek K, Miller S, Lemmon J, Nilsson M, and Bloomfield SA.  Energy and calcium 
deficits are major contributors to effect of global food restriction on metaphyseal bone in 
exercising rodents. J Bone Miner Res. 2006;21 (Suppl 1):M35. 
  
 
122
29.  Silver IA, Murrills RJ, Etherington DJ , Microelectrode studies on the acid 
microenvironment beneath adherent macrophages and osteoclasts. Exp Cell Res. 1988; 
175(2):266-76. 
30.  Bonewald LF, Mundy GR. Role of transforming growth factor-beta in bone remodeling. 
Clin Orthop Relat Res. 1990;(250):261-76. Review. 
31.  Hock, JM, Centrella, M, Canalis, E. 1998  Insulin like growth factor I (IGF-I) has 
independent effects one matrix formation and cell replication. Endocrinology.1998; 
122:254-260. 
32.  Fiedler J, Röderer G, Günther KP, Brenner RE. BMP-2, BMP-4, and PDGF-bb  
       stimulate chemotactic migration of primary human mesenchymal progenitor cells. J Cell 
Biochem. 2002; 87(3):305-12.  
33.  Recker R, Lappe J, Davies KM, Heaney R. Bone remodeling increases substantially in 
the years after menopause and remains increased in older osteoporosis patients. 
J Bone Miner Res. 2004; 19(10):1628-33. 
34.  Lang TF, Leblanc AD, Evans HJ, Lu Y Adaptation of the proximal femur to skeletal 
reloading after long-duration spaceflight. J Bone Miner Res. 2006;21(8):1224-30. 
35.  Machwate M, Zerath E, Holy X, Hott M, Modrowski D, Malouvier A, Marie PJ. Skeletal 
unloading in rat decreases proliferation of rat bone and marrow-derived osteoblastic cells. 
Am J Physiol. 1993;264(5 Pt 1):E790-9. 
36.  Patterson-Buckendahl P, Globus RK, Bikle DD, Cann CE and Morey-Holton E. Effects 
of simulated weightlessness on rat osteocalcin and bone calcium. Am J Physiol. 1989; 
257: R1103- R1109. 
  
 
123
37.  Smith SM, Wastney ME, O'Brien KO, Morukov BV, Larina IM, Abrams SA, Davis-
Street JE, Oganov V, Shackelford LC. Bone markers, calcium metabolism, and calcium 
kinetics during extended-duration space flight on the mir space station.  J Bone Miner 
Res. 2005;20(2):208-18 
38.  Collet PH, Uebelhart D, Vico L, Moro L, Harmann D, Roth M, Alexandre C. Effects of 
1- and 6- months spaceflight on bone mass and biochemistry in two humans. Bone. 
1997;20(6):547-51. 
39.  Stupakov GP, Kazeikin VS, Kozlovskii AP, Korolev VV. Evaluation of the changes in 
the bone structures of the human axial skeleton in prolonged space flight 
Kosm Biol Aviakosm Med. 1984;18(2):33-7. 
40.  LeBlanc A, Schneider V, Shackelford L, West S, Oganov V, Bakulin A, Voronin L. 
Bone mineral and lean tissue loss after long duration space flight. J Musculoskelet 
Neuronal Interact. 2000;1(2):157-60. 
41.  Cavolina JM, Evans GL, Harris SA, Zhang M, Westerlind KC, Turner RT. The effects of 
orbital spaceflight on bone histomorphometry and messenger ribonucleic acid levels for 
bone matrix proteins and skeletal signaling peptides in ovariectomized growing rats. 
Endocrinology. 1997;138(4):1567-76. 
42.  Jee WS, Wronski TJ, Morey ER, Kimmel DB Effects of spaceflight on trabecular bone 
in rats. Am J Physiol. 1983;244(3):R310-4. 
43.  Vico L, Bourrin S, Genty C, Palle S, Alexandre C. Histomorphometric analyses of 
cancellous bone from COSMOS 2044 rats.J Appl Physiol. 1993;75(5):2203-8. 
  
 
124
44.  Zerath E, Holy X, Roberts SG, Andre C, Renault S, Hott M, Marie PJ. Spaceflight 
inhibits bone formation independent of corticosteroid status in growing rats. J Bone 
Miner Res. 2000;15(7):1310-20. 
45.  Bikle DD, Halloran BP. The response of bone to unloading. J Bone Miner Metab. 
1999;17(4):233-44. Review. 
46.  Doty SB, Morey-Holton E. Alterations in bone forming cells due to reduced weight 
bearing. Physiologist. 1984;27(6 Suppl):S81-2. 
47.  Vico L, Bourrin S, Very JM, Radziszowska M, Collet P, Alexandre C. Bone changes in 
6-mo-old rats after head-down suspension and a reambulation period. J Appl Physiol. 
1995;79(5):1426-33. 
48.  Hefferan TE, Evans GL, Lotinun S, Zhang M, Morey-Holton E, Turner RT. Effect of 
gender on bone turnover in adult rats during simulated weightlessness. J Appl Physiol. 
2003;95:1775-1780. 
49.  Bloomfield SA, Allen MR, Hogan HA, Delp MD. Site- and compartment-specific 
changes in bone with hindlimb unloading in mature adult rats. Bone. 2002;31(1):149-57. 
50.  Allen MR, Bloomfield SA. Hindlimb unloading has a greater effect on cortical compared 
with cancellous bone in mature female rats. J Appl Physiol. 2003 Feb;94(2):642-50. 
51.  P. Norsk, C. Drummer, L. Rocker, F. Strollo, N. J. Christensen, J. Warberg, P. Bie, C. 
Stadeager, L. B. Johansen, M. Heer and al. et  al. Renal and endocrine responses in 
humans to isotonic saline infusion during microgravity. J Appl Physiol 1995;78: 2253-
2259. 
  
 
125
52.  Christensen NJ, Heer M, Ivanova K, Norsk P. Sympathetic nervous activity decreases 
during head-down bed rest but not during microgravity. J Appl Physiol. 
2005;99(4):1552-7.  
53.  Ertl AC, Diedrich A, Biaggioni I, Levine BD, Robertson RM, Cox JF, Zuckerman JH, 
Pawelczyk JA, Ray CA, Buckey JC Jr, Lane LD, Shiavi R, Gaffney FA, Costa F, Holt C, 
Blomqvist CG, Eckberg DL, Baisch FJ, and Robertson D. Human muscle sympathetic 
nerve activity and plasma noradrenaline kinetics in space. J Physiol. 2002;538:321–329. 
54.  Macho L, Kvetnansky R, Nemeth S, Fickova M, Popova I, Serova L, Grigoriev AI. 
Effects of space flight on endocrine system function in experimental animals. Environ 
Med. 1996;40(2):95-111.  
55.  Langlois JA, Harris T, Looker AC, Madans J. Weight change between age 50 years and 
old age is associated with risk of hip fracture in white women aged 67 years and older. 
Arch Intern Med. 1996;156(9):989-94. 
56.  Shapses SA, Von Thun N, O-Spina M, Ricci TA, Heymsfield SB, Pierson RN Jr, Stahl T 
2001 Obese premenopausal women do not decrease bone mass during moderate weight 
loss: effect of calcium supplementation. J Bone Miner Res. 2001;16:1329–1336. 
57.  Horm J, Anderson K. Who in America is trying to lose weight? Ann Intern 
Med .1993;119:672. 
58.  Lowry R, Galuska DA, Fulton JE, Burgeson CR, Kann L. Weight management goals and 
use of exercise for weight control among U.S. high school students, 1991-2001. J Adoles 
Health. 2005; 36:320-326. 
  
 
126
59.  Youth risk behavior surveillance: National college health risk behavior survey. 
Morbidity and Mortality Weekly Report. Atlanta: Center for Disease Control. 1995. 
60.  Serdula MK, Collins ME, Williamson DF, Anda RF, Pamuk E, Byers TE. Weight 
control practices of U.S. adolescents and adults. Ann Internal Med. 1993;119:667. 
61.  Neumark-Sztainer D, Sherwood NE, French SA, Jeffery RW. Weight control behaviors 
among adult men and women: Cause for concern? Obesity Res.1999;7:179-188. 
62.  Lindsay R, Cosman F, Herrington BS, Himmelstein S. Bone mass and body composition 
in normal women. J Bone Miner Res.1992;7:55-63. 
63.  Paxton RJ, Valois RF, Drane JW. Correlates of body mass index, weight goals, and 
weight-management practices among adolescents. Journal of School Health. 
2004;74:136-143. 
64.  Bacon L, Stern JS, Keim NL, Van Loan MD. Low bone mass in premenopausal chronic 
dieting obese women. Eur J Clin Nutr. 2004;58:966-971. 
65.  Compston J. Effect of diet-induced weight loss on total body bone mass. Clin Sci.     
       1992;82:429-432. 
66.  Ilich JZ, Brownbill RA, Tamborini L. Bone and nutrition in elderly women: Protein, 
energy, and calcium as main determinants of bone mineral density. Eur J Clin Nutr. 
2003;57:554-565. 
67.  Jiang Y, Zhao J, Genant HK, Dequeker J, Geusens P. Long-term changes in bone 
mineral and biomechanical properties of vertebrae and femur in aging, dietary calcium 
restricted, and/or estrogen-deprived/-replaced rats. J Bone Miner Res.1997;12:820-831. 
  
 
127
68.  Shen V, Birchman R, Xu R, Lindsay R, Dempster DW. Short-term changes in 
histomorphometric and biochemical turnover markers and bone mineral density in 
estrogen- and/or dietary calcium-deficient rats. Bone. 1995;16:149-156. 
69.  Dawson-Hughes B, Dallal GE, Krall EA, Sadowski L, Sahyoun N, Tannenbaum S: A 
controlled trial of the effect of calcium supplementation on bone density in 
postmenopausal women. N Engl J Med.1990;323:878–883. 
70.  Reid IR, Ames RW, Evans MC, Gamble GD, Sharpe SJ: Effect of calcium 
supplementation on bone loss in postmenopausal women. N Engl J Med. 1993;328:460–
464. 
71.  Devine A, Dick IM, Heal SJ, Criddle RA, Prince RL: A 4-year follow-up study of the 
effects of calcium supplementation on bone density in elderly postmenopausal women. 
Osteoporos Int.1997;7:23–28. 
72.  Prince R, Devine A, Dick I, Criddle A, Kerr D, Kent N, Price R, Randell A: The effects 
of calcium supplementation (milk powder or tablets) and exercise on bone density in 
postmenopausal women. J Bone Miner Res. 1995;10:1068–1075. 
73.  Nelson ME, Fisher EC, Dilmanian FA, Dallal GE, Evans WJ: A 1-y walking program 
and increased dietary calcium in postmenopausal women: effects on bone. Am J Clin 
Nutr. 1991;53:1304–1311. 
74.  Chevalley T, Rizzoli R, Nydegger V, Slosman D, Rapin CH, Michel JP, Vasey H, 
Bonjour JP. Effects of calcium supplements on femoral bone mineral density and 
vertebral fracture rate in vitamin-D-replete elderly patients. Osteoporos Int. 1994; 
4:245–252. 
  
 
128
75.  Haines CJ, Chung TK, Leung PC, Hsu SY, Leung DH: Calcium supplementation and 
bone mineral density in postmenopausal women using estrogen replacement therapy. 
Bone.1995;16:529–531. 
76.  Heaney RP: Estrogen-calcium interactions in the postmenopause: A quantitative 
description. Bone Miner. 1990;11:67–84. 
77.  Lips P, Hosking D, Lippuner K, Norquist JM, Wehren L, Maalouf G, Ragi-Eis S, 
Chandler J. The prevalence of vitamin D inadequacy amongst women with osteoporosis: 
An international epidemiological investigation. J Intern Med. 2006 Sep;260(3):245-54.  
78.  Aaron JE, Gallagher JC, Anderson J, Stasiak L, Longton EB, Nordin BE, Nicholson M: 
Frequency of osteomalacia and osteoporosis in fractures of the proximal femur. 
Lancet.1974; 1:229–233. 
79.  Kerstetter JE, Allen LH: Protein intake and calcium homeostasis. Adv Nutr Res. 1994; 
9:167–181. 
80.  Dawson-Hughes B. Interaction of dietary calcium and protein in bone health in humans. 
J Nutr. 2003; 133:852S-854S. 
81.  Bourrin S, Toromanoff A, Ammann P, Bonjour JP, Rizzoli R. Dietary protein deficiency 
induces osteoporosis in aged male rats. J Bone Miner Res. 2000;15:1555-1563. 
82.  Bourrin S, Ammann P, Bonjour JP, Rizzoli R. Dietary protein restriction lowers plasma 
insulin-like growth factor-1, impairs cortical bone formation, and induces osteoblastic 
resistance to insulin-like growth factor-1 in adult female rats. Endocrinol. 2000; 
141:3149-3155. 
  
 
129
83.  Cooper C, Atkinson EJ, Hensrud DD, Wahner HW, O’Fallon WM, Riggs BL, Melton LJ 
3rd. Dietary protein intake and bone mass in women. Calcif Tissue Int. 1996; 58:320–
325. 
84.  Michaelsson K, Holmberg L, Mallmin H, Wolk A, Bergstrom R, Ljunghall S: Diet, bone 
mass, and osteocalcin: a cross-sectional study. Calcif Tissue Int. 1995;57:86–93. 
85.  Geinoz G, Rapin CH, Rizzoli R, Kraemer R, Buchs B, Slosman D, Michel JP, Bonjour 
JP. Relationship between bone mineral density and dietary intakes in the elderly. 
Osteoporos Int. 1993;3(5):242-8.  
86.  Feskanich D, Willett WC, Stampfer MJ, Colditz GA. Protein consumption and bone 
fractures in women. Am J Epidemiol. 1996;143:472–479. 
87.  Meyer HE, Pedersen JI, Loken EB, Tverdal A. Dietary factors and the incidence of hip 
fracture in middle-aged Norwegians. A prospective study. Am J Epidemiol. 1997; 
145:117–123. 
88.  Abelow B, Holford T, Insogna K. Cross-cultural association between dietary animal 
protein and hip fracture: A hypothesis. Calcif Tissue Int. 1992;50:14–18. 
89.  Munger RG, Cerhan JR, Chiu BC. Prospective study of dietary protein intake and risk of 
hip fracture in postmenopausal women. Am J Clin Nutr. 1999; 69:147–152. 
90.  Schuette SA, Hegsted M, Zemel MB, Linkswiler HM. Renal acid, urinary cyclic AMP, 
and hydroxyproline excretion as affected by level of protein, sulfur amino acid, and 
phosphorus intake. J Nutr.1981;111:2106–2116. 
  
 
130
91.  Chan EL, Swaminathan R. The effect of high protein and high salt intake for 4 months 
on calcium and hydroxyproline excretion in normal and oophorectomized rats. J Lab 
Clin Med. 1994; 124:37–41, 
92.  Kerstetter J, Caseria D, Mitnick N, Ellison A, Liskov T, Carpenter T, Gundberg C, 
Insogna K. Bone turnover in response to dietary protein intake. J Clin Endo Metab. 
1999; 84:1052–1055. 
93.  Shapses SA, Robins SP, Schwartz EI, Chowdhury H. Short-term changes in calcium but 
not protein intake alter the rate of bone resorption in healthy subjects as assessed by 
urinary pyridinium cross-link excretion. J Nutr.1995;125:2814–2821. 
94.  Massey LK. Does excess dietary protein adversely affect bone? Symposium overview. J 
Nutr. 1998; 128:1048–1050. 
95.  Heaney RP. Excess dietary protein may not adversely affect bone. J Nutr.1998; 
128:1054–1057. 
96.  Barzel US, Massey LK. Excess dietary protein can adversely affect bone. J Nutr. 1998; 
128:1051–1053. 
97. Baek K, Miller S, Lemmon J, Bloomfield SA. Energy and calcium deficits are major 
contributors to effect of global food restriction on metaphyseal bone in exercising 
rodents. J Bone Miner Res. 2006;21 (Suppl 1): M359. 
98.  Kerstetter JE, O'Brien KO, Insogna KL. Low protein intake: The impact on calcium and 
bone homeostasis in humans.  J Nutr. 2003;133(3):855S-861S. Review. 
99.  Cifuentes M, Morano AB, Chowdhury HA, Shapses SA. Energy restriction reduces   
        fractional calcium absorption in mature obese and lean rats. J Nutr. 2002;132(9):2660-6. 
  
 
131
100. Talbott SM, Rothkopf MM, Shapses SA.  Dietary restriction of energy and calcium 
alters bone turnover and density in younger and older female rats. 
J Nutr. 1998;128(3):640-5. 
101. Lee CJ, Panemangalore M, Wilson K. Effect of dietary restriction on bone mineral 
content of mature rats. Nutr Res. 1986;6:51-59. 
102. Ricci TA, Heymsfield SB, Pierson RN Jr, Stahl T, Chowdhury HA, Shapses SA. 
Moderate energy restriction increases bone resorption in obese postmenopausal women. 
Am J Clin Nutr. 2001;73:347-352. 
103. Ihle R and Loucks AB. Dose–response relationships between energy availability and   
        bone turnover in young exercising women. J Bone Mineral Res. 2004; 19(8);1231-1240. 
104. Okazaki R, Inoue D, Shibata M, Saika M, Kido S, Ooka H, Tomiyama H, Sakamoto Y, 
Matsumoto T. Estrogen promotes early osteoblast differentiation and inhibits adipocyte 
differentiation in mouse bone marrow stromal cell lines that express estrogen receptor 
(ER) alpha or beta. Endocrinology. 2002;143(6):2349- 56 
105. Fujita M, Urano T, Horie K, Ikeda K, Tsukui T, Fukuoka H, Tsutsumi O, Ouchi Y, 
Inoue S. Estrogen activates cyclin-dependent kinases 4 and 6 through induction of cyclin 
D in rat primary osteoblasts. Biochem Biophys Res Commun. 2002; 299(2):222-8. 
106. Cheng MZ, Rawlinson SC, Pitsillides AA, Zaman G, Mohan S, Baylink DJ, Lanyon LE. 
Human osteoblasts' proliferative responses to strain and 17beta-estradiol are mediated by 
the estrogen receptor and the receptor for insulin-like growth factor I. J Bone Miner Res. 
2002;17(4):593-602. 
  
 
132
107. von Stechow D, Zurakowski D, Pettit AR, Müller R, Gronowicz G, Chorev M, Otu H, 
Libermann T, Alexander JM. Differential transcriptional effects of PTH and estrogen 
during anabolic bone formation. J Cell Biochem. 2004; 93(3):476-90.  
108. Plant A, Tobias JH. Increased bone morphogenetic protein-6 expression in mouse long 
bones after estrogen administration. J Bone Miner Res. 2002;17(5):782-90. 
109. Syed F, Khosla S. Mechanisms of sex steroid effects on bone. Biochem Biophys Res 
Commun. 2005;328(3):688-96. Review.  
110. Rogers A, Eastell R. Effects of estrogen therapy of postmenopausal women on 
cytokines measured in peripheral blood. J Bone Miner Res. 1998;13(10):1577-86.  
111. Trayhurn P, Hoggard N, Mercer JG, Rayner DV. Leptin: Fundamental aspects. 
Int J Obes Relat Metab Disord. 1999;23 Suppl 1:22-8. Review. 
112. Zauner C, Schneeweiss B, Kranz A, Madl C, Ratheiser K, Kramer L, Roth E, Schneider 
B, Lenz K. Resting energy expenditure in short-term starvation is increased as a result of 
an increase in serum norepinephrine. Am J Clin Nutr. 2000;71(6):1511-5. 
113. Bjurholm A. Neuroendocrine peptides in bone. Int Orthop. 1991;15:325–329. 
114. Hohmann EL, Elde RP, Rysavy JA, Einzig S, and Gebhard RL. Innervation of 
periosteum and bone by sympathetic vasoactive intestinal peptide-containing nerve 
fibers. Science. 1986;232:868– 871. 
115. Cherruau M, Facchinetti P, Baroukh B, and Saffar JL. Chemical sympathectomy 
impairs bone resorption in rats: A role for the sympathetic system on bone metabolism. 
Bone.1999;25:545– 551. 
  
 
133
116. Hill EL, Turner R, and Elde R. Effects of neonatal sympathectomy and capsaicin 
treatment on bone remodeling in rats. Neuroscience. 1991;44:747–755. 
117. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, 
Rueger JM, Karsenty G. Leptin inhibits bone formation through a hypothalamic relay: A 
central control of bone mass. Cell. 2000;100(2):197-207. 
118. Moore RE, Smith CK II, Bailey CS, Voelkel EF, and Tashijian AH. Characterization of 
beta-adrenergic receptors on rat and human osteoblast-like cells and demonstration that 
betareceptor agonists can stimulate bone. Bone Miner. 1993; 23: 301–315. 
119. Takeuchi T, Tsuboi T, Arai M, and Togari A. Adrenergic stimulation of 
osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-
E1 osteoblast-like cells. Biochem Pharmacol. 2001;61:579–586. 
120. Majeska RJ, Minkowitz B, Bastian W, Einhorn TA. Effects of beta-adrenergic blockade 
in an osteoblast-like cell line. J Orthop Res. 1992;10(3):379-84.  
121. Akiyoshi M, Shimizu Y, and Saito M. Interleukin-1 increases norepinephrine turnover 
in the spleen and lung in rats. Biochem Biophys Res Commun. 1990;173:1266–1270. 
122. Grenett HE, Fuentes NL, and Fuller GM. Cloning and sequence analysis of the cDNA 
for murine interleukin-6 (Abstract). Nucleic Acids Res. 1990;18:6455. 
123. Murammai N, Fukata J, Tsukada T, Kobayashi H, Ebisui O, Segawa H, Muro S, Imura 
H, and Nakao K. Bacterial lipopolysaccharide-induced expression of interleukin-6 
messenger ribonucleic acid in the rat hypothalamus, pituitary, adrenal grand, and spleen. 
Endocrinology. 1993;133:2574–2578. 
  
 
134
124. Song DK, Im YB, Jung JS, Suh HW, Huh SO, Park SW, Wie MB, and Kim YH. 
Differential involvement of central and peripheral norepinephrine in the central 
lipopolysaccharide-induced interleukin-6 responses in mice. J Neurochem. 
1999;72:1625– 1633 
125. Kondo A, Togari A. In vivo stimulation of sympathetic nervous system modulates 
osteoblastic activity in mouse calvaria. Am J Physiol Endocrinol Metab. 2003; 
285(3):E661-7. 
126. Yirmiya R, Goshen I, Bajayo A, Kreisel T, Feldman S, Tam J, Trembovler V, Csernus 
V, Shohami E, Bab I. Depression induces bone loss through stimulation of the 
sympathetic nervous system.  Proc Natl Acad Sci USA. 2006;103(45):16876-81. 
127. Mattison JA, Lane MA, Roth GS, Ingram DK. Calorie restriction in rhesus monkeys. 
Exp Gerontol. 2003;38:35–46. 
128. Bodkin NL, Alexander TM, Ortmeyer HK, Johnson E, Hansen BC. Mortality and 
morbidity in laboratory-maintained Rhesus monkeys and effects of long-term dietary 
restriction. J Gerontol A Biol Sci Med Sci. 2003;58:212–9.  
129. Gan SK, Kriketos AD, Ellis BA, Thompson CH, Kraegen EW, Chisholm DJ. Changes 
in aerobic capacity and visceral fat but not myocyte lipid levels predict increased insulin 
action after exercise in overweight and obese men. Diabetes Care. 2003;26:1706–13.  
130. Dimarco NM, Dart L, Sanborn CF. Modified activity-stress paradigm in an animal 
model of the female athlete triad. J Appl Physiol. 2007 Aug 9; [Epub ahead of print] 
131. Jensen LB, Quaade F, Sørensen OH. Bone loss accompanying voluntary weight loss in 
obese humans. J Bone Miner Res. 1994;9(4):459-63.  
  
 
135
132. Freedman MR, King J, Kennedy E. Popular diets: A scientific review. Obes Res. 2001; 
9(Suppl 1):1S-40S.  
133. National Heart, Lung and Blood Institute. Clinical guidelines on the identification, 
evaluation, and treatment of overweight and obesity in adults. The evidence report. NIH 
Publication No. 98-4083; 1998 September. 
134. Yu-Poth S, Zhao G, Etherton T, Naglak M, Jonnalagadda S, Kris-Etherton PM. Effects 
of the National Cholesterol Education Program's Step I and Step II dietary intervention 
programs on cardiovascular disease risk factors: a meta-analysis. Am J Clin Nutr. 
1999;69:632-46.  
135. Miller ER 3rd, Erlinger TP, Young DR, Jehn M, Charleston J, Rhodes D, Wasan SK, 
Appel LJ. Results of the Diet, Exercise, and Weight Loss Intervention Trial (DEW-IT). 
Hypertension. 2002;40:612-8.  
136. National Task Force on the Prevention and Treatment of Obesity. Very low-calorie diets. 
JAMA. 1993;270:967-74. 
137. Position of the American Dietetic Association. Weight management. J Am Diet Assoc. 
2002;102:1145-55.  
138. Andersen RE, Wadden TA, Herzog RJ. Changes in bone mineral content in obese 
dieting women. Metabolism. 1997;46:857861. 
139. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning 
of the mouse obese gene and its human homologue. Nature. 1994;372(6505):425-32.  
  
 
136
140. Hoggard N, Hunter L, Duncan JS, Williams LM, Trayhurn P and Mercer JG, Leptin and 
leptin receptor mRNA and protein expression in the murine fetus and placenta, Proc Natl 
Acad Sci. USA. 1997;94:11073–11078.  
141. Wang J, Liu R, Hawkins M, Barzilai N and Rossetti L, A nutrient-sensing pathway 
regulates leptin gene expression in muscle and fat, Nature. 1998;393:684–688.  
142. Castellucci M, De Matteis R, Meisser A, Cancello R, Monsurro Vand Islami D et al., 
Leptin modulates extracellular matrix molecules and metalloproteinases: Possible 
implications for trophoblast invasion. Mol Hum Reprod. 2000;6:51–958. 
143. Reseland JE, Syversen U, Bakke I, Qvigstad G, Eide LG and Hjertner O et al., Leptin is 
expressed in and secreted from primary cultures of human osteoblasts and promotes 
bone mineralization. J Bone Miner Res. 2001;16:1426–1433.  
144. Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J and Devos R et al., 
Identification and expression cloning of a leptin receptor, OB-R. Cell. 1995;83:263–
1271.  
145. Steppan CM, Crawford DT, Chidsey-Frink KL, Ke H and Swick AG, Leptin is a potent 
stimulator of bone growth in ob/ob mice. Regul Pept. 2000;92:73–78.  
146. Lonnqvist F, Nordfors L, Jansson M, Thorne A, Schalling M, Arner P. Leptin secretion 
from adipose tissue in women. Relationship to plasma levels and gene expression. J Clin 
Invest. 1997;99(10):2398-404. 
147.  Couillard C, Mauriege P, Prud'homme D, Nadeau A, Tremblay A, Bouchard C, and 
Despres JP. Plasma leptin response to an epinephrine infusion in lean and obese women. 
Obes Res. 2002;10:6–13. 
  
 
137
148. Donahoo WT, Jensen DR, Yost TJ, and Eckel RH. Isoproterenol and somatostatin 
decrease plasma leptin in humans: A novel mechanism regulating leptin secretion. J Clin 
Endocrinol Metab. 1997;82:4139–4143. 
149. Ricci MR and Fried SK. Isoproterenol decreases leptin expression in adipose tissue of 
obese humans. Obes Res. 1999;7:233–240. 
150. Orban Z, Remaley AT, Sampson M, Trajanoski Z, and Chrousos GP. The differential 
effect of food intake and beta-adrenergic stimulation on adipose-derived hormones and 
cytokines in man. J Clin Endocrinol Metab. 1999;84:2126–2133. 
151. Korczynska J, Stelmanska E, Swierczynski J. Differential effect of long-term food 
restriction on fatty acid synthase and leptin gene expression in rat white adipose tissue. 
Horm Metab Res. 2003;35(10):593-7. 
152. Lee GH, Proenca R, Montez JM, Carroll KM, Darvishzadeh JG, Lee JI, Friedman JM. 
Abnormal splicing of the leptin receptor in diabetic mice. 
Nature. 1996;379(6566):632-5.  
153. Lammert A, Kiess W, Bottner A, Glasow A, Kratzsch J. Soluble leptin receptor 
represents the main leptin binding activity in human blood. Biochem Biophys Res 
Commun. 2001;283(4):982-8.  
154. Zastrow O, Seidel B, Kiess W, Thiery J, Keller E, Böttner A, Kratzsch J. The soluble 
leptin receptor is crucial for leptin action: evidence from clinical and experimental data. 
Int J Obes Relat Metab Disord. 2003;27(12):1472-8.  
  
 
138
155. Emilsson V, Liu YL, Cawthorne MA, Morton NM, Davenport M. Expression of the 
functional leptin receptor mRNA in pancreatic islets and direct inhibitory action of leptin 
on insulin secretion. Diabetes. 1997;46(2):313-6. 
156. Hoggard N, Mercer JG, Rayner DV, Moar K, Trayhurn P, Williams LM. Localization of 
leptin receptor mRNA splice variants in murine peripheral tissues by RT-PCR and in situ 
hybridization. Biochem Biophys Res Commun. 1997;232(2):383-7. 
157. Kielar D, Clark JS, Ciechanowicz A, Kurzawski G, Sulikowski T, Naruszewicz M. 
Leptin receptor isoforms expressed in human adipose tissue. Metabolism. 
1998;47(7):844-7.  
158. Löllmann B, Grüninger S, Stricker-Krongrad A, Chiesi M. Detection and quantification 
of the leptin receptor splice variants Ob-Ra, b, and, e in different mouse tissues. 
Biochem Biophys Res Commun. 1997;238(2):648-52.  
159. Tu H, Pan W, Feucht L, Kastin AJ. Convergent trafficking pattern of leptin after 
endocytosis mediated by ObRa-ObRd. J Cell Physiol. 2007;212(1):215-22. 
160. Everts S. Researchers are tackling the grueling challenge of getting brain therapies 
across the blood-brain barrier. Chemical & Engineering News.  2007; 85: 33-36 . 
161. Brightman MW, Reese TS. Junctions between intimately apposed cell membranes in the 
vertebrate brain. J Cell Biol. 1969;40:648–677. 
162. Engelhardt B. Development of the blood-brain barrier. Cell Tissue Res. 
2003;314(1):119-29.  
163. Krisch B, Leonhardt H, Buchheim W. The functional and structural border between the 
CSF- and blood-milieu in the circumventricular organs (organum vasculosum laminae 
  
 
139
terminalis, subfornical organ, area postrema) of the rat. Cell Tissue Res. 
1978;195(3):485-97. 
164. Banks WA, Lebel CR. Strategies for the delivery of leptin to the CNS. J Drug Target. 
2002;10(4):297-308. Review. 
165.  Bryson JM. The future of leptin and leptin analogues in the treatment of obesity. 
Diabetes Obes Metab. 2000;2(2):83-9. Review 
166. Halaas JL, Boozer C, Blair-West J, Fidahusein N, Denton DA, Friedman JM. 
Physiological response to long-term peripheral and central leptin infusion in lean and 
obese mice. Proc Natl Acad Sci USA. 1997;94(16):8878-83. 
167. Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T, Lubina JA, 
Patane J, Self B, Hunt P, McCamish M. Recombinant leptin for weight loss in obese and 
lean adults: A randomized, controlled, dose-escalation trial. JAMA. 1999;282(16):1568-
75.  
168. Bjorbaek C, El-Haschimi K, Frantz JD, Flier JS. The role of SOCS-3 in leptin signaling 
and leptin resistance. J Biol Chem. 1999;274(42):30059-65. 
169. Mori H, Hanada R, Hanada T, Aki D, Mashima R, Nishinakamura H, Torisu T, Chien 
KR, Yasukawa H, Yoshimura A. Socs3 deficiency in the brain elevates leptin sensitivity 
and confers resistance to diet-induced obesity. Nat Med. 2004;10(7):739-43.  
170. Zhang F, Chen Y, Heiman M, Dimarchi R. Leptin: structure, function and biology. 
Vitam Horm. 2005;71:345-72. Review. 
  
 
140
171. Kristensen P, Judge ME, Thim L, Ribel U, Christjansen KN, Wulff BS, Clausen JT, 
Jensen PB, Madsen OD, Vrang N, Larsen PJ, Hastrup S. Hypothalamic CART is a new 
anorectic peptide regulated by leptin. Nature. 1998;393(6680):72-6.  
172. Huo L, Munzberg H, Nillni EA, Bjorbaek C. Role of signal transducer and activator of 
transcription 3 in regulation of hypothalamic trh gene expression by leptin. 
Endocrinology. 2004;145(5):2516-23. 
173. Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Muller C, Carling D, Kahn BB. Leptin 
stimulates fatty-acid oxidation by activating AMP-activated protein kinase. 
Nature. 2002;415(6869):339-43. 
174. Burguera B, Brunetto A, Garcia-Ocana A, Teijeiro R, Esplen J, Thomas T, Couce ME, 
Zhao A. Leptin increases proliferation of human steosarcoma cells through activation of 
PI(3)-K and MAPK pathways. Med Sci Monit. 2006;12(11):BR341-9. 
175. Cornish J, Callon KE, Bava U, Lin C, Naot D, Hill BL, Grey AB, Broom N, 
        Myers DE, Nicholson GC, Reid IR. Leptin directly regulates bone cell 
        function in vitro and reduces bone fragility in vivo. J Endocrinol. 2002;175:405–415 
176. Thomas T, Gori F, Khosla S, Jensen MD, Burguera B, Riggs BL. Leptin 
       acts on human marrow stromal cells to enhance differentiation to osteoblasts 
       and to inhibit differentiation to adipocytes. Endocrinology. 1999;140:1630–1638 
177. Holloway T, Collier F, Aitken C, Myers D, Hodge J, Malakellis M., Gough T, Collier G, 
Nicholson G. Leptin inhibits osteoclast generation. J Bone Miner Res. 2002; 17(2): 200-
209 
  
 
141
178. Cornish J, Callon KE, Bava U, Lin QX, Naot D, Hill BL, Broom ND, Reid IR. The 
direct actions of leptin on bone cells increase bone strength in vivo – an explanatin of 
low fracture rates in obesity. Bone. 2001;28(Suppl):S88  
179. Steppan CM, Crawford DT, Chidsey-Frink KL, Ke H, Swick AG.  Leptin is a potent 
stimulator of bone growth in ob/ob mice. Regul Pept. 2000;92:73-8  
180. Liu C, Grossman A,  Bain S, Strachan M, Puerner D, Bailey C, Humes J, Lenox J, 
Yamamoto G, Sprugel K, Kuiper J, Weigle S, Durman D, Moore E. Leptin stimulates 
cortical bone formation in ob/ob mice. J Bone Miner Res. 1997;12 (Suppl 1):S115 
181. Hamrick MW, Pennington C, Newton D, Xie D, Isales C. Leptin deficiency produces 
contrasting phenotypes in bones of the limb and spine. Bone. 2004;34(3):376-83. 
182. Hamrick M, Fera MA,Choi YH, Hartzell D, Pennington C, Baile CA. Injections of  
       leptin into rat ventromedial hypothalamus increase adipocyte apoptosis in peripheral fat 
and in bone marrow. Cell Tissue Res. 2007;327:133–141. 
183. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and 
reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 
1981;304:801–7.  
184. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in 
patients with acute myocardial infarction. I. Mortality results. JAMA. 1982;247:1707–14.  
185. Hjalmarson A, Elmfeldt D, Herlitz J, Holmberg S, Málek I, Rydén L, Swedberg K et al., 
Effect on mortality of metoprolol in acute myocardial infarction. A double-blind 
randomised trial, Lancet. 1981;2:823–827.  
  
 
142
186. Teo KK, Yusuf S and Furberg CD. Effects of prophylactic antiarrhythmic drug therapy 
in acute myocardial infarction. An overview of results from randomized controlled trials, 
JAMA. 1993;270:1589–1595.  
187. Yusuf S, Peto R, Lewis J, Collins R and Sleight P, Beta blockade during and after 
myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985; 
27:335–371.  
188. Hjalmarson A, Effects of beta blockade on sudden cardiac death during acute 
myocardial infarction and the postinfarction period. Am J Cardiol. 1997;80:35J–39J.  
189. Norris RM, Barnaby PF, Brown MA, Geary GG, Clarke ED, Logan RL, Sharpe DN. 
Prevention of ventricular fibrillation during acute myocardial infarction by intravenous 
propranolol. Lancet. 1984;2:883–886.  
190. Rydén L, Ariniego R, Arnman K, Herlitz J, Hjalmarson A et al., A double-blind trial of 
metoprolol in acute myocardial infarction. Effects on ventricular tachyarrhythmias, N 
Engl J Med. 1983; 308: 614–618.  
191. Guyton AC, Hall JE. Textbook of Medical Physiology. 10th ed. Philadelphia, 
Pennsylvania: W.B. Saunders Company; 2002. p.770. 
192. Yang X., Matsuda K., Bialek P., Jacquot S., Masuoka H. C., Schinke T. et al. ATF4 is a 
substrate of RSK2 and an essential regulator of osteoblast biology; implication for 
Coffin- Lowry Syndrome. Cell. 2004;117(3):387-398. 
193. Elefteriou F. Neuronal signaling and the regulation of bone remodeling.  
        CMLS, Cell Mol Life Sci. 2005;62:2339–2349. 
  
 
143
194. Kondo A., Mogi M., Koshihara Y. and Togari A. Signal transduction system for 
interleukin-6 and interleukin-11 synthesis stimulated by epinephrine in human 
osteoblasts and human osteogenic sarcoma cells. Biochem. Pharmacol. 2001;61(3):319 
326. 
195. Togari A, Arai M, Kondo  A. The role of the sympathetic nervous system in controlling 
bone metabolism.  Expert Opinion on Therapeutic Targets. 2005;5:931-940. 
196. Bourque D, Daoust R, Huard V, Charneux M. beta-Blockers for the treatment of cardiac 
arrest from ventricular fibrillation? Resuscitation. 2007;3340:11-18.  
197. Morey-Holton ER, Globus RK. Hindlimb unloading of growing rats: A model for  
        predicting skeletal changes during space flight. Bone. 1998;22 (5 Suppl):83S-88S. 
Review. 
198. Lane HW. Energy requirements for space flight. J Nutr. 1992;122:13-18. 
199. Bourland C, Kloeris V, Rice DL and Vodovotz Y. Food systems for space and planetary 
flights. In: Nutrition in Spaceflight and Weightlessness Models, edited by Lane HW and 
Schoeller DA. Boca Raton, FL: CRC Press. 2000; p.19-40. 
200. Lane HW and Rambaut PC. Nutrition. In: Space Physiology and Medicine. 3rd ed. 
edited by Nicogossian AE, Huntoon CL and Pool SL. Philadelphia: Lea & Fibiger. 1993; 
p.305-316.  
201. Gretebeck RJ, Socki RA, Davis-Street J, Schoeller D, Gibson EK and Lane HW. Energy 
utilization during space flight: doubly-labeled water measurements. FASEB Journal. 
1993;7:A840. 
  
 
144
202. Eriksen, E.F., Langdahl, B., Vesterby, A., Rungby, J., and Kassem, M. Hormone 
replacement therapy prevents osteoclastic hyperactivity: A histomorphometric study in 
early postmenopausal women. J Bone Miner Res. 1999;14:1217-1221. 
203. Mukherjee A, Murray RD, Shalet SM. Impact of growth hormone status on body 
composition and the skeleton. Horm Res. 2004;62 Suppl 3:35-41. 
204. Johansson G., Burman P, Westermark K and Ljunghall S. The bone mineral density in 
acquired growth hormone deficiency correlates with circulating levels of insulin-like 
growth factor I. J Internal Medicine. 1992;232:447–452.  
205. Kemink SA, Hermus AR, Swinkels LM, Lutterman JA, Smals AG. Osteopenia in 
insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology. J 
Endocrinol Invest. 2000;23:295-303. 
206. Ali O, Shim M, Fowler E, Cohen P, Oppenheim W. Spinal bone mineral density, IGF-1 
and IGFBP-3 in children with cerebral palsy. Horm Res. 2007;68(6):316-320. 
207. Lee WY, Oh KW, Rhee EJ, Jung CH, Kim SW, Yun EJ, Tae HJ, Baek KH, Kang MI, 
Choi MG, Yoo HJ, Park SW. Relationship between subclinical thyroid dysfunction and 
femoral neck bone mineral density in women. Arch Med Res. 2006;37(4):511-6. 
208. Ishikawa Y, Wu LN, Genge BR, Mwale F and Wuthier RE. Effects of calcitonin and 
parathyroid hormone on calcification of primary cultures of chicken growth plate 
chondrocytes, J Bone Miner Res. 1997;12:356–366.  
209. Narayanan R, Allen MR, Gaddy D, Bloomfield SA, Smith CL, Weigel NL. Differential 
skeletal responses of hindlimb unloaded rats on a vitamin D-deficient diet to 1,25-
dihydroxyvitamin D3 and its analog, seocalcitol (EB1089).Bone. 2004;35(1):134-43. 
  
 
145
210. Bloomfield SA, Baek K , Stallone JL,  Allen MR. Intermittent PTH during recovery 
replaces cancellous bone lost during hindlimb unloading by increasing bone formation 
rate.  FASEB Journal. 2004;18(4):455.4 
211. Subcommittee on Laboratory Animal Nutrition CoAN, Board on Agriculture, National 
Research Council. Nutrient Requirements of Laboratory Animals.Washington, D.C.: 
National Academy of Sciences; 1995. 
212. Reeves PG, Nielsen FH and Fahey GC. AIN-93 purified diets for laboratory rodents: 
final report of the American Institute of Nutrition Ad Hoc Writing Committee on the 
reformulation of the AIN-76A diet. J Nutr. 1993:123;1939-1951. 
213. Bloomfield SA, Girten BE and Weisbrode SE. Effects of vigorous exercise training and 
β-agonist administration on bone response to hindlimb suspension. J Appl Physiol. 1997; 
83:172–178. 
214. Ferretti  JL. Perspectives of pQCT technology associated to biomechanical studies in 
skeletal research employing rat models. Bone. 1995;17 (Suppl 4):353S-364S. 
215. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, and 
Recker RR. Bone histomorphometry: Standardization of nomenclature, symbols, and 
units. J Bone Miner Res.1997;2:595–610. 
216. Banu MJ, Orhii PB, Mejia W, McCarter RJ, Mosekilde L, Thomsen JS, Kalu DN. 
Analysis of the effects of growth hormone, voluntary exercise, and food restriction on 
diaphyseal bone in female F344 rats. Bone. 1999;25(4): 469-80. 
217. Fisher JS, Kohrt WM, Brown M. Food restriction suppresses muscle growth and 
augments osteopenia in ovariectomized rats. J Appl Physiol. 2000 Jan; 88(1):265-71. 
  
 
146
218. Pedrini-Mille A, Maynard JA, Durnova GN, Kaplansky AS, Pedrini V A, Chung CB 
and Fedler- Troester J. Effects of microgravity on the composition of the intervertebral 
disk. J Appl Physiol. 1992;73:26S-32S. 
219. Yagasaki Y, Yamaguchi T, Watahiki J, Konishi M, Katoh H, Maki K. The role of 
craniofacial growth in leptin deficient (ob/ob) mice. Orthod Craniofac Res. 2003; 
6(4):233-240. 
220. John FN, Suleiman BW, Regulation of leptin release by mammalian adipose tissue.  
Biochemical and Biophysical Research Communication. 2000; 274: 571-575.  
221. Holick M.F.  Perspective on the impact of weightlessness on calcium and bone 
metabolism. Bone. 1998;22:1–5S. 
222. Bigbee AJ, Grindeland RE, Roy RR, Zhong H, Gosselink KL, Arnaud S, Edgerton VR. 
Basal and evoked levels of bioassayable growth hormone are altered by hindlimb 
unloading. J Appl Physiol. 2006;100(3):1037-42. 
223. Stein TP, Schluter MD, Leskiw MJ. Cortisol, insulin and leptin during space flight and 
bed rest. J Gravit Physiol. 1999;6(1):85-6.  
224. Strollo F, Strollo G, More M, Ferretti C, Mangrossa N, Casarosa E, Luisi M, Riondino 
G. Changes in human adrenal and gonadal function on board Spacelab. J Gavit Physiol. 
1997;4(2):103-4. 
225. Baek K, Currado A, Allen M.R, and Bloomfield S.A. Effect of food restriction and 
hindlimb unloading on serum leptin and histomorphometric measures of cancellous bone. 
J Bone Miner Res. 2004;19(Suppl 1):M377 
  
 
147
226. Bonnet N, Laroche N, Vico L, Dolleans E, Benhamou CL, Courteix D. Dose effects of 
propranolol on cancellous and cortical bone in ovariectomized adult rats. 
J Pharmacol Exp Ther. 2006;318(3):1118-27. 
227. Hamrick MW, Della-Fera MA, Choi YH, Pennington C, Hartzell D, Baile CA. Leptin 
treatment induces loss of bone marrow adipocytes and increases bone formation in leptin 
–deficient ob/ob mice. J Bone Miner Res. 2005;20(6):994-1001. 
228. Burguera B, Hofbauer LC, Thomas T, Gori F, Evans GL, Khosla S, Riggs BL, Turner 
RT. Leptin reduces ovariectomy-induced bone loss in rats. Endocrinology. 
2001;142(8):3546-53. 
229. Reseland JE, Syversen U, Bakke I, Qvigstad G, Eide LG, Hjertner O, Gordeladze JO, 
Drevon CA. Leptin is expressed in and secreted from primary cultures of human 
osteoblasts and promotes bone mineralization. J Bone Miner Res. 2001;16:1426–1433 
230. Lamghari M, Tavares L, Camboa N, Barbosa MA. Leptin effect on RANKL and OPG 
expression in MC3T3-E1 osteoblasts. J Cell Biochem. 2006;98(5):1123-9.  
231. Reeves PG, Rossow KL, Lindlauf J. Development and testing of the AIN-93 purified 
diets for rodents: Results on growth, kidney calcification and bone mineralization in rats 
and mice. J Nutr. 1993;123:1923-1931. 
232. Hsu SM, Raine L, Fanger H Use of avidin-biotin-peroxidase complex (ABC) in 
immunoperoxidase techniques: a comparison between ABC and unlabeled antibody 
(PAP) procedures. J Histochem Cytochem. 1981;29(4):577-80. 
233. Himms-Hagen. J Physiological roles of the leptin endocrine system: Differences 
between mice and humans. Crit Rev Clin Lab Sci. 1999;36(6):575-655. Review.  
  
 
148
234. Fain JN, Cowan GS Jr, Buffington C, Li J, Pouncey L, Bahouth SW 
       Synergism between insulin and low concentrations of isoproterenol in the stimulation of 
leptin release by cultured human adipose tissue. Metabolism. 2000;49(6):804-9. 
235. Elefteriou F, Ahn JD, Takeda S, Starbuck M, Yang X, Liu X, et al. Leptin 
        regulation of bone resorption by the sympathetic nervous system and CART. Nature. 
2005;434:514–20. 
236. Pasco JA, Henry MJ, Sanders KM, Kotowicz MA, Seeman E, and Nicholson GC. Beta-
adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: 
Geelong Osteoporosis Study. J Bone Miner Res. 2004;19:19–24. 
237. Schlienger RG, Kraenzlin ME, Jick SS, and Meier CR. Use of beta-blockers and risk of 
fractures. J Am Med Assoc. 2004; 292:1326–1332. 
238. Reid IR, Gamble GD, Grey AB, Black DM, Ensrud KE, Browner WS, and Bauer DC. 
Beta-blocker use, BMD, and fractures in the study of osteoporotic fractures. J Bone 
Miner Res. 2005;20:613–61. 
 
 
 
 
150
APPENDIX 
IMMUNOHISTOCHEMICAL ANALYSIS OF ANTIGEN 
EXPRESSION USING HISTOLOGICAL SECTIONS OF PARAFFIN-
EMBEDDED BONE SAMPLES 
 
Necropsy 
 
Immediately after tissue harvest, put bones in 4% paraformaldehyde/0.02 M sodium 
phosphate buffer. Store in room temperature for less than 24 hours.  
  
 
Demineralization (decalcification) of bone with formic acid/sodium citrate solution.  
 
 
A) Prepare a 50% formic acid/distilled water decoction:  
   
B) Prepare a 20% sodium citrate/distilled water decoction:  
   
C) Mix solution (A) and solution (B) together 1:1 ratio.  
     Put bone samples in the mixed solution and gently agitate for 2~3 days at 4ºC. 
     Change solution everyday.  
 
D) Put samples in 70% ETOH and store in refrigerator before processing for embedding. 
 
 
Tissue processing+ Paraffin Embedding 
 
1. - Original fixative  
2. 45 minutes 70% Alcohol   40’C 
3. 45 minutes 80% Alcohol  40’C 
4. 45 minutes 95% Alcohol  40’C 
5. 45 minutes 100% Alcohol  40’C 
6. 60 minutes 100% Alcohol  40’C 
7. 60 minutes 100% Alcohol  40’C 
8. 60 minutes Clearing Reagent (xylene)  40’C 
9. 60 minutes Clearing Reagent (xylene)  40’C 
10. 60 minutes Paraffin 1  58’C 
11. 60 minutes Paraffin 2  58’C 
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12. 60 minutes Paraffin 3  58’ 
 
                                                 Immunohistochemistry Day 1 
 
 
Melt Paraffin on Slides 
Place slides in glass holders (empty bottom) and put in a 56-58 degree C. oven for 10-15 
minutes.  
 
1. Deparaffinize slides 
 
Quench the slides in the following graded series of xylenes and alcohol: 
 
1. Xylene 5 min 
2. Xylene 5 min 
3. 100% ethanol 3 min 
4. 100% ethanol 3 min 
5. 95% ethanol 3 min 
6. 70% ethanol 3 min 
 
2. Quench sections with 0.3% H2O2 in DI water for 30 min  
 
3. Prepare an incubation box of ~ 15 cm (width) x 30 cm (length) x 10 cm (height) 
dimensions. Put two 25 cm round plastic tubes at the bottom approximately a slide 
length apart. Secure them so the slides lie flat/perpendicular to bottom of the box when 
you put them in.   
 
4. Rinse with PBS using a transfer pipette: 2 times for 5 minutes each. 
 
5. Make “wells” around each sample with Elmer’s Rubber Cement Glue around each 
bone slice. 
 
6. Permeabilize with PBS/0.5% Triton for 5 minutes at room temperature.  
 
7. Rinse with PBS 2 times for five minutes each. 
 
8. Avidin D solution blocking step to reduce background noise: Incubate for 15 min at 
room temperature. Make sure that the avidin D covers the bone sample. This chemical is 
supplied by Vector Laboratories in a separate Avidin D/Biotin blocking kit.  
 
In this step, the glycoprotein avidin will bind with extremely high affinity to 
endogenous biotins (a vitamin) or lectins expressed in your sample. This leads to 
an irreversible binding of the biotin molecules that otherwise increase non-
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specific binding by interfering with the biotinylated secondary antibody action or 
the avidin/biotinylated horseradish peroxidase macromolecular complex. 
 
9. Rinse slightly with PBS 
 
10. Biotin blocking step for 15 minutes at room temperature. Make sure that the biotin 
covers the bone sample.  
 
Since avidin has several binding sites for biotin, the “avidin blocking step” is 
followed by an incubation period with biotin itself. This will irreversibly occupy 
all biotin binding sites on the avidin molecule so when the secondary 
biotinylated anti-body is added it will not be subjected to non-specific binding to 
the avidin blocking solution. In addition, the added biotins appear not to be 
subject to binding with the avidin/biotinylated horseradish peroxidase 
macromolecular complex [which is added last and should only bind to the 
biotinylated secondary anti body].        
 
11. Rinse with PBS 3 times for 5 minutes each. 
 
12. Normal goat serum (NGS) blocking step diluted in PBS/2% BSA buffer. Follow the 
vendor’s protocol.  
 
13. Rinse with PBS/2%BSA one time for 5 minutes. 
 
14.  Dilute the primary antibody (Ob (A20) SC 842) in buffer (PBS/2%BSA) to yield a 
concentration that is most effective for binding to the target antigen in your specific 
tissue  
 
14. Apply primary antibody/buffer solution to each well i.e. ~ 300 μl/well. Make sure the 
bone sample is covered and that the well is not leaking. In order to ensure method 
specificity you must have a “negative control” that does not receive the primary antibody.  
 
15. Incubate overnight at 4 ºC in a humidified chamber. 
 
 
Immunohistochemistry Day 2 
 
16. Rinse with PBS/2%BSA/0.2%Tween: 2 times 5 minutes each. 
 
17. Rinse with PBS/2%BSA twice 
 
18. Dilute the biotinylated secondary antibody [anti-rabbit IgG, made in goats] to 1/200 
with PBS/2%BSA/~1.5-5%NGS. In order to ensure method specificity you must have a 
“negative control” that does not receive the secondary antibody.  
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19. Prepare the VECTASTAIN ABC reagent and keep in dark for 30 minutes at room 
temperature.  
 
20. Rinse with PBS/2%BSA one time for 5 minutes. 
 
21. Rinse with PBS three times for 5 minutes each. 
 
22. Add ABC reagent and incubate in the dark for 30 minutes at room temperature. Put 
the lid on the box again.  
 
23. Rinse with PBS 3 times 3 minutes each. 
 
24. Peroxidase activity must now be revealed by adding NOVA RED  
Develop with freshly prepared NOVA RED for a minimum of 5 minutes. The bone 
samples should turn pinkish/reddish soon after adding this stain.  
 
Deionized water may inhibit peroxidase reaction! Only use distilled (DI) water.     
 
25. Add tap water to stop developing the peroxidase activity. Rinse slides for 5 minutes 
using tap water [at room temperature].     
 
26. Counterstain with hematoxylin for 1 min at room temperature. 
 
27. Rinse slides with tap water for 15 minutes.  Remove Elmer’s wells with an 18-gauge needle in 
preparation for the last quenching step. 
 
28. Deshydride slides with increasing grades of alcohol and two xylene (this stops 
potential sample shrinkage).  
 
 
1. 70% ethanol 3 min  
2. 95% ethanol 3 min  
3. 100% ethanol 3 min 
4. 100% ethanol 3 min  
5. Xylene 5 min 
6. Xylene 5 min 
 
29. Coverslip one slide at a time with Eukitt glue. If the glue is too solid, soften it by 
adding xylenes. 
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